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ABSTRACT 
 
Hepatitis C virus (HCV) is a single-stranded plus-sense RNA virus that is transmitted by 
blood-to-blood contact, and infects the human liver. HCV has a unique dependence on the liver-
specific microRNA miR-122, where miR-122 binds the 5´ un-translated region of the viral RNA 
at two tandem sites and increases viral RNA abundance. The mechanisms of augmentation are not 
yet fully understood, but the interaction is known to stabilize the viral RNA, increase translation 
from the viral internal ribosomal entry site (IRES), and result in increased viral yield. 
In an attempt to create a small animal model for HCV, we added miR-122 to mouse cell lines 
previously thought non-permissive to HCV, which rendered these cells permissive to the virus, 
additionally showing that miR-122 is one of the major determinants of HCV hepatotropism. We 
found that some wild-type and knockout mouse cell lines – NCoA6 and PKR knockout embryonic 
fibroblasts – could be rendered permissive to transient HCV sub-genomic, but not full-length, 
RNA replication upon addition of miR-122, and that other wild-type and knockout cell lines 
cannot be rendered permissive to HCV replication by addition of miR-122. These knockout cell 
lines demonstrated varying permissiveness phenotypes between passages and isolates and 
eventually completely lost permissiveness, and we were unable to achieve sub-genomic RNA 
replication in PKR knockout primary hepatocytes. Knockdown of NCoA6 and PKR in Huh7.5 
cells did not substantially impact sub-genomic replication, leading us to conclude that there are 
additional factors within the cell lines that affect their permissiveness for HCV replication such as 
epigenetic regulation during passage or transformation and immortalization. 
We also added miR-122 to Hep3B cells, a human hepatoma cell line lacking expression of 
miR-122 and previously thought to be non-permissive to HCV replication. Added miR-122 
rendered the cells as highly permissive to HCV replication as the Huh7-derived cell lines 
commonly used to study the virus. In these cells, we were also able to observe miR-122-
independent replication of sub-genomic HCV RNA. This was verified by use of a miR-122 
antagonist that had no impact on the putative miR-122-independent replication, and by mutating 
the miR-122 binding sites to make them dependent on a single nucleotide-substituted microRNA. 
This replication in the absence of miR-122 was not detected in full-length HCV RNA, but was 
detectable using a bi-cistronic full-length genomic replicon, suggesting that the addition of a 
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second IRES in sub-genomic and full-genomic replicons altered replication dynamics enough to 
allow detectable RNA replication without miR-122 binding. 
Because miR-122 has been implicated in protecting the viral RNA from destabilization and 
degradation by Xrn1, the main cytoplasmic 5´ to 3´ RNA exonuclease, we employed our miR-
122-independent system to test this miR-122-mediated protection. We verified that miR-122 
functions to protect the viral RNA from Xrn1, but this was insufficient to account for the overall 
impact of miR-122 on replication, meaning that miR-122 has further functions in the virus’ life 
cycle. We showed that the effect of miR-122 on translation is due to stabilization of the RNA by 
protecting it from Xrn1, through binding at both sites. We further evaluated the role of each miR-
122 binding site (S1 and S2) in the virus life cycle, and found that binding at each site contributes 
equally to increasing viral RNA replication, while binding at both sites exerts a co-operative effect. 
Finally, we determined that binding of miR-122 at site S2 is more important for protection from 
Xrn1, suggesting that miR-122 binding at S1 is more important for the additional functions of 
miR-122 in enhancing HCV RNA accumulation. 
Altogether, we have shown that miR-122 is partially responsible for the hepatotropic nature of 
Hepatitis C virus, and that supplementation with this microRNA can render non-permissive cells 
permissive to viral replication. We have also identified and confirmed replication of both sub-
genomic and full-length HCV RNA in the absence of miR-122. Finally, we have characterized the 
impact of the host RNA exonuclease Xrn1 on the HCV life cycle, and determined the roles of each 
miR-122 binding site in shielding the viral RNA from this host restriction factor. 
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1.0 Literature Review 
1.1 Hepatitis C Virus 
1.1.1 Viral Classification and Characteristics 
Hepatitis C virus (HCV) is a member of the Flaviviridae family, genus Hepacivirus, and is an 
enveloped, single-stranded positive sense RNA virus (Smith et al., 2014). Within the viral species, 
Hepatitis C is classified into seven numbered genotypes which are further broken down by 
subtypes denoted by lowercase letters (e.g. genotype 1a, genotype 6c) (Smith et al., 2014). The 
Pestivirus, Pegivirus, and Flavivirus genera in the Flaviviridae family contain many other human 
pathogens, but HCV is the only member of the Hepacivirus genus currently known to infect 
humans (Pybus and Gray, 2013; Stapleton et al., 2011). Recently, hepacivirus sequences have been 
isolated from primates, dogs, horses, bats, and rodents, but no virus has been cultured yet (Burbelo 
et al., 2012; Drexler et al., 2013; Kapoor et al., 2011; Lauck et al., 2013; Lyons et al., 2012; Quan 
et al., 2013; Silva et al., 2012). 
The viral genome is approximately 9.6 kilobases in length, and also directly acts as the virus’ 
mRNA (Moradpour et al., 2007). The 5´ un-translated region (UTR) of the viral RNA is comprised 
of several stem-loop structures essential for the virus life cycle; it bears two microRNA-122 (miR-
122) binding sequences following stem-loop I, and stem-loops II and III comprise the structure of 
the viral internal ribosomal entry site (IRES) that drives viral translation (Hoffman and Liu, 2011; 
Jopling et al., 2008; Lukavsky, 2009). The viral start codon is located in stem-loop IV, and the 
remainder of the viral RNA is translated as a single polyprotein, which is post-translationally 
cleaved by host and viral proteases into ten essential proteins. Core, E1, E2, p7, and NS2 are 
classified as the assembly module (structural and scaffolding proteins) while NS3, NS4a, NS4b, 
NS5a, and NS5b are non-structural replicase proteins, although they have all been implicated in 
aiding assembly as well (Moradpour and Penin, 2013). Finally, the viral RNA has a 3´ UTR which 
also contains significant RNA secondary structure critical to both viral translation and replication 
(Bung et al., 2010; Hoffman and Liu, 2011; Yi and Lemon, 2003).  
The HCV virion is comprised of a single copy of the viral RNA genome encased in Core 
protein, and further protected by a lipid membrane and viral envelope glycoproteins E1 and E2. 
Infectious virus particles in patient serum are associated with both very low-density lipoproteins 
(VLDL) and low-density lipoproteins (LDL) to form a lipoviral particle (LVP) that may aid in the 
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early steps of attachment to target cells (Lindenbach and Rice, 2013; Vieyres and Pietschmann, 
2013).  
 
1.1.2 Hepatitis C Virus Life Cycle 
1.1.2.1 Entry 
HCV utilizes a series of host proteins to attach to and enter the host cell. Because the virion is 
associated with host lipoproteins and lipid droplets, attachment may be mediated by binding of the 
lipid droplet components to heparan sulfate proteoglycan, the low-density lipid receptor (LDL-R), 
and scavenger receptor B1 (SR-B1), although these initial interactions may not be essential for 
entry (Acton et al., 1996; Albecka et al., 2012; Bartosch et al., 2003; Germi et al., 2002; Heo, 2008; 
Maillard et al., 2006; Mazumdar et al., 2011; Monazahian et al., 1999; Owen et al., 2009; Prentoe 
et al., 2014). The E2 protein of HCV specifically interacts with the cell surface protein CD81, and 
further signalling via receptor tyrosine kinases (epidermal growth factor receptor – EGFR and 
ephrin receptor A2 – EphA2) and RAS and RHO GTPases (HRas, Rac1, RhoA, and Ccd42) 
facilitates interaction with Claudin-1 at cellular tight junctions (Brazzoli et al., 2008; Evans et al., 
2007; Farquhar et al., 2011; Farquhar et al., 2012; Harris et al., 2010; Lupberger et al., 2011; 
Wunschmann et al., 2000; Zona et al., 2013). E1 is not thought to interact with any of the receptors, 
but is implicated in modifying and maintaining the structure of E2 to permit its direct interaction 
with HCV receptors (Douam et al., 2014; Wahid et al., 2013). SR-B1 and Occludin, and possibly 
phospholipid scramblase-1 are also involved in this step, which ultimately leads to the initiation 
of clathrin-mediated endocytosis of the lipoviral particle (Blanchard et al., 2006; Dao Thi et al., 
2012; Gong et al., 2011; Ploss et al., 2009; Sourisseau et al., 2013; Zahid et al., 2013). Additional 
host proteins Niemann-Pick C1-Like 1 (NPC1L1) and transferrin receptor 1 (TfR1) are likely also 
involved in this later stage of entry (Martin and Uprichard, 2013; Sainz et al., 2012a). Once 
endocytosed, lowered pH triggers the virion envelope proteins to initiate fusion with the early 
endosomal membrane and release the RNA genome into the cytoplasm for translation and 
replication (Blanchard et al., 2006; Codran et al., 2006; Coller et al., 2009; Farquhar et al., 2012; 
Sharma et al., 2011; Zeisel et al., 2013).  
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1.1.2.2 Translation 
Translation of its genome is the first step that HCV must take once the virus has escaped the 
endosome, as no replication can occur until the requisite proteins have been synthesized. Hepatitis 
C virus drives its translation through a Type 3 internal ribosomal entry site (IRES) located in 
nucleotides 40 to 374 in the 5´ UTR of its genome that functions independently of many of the 
initiation factors required to begin host mRNA translation (Hellen, 2009; Lukavsky, 2009; 
Tsukiyama-Kohara et al., 1992). The secondary structure of the HCV IRES recruits the 40S 
ribosomal subunit via stem-loops IIIcdef, along with a GTP-bound initiator tRNA (GTP/Met-
tRNAMet) and the eukaryotic initiation factor 2 (eIF2) at the polyprotein start codon (nucleotides 
342 to 344), without requirement for the vast majority of other mRNA initiation factors (Ji et al., 
2004; Lukavsky, 2009). Often, eIF3(abdf) is included in this complex on the IRES, but it may also 
bind separately via HCV’s stem-loop IIIb to stabilize the now-48S ribosome (Hellen, 2009; Ji et 
al., 2004; Lukavsky, 2009; Shi and Lai, 2006). By analogy to classical swine fever virus (CSFV) 
IRES function (a Pestivirus bearing another Type 3 IRES), the 48S subunit uses eIF5 to hydrolyze 
the GTP/Met-tRNAMet and liberate eIF2 and GDP, leading to eIF5B-mediated subunit joining by 
the 60S ribosomal subunit to form the functional 80S ribosome (Hellen, 2009; Locker et al., 2007; 
Otto and Puglisi, 2004). Upon assembly of the ribosome, translation begins at the core methionine 
without scanning and produces the viral polyprotein that must be cleaved by host signal peptidase 
and signal peptide peptidases (Core to p7), and the viral NS2 and NS3/4a proteases (NS2 and NS3 
to NS5b, respectively) (Bartenschlager et al., 2010; Choo et al., 1989; Lin et al., 1994; Lohmann 
et al., 1996; Reynolds et al., 1996). After translation, all of these proteins are directly required for 
replication and packaging of the viral RNA. Viral proteins, which are produced in excess, also 
modulate the host cell environment to best suit the virus by modulating metabolic processes, 
manipulating innate immune sensing, and minimizing adaptive host-wide immune responses, 
among others (Alvisi et al., 2011; Macdonald and Harris, 2004; Shulla and Randall, 2012). 
 
1.1.2.3 RNA Replication 
Making the change from translation of the genome to replication of the RNA is managed by 
both host and viral proteins, although the exact mechanism is not yet known. Some likely candidate 
host proteins include the La autoantigen and hnRNP-D (an RNA binding protein) found to bind 
the 5´ UTR, PCBP2 (poly-C binding protein 2), which binds the viral 5´ UTR and is implicated in 
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circularization of the genome, PTB (polypyrimidine tract binding protein), known to bind the viral 
3´ UTR, and hVAP-A (human vesicle-associated membrane protein-associated protein A), which 
recruits NS5a to NS5b and may recruit both to NS4b (Chang and Luo, 2006; Paek et al., 2008; 
Ray and Das, 2011; Tu et al., 1999; Wang et al., 2011). Additionally, miR-122, which also binds 
the 5´ UTR, has been suggested as a regulator of the switch between translation and replication, 
although the evidence for this is not strong (Diaz-Toledano et al., 2009). The viral NS5a protein 
has been heavily implicated in defining the switch to replication; in particular, the phosphorylation 
status of the protein is suggested to help define translation versus replication, but the specific 
kinases responsible for phosphorylation of NS5a are not all yet known (Huang et al., 2007b; Hundt 
et al., 2013; Macdonald and Harris, 2004). Particularly, only casein kinase-1α and Polo-like 
kinase-1 have been shown to specifically phosphorylate NS5a, although kinase screens and 
inhibitor studies have implicated MAP kinases, AKT, and glycogen synthase kinase-3 (Chen et 
al., 2010; Coito et al., 2004; Hundt et al., 2013; Quintavalle et al., 2007; Tellinghuisen et al., 2008). 
Therefore, it is still unclear how the transition from translation to replication of the viral RNA is 
regulated. 
Replication of the viral genome is dependent on the viral proteins: the non-structural proteins 
NS3 through NS5b are required and sufficient for replication of the viral RNA, but generally must 
be provided in cis – that is, translated from the same RNA that they will then replicate (Appel et 
al., 2005; Evans et al., 2004a; Herod et al., 2014). This creates an extra hurdle in exploring the 
process of HCV RNA replication, which is therefore still incompletely understood (Brass et al., 
2009; Fournier et al., 2013; Lohmann, 2013). All of the viral non-structural proteins are 
membrane-bound, which presumably facilitates their efficient interactions by preventing diffusion 
throughout the cell. The membranous web initiated by viral proteins also serves to protect the virus 
from host defenses and is a scaffolding to regulate the various stages of the virus life cycle 
(Lohmann, 2013; Moradpour and Penin, 2013; Moradpour et al., 2007; Paul and Bartenschlager, 
2013). The viral NS3/4a functions in complex as the main viral protease, cleaving the non-
structural viral proteins from each other after translation of the viral polyprotein (Moradpour and 
Penin, 2013; Phan et al., 2011). During replication, NS3 also activates the viral polymerase and 
further acts as a helicase, unwinding the secondary structure and/or dsRNA replication 
intermediates, while NS4a is also implicated in the regulation of NS5a phosphorylation discussed 
previously (Binder et al., 2007; Lindenbach et al., 2007; Morikawa et al., 2011; Piccininni et al., 
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2002). NS4b, in concert with NS5a, is understood to be involved in remodelling the host cell 
membranes to form a structures collectively known as the membranous web, which is used to 
house viral replication complexes (Alvisi et al., 2011; Egger et al., 2002; Gouttenoire et al., 2010). 
NS4b has also been implicated in catalyzing the formation of the replication complex (Gouttenoire 
et al., 2009; Gouttenoire et al., 2010; Jones et al., 2009). NS5a is involved in formation of the 
membranous web, regulation of translation and replication, and anchoring the replication complex 
to the membranous web (Lundin et al., 2006; Macdonald and Harris, 2004).  
Finally, NS5b is the viral polymerase that is key to production of both positive and negative-
sense viral genomes; NS3 and NS5a have both been shown to increase its polymerase activity (Lee 
et al., 2006; Moradpour et al., 2007; Piccininni et al., 2002; Shi and Lai, 2006; Shimoike et al., 
2006). By analogy to other Flaviviruses, replication of the viral genome may also require 
circularization of the RNA, perhaps to catalyze assembly of the active replicase, which could be 
mediated by viral proteins such as NS3 and NS5a, as they are known for binding both ends of the 
viral genome, or by other host proteins such as those involved in translation regulation (Ray and 
Das, 2011; Toroney et al., 2010; Villordo and Gamarnik, 2009; Wang et al., 2011). Along with the 
host proteins mentioned above that potentially regulate a switch to replication such as hVAP-A 
and PCBP2, host protein PI4KIII is required for membranous web formation and thus replication 
complex assembly, while cyclophilin A is required for HCV RNA replication, and hnRNP-L and 
NF90 have recently also been implicated in facilitating RNA replication (Alvisi et al., 2011; Berger 
et al., 2009; Evans et al., 2004b; Gao et al., 2004; Li et al., 2014; Rosnoblet et al., 2012; Tai et al., 
2009; Tu et al., 1999; Wang et al., 2011; Weng et al., 2012). 
Replication involves specific structural elements in the NS5b coding region and 3´ UTR of the 
positive sense RNA (Cai et al., 2004; Friebe et al., 2005; Yi and Lemon, 2003; You and Rice, 
2008). The resulting negative sense RNA acts as a template for more genomic RNA, and although 
its 3´ sequence is complementary to the genomic 5´ UTR, its secondary structure is significantly 
different and presumed to be critical for initiation of positive sense RNA production. The sole 
known function of the negative sense RNA is to provide a template for further positive sense RNA 
production, and this is supported by an observed 1:10 ratio of negative sense genomes to positive 
sense genomes in the host cell (Bartenschlager et al., 2010; Binder et al., 2007; Keum et al., 2012; 
Lohmann, 2013). The positive sense RNA genomes are then used as further templates for 
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translation and replication, or are packaged into virions for further infection (Bartenschlager et al., 
2010; Moradpour et al., 2007). 
 
1.1.2.4 Virion Production 
Understanding of HCV infectious virion production is limited by our current cell culture 
systems. Egress of infectious virus particles is associated with very low-density lipoprotein 
(VLDL) secretion, but the major cell culture model (Huh7-derived cells) are deficient in 
production of Apolipoprotein B (ApoB), which is known to be associated with patient serum-
derived infectious particles (Huang et al., 2007a; Icard et al., 2009). Thus, the lipoviroparticles 
produced in cell culture thus have different properties from patient serum-derived virus particles, 
suggesting that models based on information from cell culture-derived virus are incomplete (Andre 
et al., 2002; Jiang and Luo, 2009; Lindenbach and Rice, 2013; Nielsen et al., 2006; Podevin et al., 
2010).  
The viral proteins NS2 and p7 coordinate relocation of other non-structural and structural 
proteins to the site of viral assembly on the endoplasmic reticulum (ER), but the order of 
recruitment and component assembly is not fully known (Boson et al., 2011; Corless et al., 2010; 
Gentzsch et al., 2013; Jirasko et al., 2010; Lindenbach, 2013; Popescu et al., 2011; Vieyres et al., 
2013). Core, which functions as the nucleocapsid of the virion, is recruited to this site from 
cytoplasmic lipid droplets by interactions with the putative NS2-p7 scaffolding complex and the 
host protein DGAT1, as well as through interactions with NS3/4a and NS5a (Boson et al., 2011; 
Camus et al., 2013; Counihan et al., 2011; Herker et al., 2010; Ma et al., 2008; Masaki et al., 2008; 
Stapleford and Lindenbach, 2011). The envelope proteins E1 and E2 exist as a heterodimer 
localized to the ER, and are also likely brought to the site of assembly by NS2 and p7 (Brazzoli et 
al., 2005; Dubuisson et al., 1994; Jirasko et al., 2010; Ma et al., 2011; Popescu et al., 2011; 
Stapleford and Lindenbach, 2011). At some point in this process, the viral RNA is also recruited 
to this site, perhaps by relocation of the replicase due to interactions between structural and non-
structural proteins, where it is suggested that the NS3 helicase is responsible for incorporation of 
viral RNA into the capsid (Bartenschlager et al., 2011; Lindenbach and Rice, 2013; Popescu et al., 
2011). 
The virion uses early-to-late endosomal tracking (the ESCRT pathway; the endosomal sorting 
complex required for transport) to mediate secretion into the extracellular milieu (Ariumi et al., 
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2011b; Corless et al., 2010; Lai et al., 2010; Tamai et al., 2012). E1 and E2 become glycosylated 
during egress, possibly at the Golgi apparatus (Coller et al., 2012; Vieyres et al., 2010). During 
secretion, the p7 protein remains associated with the virion, acting as an ion channel to retain an 
appropriate pH balance to stabilize viral particles until egress, but it is not associated with the 
secreted viral particle (Clarke et al., 2006; Steinmann et al., 2007; Vieyres et al., 2013; Wozniak 
et al., 2010). Upon assembly of the viral structural proteins and viral RNA into a virion, the 
sequence of its association with lipid droplets and/or their components is likewise uncertain. 
Recently, both ApoB and ApoE have been found to be associated E1 and E2 at the ER membrane, 
as well as associated with intracellular infectious virus particles, showing that the association of 
the virion with lipoproteins occurs early in trafficking, and ApoE has been found to associate with 
NS5a on lipid droplets, suggesting that ApoE could be involved in early assembly of the virion 
(Benga et al., 2010; Boyer et al., 2014; Coller et al., 2012). Other results suggest that this is not 
the case, and that association with ApoE is unnecessary for assembly, and is only mechanistically 
relevant at a late stage of trafficking and egress (Hueging et al., 2014). It is therefore not certain 
whether virion/Apolipoprotein intracellular association is coincidental due to virion association 
with ApoE, ApoC, and ApoB along the same secretion pathway, or whether the virus directly and 
specifically associates with VLDLs during assembly and/or secretion (Gastaminza et al., 2008; 
Huang et al., 2007a; Jiang and Luo, 2009; Lindenbach and Rice, 2013; Merz et al., 2011; Meunier 
et al., 2008). There are currently two models of how this viral particle associates with the host cell 
lipid droplets in the serum. The secreted lipoviral particles include the virion, as well as some – 
but not necessarily all – components of VLDLs, but it is not yet clear whether the viral particle is 
encased in the lipoprotein(s) or whether it is merely associated with the outer surface of the VLDL 
(Catanese et al., 2013; Gastaminza et al., 2010; Lindenbach and Rice, 2013; Merz et al., 2011).  
 
1.1.3 Treatment and Prevention of Hepatitis C Virus Infection 
1.1.3.1 Epidemiology and Transmission 
Hepatitis C virus infects an estimated 150 million people world-wide, and over 250,000 people 
in Canada (Myers et al., 2014; WHO, 2012). Many who are infected are unaware of their status; 
the virus is spread by blood-to-blood contact (parenteral exposure), which can include exposure to 
improperly sterilized medical equipment, contaminated blood or blood products, sexual contact, 
or sharing needles and other drug paraphernalia (Denniston et al., 2012; Ghany et al., 2009). In 
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Canada, the major populations at-risk for acquiring or harbouring the virus are people who inject 
drugs, adults born between 1945 and 1975, and immigrants from countries with high HCV 
prevalence (Cornberg et al., 2011; Grebely et al., 2013; Myers et al., 2014; Ward, 2013). World-
wide, there are an estimated 3-4 million new infections with HCV every year (Mohd Hanafiah et 
al., 2013). 
 
1.1.3.2 Clinical Infection 
Infection with HCV is largely asymptomatic; although acute infection may initially present 
with non-specific flu-like symptoms (fever, malaise, aches, etc.), cases of fulminant, symptomatic 
hepatitis from infection with HCV are very rare (Thomas, 2013; Thomas and Seeff, 2005). The 
acute phase of infection can last up to 6 months, and a minority of patients (approximately 20%) 
can spontaneously clear the infection during this time (Cox et al., 2005). Thereafter, the infection 
becomes chronic, which can last up to three decades; spontaneous clearance during the chronic 
phase is less common (Cox et al., 2005; Thomas and Seeff, 2005). Chronic infection can lead to a 
variety of clinical sequelae: liver-related outcomes include steatosis, fibrosis and cirrhosis, 
decompensated liver disease and failure, and hepatocellular carcinoma (Thomas, 2013; Zampino 
et al., 2013). Other effects of a chronic HCV infection include metabolic disease; mixed 
cryoglobulinemia and other lymphoproliferative disorders; glomerulonephritis; autoimmune 
sequelae such as hypothyroidism and rheumatic disorders; cardiovascular diseases; and a host of 
neuropsychiatric symptoms (Zampino et al., 2013; Zignego et al., 2012). 
 
1.1.3.3 Treatment 
All genotypes of Hepatitis C virus can be treated with a combination therapy of the general 
antiviral drug ribavirin (Rbv) and pegylated interferon alpha or beta (peg-IFNα or β); the peg-IFN 
is delivered by weekly injection, and Rbv is taken orally twice per day, with therapy lasting from 
24 to 48 weeks, depending on viral genotype and host factors – including change in viral load at 
defined points during therapy (Sherman et al., 2007). This treatment, however, has varying 
effectiveness depending on viral genotype and host genetics; it can also have severe side-effects 
that reduce patient adherence to treatment, particularly since the therapy (and side-effects) can last 
for nearly a year (Lieveld et al., 2013). Because genotype 1 infections are more prevalent in 
developed nations than other genotypes, and because genotype 1 infections respond relatively 
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poorly to peg-IFN/Rbv therapy (approximately 50-60% effective), initial direct-acting anti-viral 
(DAA) drug development has targeted genotype 1 infections. In 2011, two protease inhibitors 
(boceprevir and telaprevir) were approved for use in combination with peg-IFN/Rbv therapy to 
treat genotype 1 infections, increasing response to treatment in naïve patients by 30% and in 
previous non-responders by up to 60% (Conteduca et al., 2014; Myers et al., 2012). Additionally, 
a third protease inhibitor (simeprevir) was approved in 2013 for use in genotype 1, 2, and 4 
infections, in combination with peg-IFN/Rbv (Conteduca et al., 2014). These drugs all select for 
pre-existing resistance mutations, however, which is why they must still all be used as part of 
combination therapy (deLemos and Chung, 2014). Unfortunately, these protease inhibitors also 
come with their own host of side-effects that can lead to cessation of treatment with these DAAs. 
Because many of the viral proteins differ widely between genotypes, early-generation DAAs 
target a limited range of viral genotypes. However, a fourth DAA – sofosbuvir – was approved in 
late 2013 that is both pan-genotypic (approved for use in genotypes 1-4), and can be used with 
only ribavirin in patients with genotype 2 (94% effective) and genotype 3 (62%) infections when 
interferon is contraindicated (Conteduca et al., 2014; deLemos and Chung, 2014; Lawitz et al., 
2013). Sofosbuvir targets the active site of the NS5b polymerase, which is much more conserved 
across viral genotypes, and is less able to generate resistance mutations (Asselah, 2014). It is also 
very effective when used in combination with peg-IFN/Rbv (Lawitz et al., 2013).  
Future DAAs are anticipated to reduce side-effects while increasing effectiveness – both in 
treatment-naïve patients and in previous non-responders – and decreasing length and frequency of 
treatment (Conteduca et al., 2014; Grebely et al., 2013). When used in combination with other 
DAAs targeting viral proteins (NS3/4a, NS5a, and NS5b) and/or with drugs targeting essential 
host factors (miRNA-122, cyclophilin A, and TLR-7), new treatment regimens should no longer 
require use of either interferon or ribavirin, reducing many of the issues of treatment toxicity and 
patient adherence (Conteduca et al., 2014; deLemos and Chung, 2014; Feld, 2014).  
 
1.1.3.4 Prevention 
Hepatitis C virus infection is currently prevented by minimizing risk of exposure: avoiding 
needle-sharing, screening blood and blood products, properly sterilizing medical equipment, and 
not re-using needles and syringes (Thomas, 2013). Additionally, when exposure (such as a needle-
stick injury in a healthcare provider) is expected but infection has not yet been detected, post-
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exposure prophylaxis with peg-IFN/Rbv can also be employed to prevent establishment of 
infection (Myers et al., 2012; Thomas, 2013).  
Unlike Hepatitis A and B, no vaccine is available for Hepatitis C virus. Although patients and 
chimpanzees who spontaneously clear infection may retain some immunity to re-infection, this is 
not always the case, and what, precisely, defines their ability to resist re-infection is controversial 
(Fauvelle et al., 2013). Because of this, and because of the broad range of genotypes and 
antigenicity the vaccine needs to cover, developing a preventative vaccine is difficult (Shi and 
Ploss, 2013). Both neutralizing antibodies and broad-epitope CD4 and CD8 T-cell responses are 
expected to be important for a putative vaccine, but defining specific antigens and formulations to 
drive the desired responses remains challenging (Fauvelle et al., 2013). Some vaccines are 
currently in Phase I clinical trials to assess safety and immunogenicity; combined with in vitro 
testing, there is hope that these trials and others soon to follow will provide insight into an effective 
preventative HCV vaccine (Fauvelle et al., 2013; Shi and Ploss, 2013). 
 
1.2 microRNA-122 
1.2.1 microRNA Pathway and Functions 
microRNAs (miRNAs) are short, double-stranded non-coding RNAs that post-
transcriptionally regulate translation of cellular mRNAs (Sand, 2014). They play a regulatory role 
in essentially every cellular process, targeting an estimated 30-60% of the mRNAs encoded by the 
human genome (Friedman et al., 2009; Lewis et al., 2005). Mature miRNAs are between 17-23 
nucleotides (nt) in length, with a 2-nt 3´ overhang on each strand; the passenger strand of the 
miRNA is discarded, while the guide strand is loaded into an RNA-induced silencing complex 
(RISC) to target specific mRNAs for translational silencing (Sand, 2014). As depicted in Figure 
1.1, pri-miRNAs are encoded in transcripts from RNA polymerase II (PolII) – meaning they are 
capped and poly-adenylated – of both coding and non-coding genes (Kim and Kim, 2007). The 
pri-miRNA hairpins are excised from the transcript in the nucleus by a microprocessor complex 
containing Drosha (an RNaseIII enzyme) and Pasha (DGCR8, an RNA binding protein implicated 
in regulating Drosha activity) (Gregory et al., 2004); the miRNAs can be encoded within both 
introns and exons, and in coding transcripts, pri-miRNA excision may occur prior to or during 
intron processing and still permit the full transcript to function as an mRNA afterwards (Kim and 
Kim, 2007). PolII can also produce poly-cistronic pri-miRNA transcripts, which are a series of 
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Figure 1.1 miRNA processing pathway. 
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miRNA hairpins on the same dedicated transcript that are processed by Drosha into several 
different pre-miRNAs (Hammond, 2006; Sand, 2014). 
The newly-processed pre-miRNA (typically a ~70nt hairpin with a characteristic 2-nt 3´ 
overhang) is exported from the nucleus to the cytoplasm by Exportin-5, where it is collected by 
Dicer for further processing (Lee et al., 2002). Along with its co-factors TRBP and PACT-1, Dicer 
utilizes its RNaseIII activity to cleave the pre-miRNA into a mature miRNA of ~22 nt by removing 
the hairpin loop and leaving the dsRNA stem with both ends displaying a 2-nt 3´ overhang (Kok 
et al., 2007). This complex of proteins then selects the guide strand of the miRNA (based on 
activity of the co-factors and thermodynamic stability of the strands’ 5´ end) to load into the RISC 
and produce the miRISC, discarding the passenger strand (often denoted with an asterisk, e.g. miR-
199a*) (Ambros et al., 2003; Noland and Doudna, 2013). The minimal functional components of 
the miRISC are considered to be the guide strand of the miRNA and an Argonaute (Ago1, 2, 3, or 
4) protein, but TNRC6A (GW182) has recently been implicated as essential to RISC function as 
well, by mediating interactions between the RISC and the downstream silencing machinery 
(Carthew and Sontheimer, 2009; Pfaff and Meister, 2013; Takahashi et al., 2014). Dicer and its 
binding partners, as well as several other proteins have been associated with the RISC as well, 
although they may not be critical for the complex’s ability to silence RNA translation (Carthew 
and Sontheimer, 2009; Takahashi et al., 2014). One of the Argonaute proteins cradles the guide 
strand of the miRNA and uses its seed sequence (the first 7-9 nt of the guide strand) to target 
mRNAs for translational suppression by imperfect sequence complementarity to the target 
sequence on the mRNA (Carthew and Sontheimer, 2009; Sashital and Doudna, 2010). GW182 
mediates the interaction between the mRNA-RISC complex and components such as poly-A 
binding protein (PABP1) and the CCR4-NOT complex in a cytoplasmic processing body (P-body), 
where the mRNA can be either stored or degraded (Fabian et al., 2010; Liu et al., 2005; Pfaff and 
Meister, 2013; Zekri et al., 2013). P-bodies have a variable composition that includes proteins that 
sequester and store mRNAs for future translation, as well as components of several different 
mRNA degradation pathways such as Xrn1 that permanently remove the mRNA from translation 
(Decker and Parker, 2012).  
miRNAs typically bind the 3´ un-translated region of their target mRNAs and lead to 
translational suppression and/or degradation as described, but they can also function by binding 
elsewhere on the mRNA, and there is evidence that in some cases, miRNAs can cause increased 
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translation instead of translational suppression when the cell undergoes certain stresses (Fabian et 
al., 2010; Ørom et al., 2008; Vasudevan et al., 2007). There are also alternative pathways for 
biogenesis of certain miRNAs that bypass different steps in canonical biogenesis, and some of 
these may come into play when the cell is under particular stresses, but the vast majority of 
miRNAs identified so far are produced in this canonical manner (Yang and Lai, 2011; Yeo and 
Chong, 2011).  
 
1.2.2 Functions of microRNA-122 in the Host 
Human hsa-miR-122 is produced in a canonical manner by PolII from the non-coding hcr gene 
on chromosome 18 (Chang et al., 2004; Jopling, 2012; Li et al., 2011b). microRNA-122 (miR-
122) levels are highest in the liver, representing approximately 70% of its total small RNA 
transcripts, but expression has also been detected in nervous, respiratory, and hematopoeic tissues 
(Chang et al., 2004; Landgraf et al., 2007). Transcription of miR-122 appears to be driven by 
several liver-enriched transcription factors, including hepatocyte nuclear factor 4α (HNF4α), 
HNF1A, HNF3A and HNF3B, and to a lesser extent HNF4G and HNF6 (Coulouarn et al., 2009; 
Li et al., 2011b; Xu et al., 2010). Peroxisome proliferator activated receptor-gamma (PPARγ) and 
retinoid X receptor alpha (RXRα) can activate transcription of miR-122, while the circadian 
rhythm regulator REV-ERBα suppresses transcription at specific times in the cell’s “day” (Gatfield 
et al., 2009; Song et al., 2013). Like many miRNAs, miR-122 is believed to play a role in 
embryonic development by driving differentiation of hepatocytes (Chang et al., 2004). CUTL1, a 
repressor of genes required for hepatocyte differentiation, is targeted for post-transcriptional 
suppression by miR-122 (Xu et al., 2010). Additionally, in a positive-feedback loop, HNF6 
promotes transcription of miR-122, which in turn enhances expression of HNF6 and the other 
liver-enriched transcription factors to stimulate terminal differentiation of hepatocytes (Kyrmizi et 
al., 2006; Laudadio et al., 2012).  
In the mature liver, miR-122 is a regulator of lipid metabolism, and in mice, chimpanzees, and 
humans, antagonism of miR-122 leads to a reduction in serum cholesterol (Elmen et al., 2008; 
Janssen et al., 2013; Lanford et al., 2010). Use of microarrays has shown that antagonism of miR-
122 causes down-regulation of mRNAs for major players in cholesterol synthesis, fatty acid 
synthesis, and lipid metabolism, suggesting that miR-122 targets and down-regulates one or more 
transcriptional suppressors of lipid metabolism (Esau et al., 2006; Norman and Sarnow, 2010). 
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Two of the known direct targets for miR-122 are involved in lipid metabolism: AGPAT1 
stimulates the conversion of fatty acids into triglycerides (Hsu et al., 2012; Ruan and Pownall, 
2001), while CIDEC is differentially expressed during fasting and is associated with lipid droplets 
and regulates triglyceride storage and fatty acid oxidation (Hsu et al., 2012; Keller et al., 2008; 
Vila-Brau et al., 2013).   
miR-122 is also known to be involved in maintaining liver homeostasis. Cationic amino acid 
transporter-1 (CAT-1) was the earliest discovered mRNA to directly interact with miR-122: this 
interaction functions to regulate liver homeostasis by preventing degradation of plasma arginine 
under most conditions, and CAT-1 is only relieved from miR-122-mediated suppression when the 
hepatocyte requires an influx of lysine and arginine for increased protein synthesis (Bhattacharyya 
et al., 2006; Chang et al., 2004). miR-122 depletion has been shown to cause iron deficiency: miR-
122 directly binds and suppresses both the hemochromatosis (Hfe) and hemojuvelin (Hjv) mRNAs; 
these proteins activate hepcidin and result in degradation of an iron efflux channel (ferroportin), 
and when this is suppressed by miR-122 more iron can be released from storage into the body 
(Castoldi and Muckenthaler, 2012; Castoldi et al., 2011). Precursor miR-122 (pre-miR-122 and 
pri-miR-122) levels fluctuate with the circadian rhythms of the cell, and although mature miR-122 
levels do not vary significantly, this still affects downstream targets of the miRNA (Gatfield et al., 
2009). Interestingly, some of the direct miR-122 binding targets identified when analyzing the 
circadian pattern of miR-122 levels included Nocturnin, Smarcd1/Baf60a, and PPARβ/δ, which 
are nuclear proteins that are also implicated in regulating lipid metabolism (Gatfield et al., 2009; 
Kojima et al., 2010). 
Finally, miR-122 has been identified as a tumour suppressor. Most recently, miR-122 knockout 
mice were generated independently by two different research groups who both observed a drastic 
increase in liver cancer in these mice (Hsu et al., 2012; Tsai et al., 2012). Genes pinpointed in these 
mice, combined with previous research suggesting a role for miR-122 in reducing cellular 
proliferation and limiting fibrosis, and the observation that miR-122 expression is reduced or 
absent in many cases of liver cancer, has led to a view of miR-122 as a key player in suppressing 
development of liver cancer (Bai et al., 2009; Coulouarn et al., 2009; Fan et al., 2011; Fornari et 
al., 2009; Gao et al., 2009; Gramantieri et al., 2008; Hsu et al., 2012; Jung et al., 2011; Kutay et 
al., 2006; Li et al., 2013b; Tsai et al., 2009; Tsai et al., 2012; Xu et al., 2012). Both cell cycle and 
growth dysregulation, and regulation (or de-regulation) of the immune response are associated 
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with carcinogenesis, and miR-122 is implicated in both processes. (Li et al., 2013a; Pedersen et 
al., 2007; Qian et al., 2010). As examples, levels of mature miR-122 fluctuate in the cell throughout 
cell cycle progression (from high levels during G0 to low levels during S-phase), and miR-122 can 
promote Type I interferon production by suppressing SOCS1, “suppressor of cytokine signaling-
1” (Fehr et al., 2012; Li et al., 2013a). 
Interestingly, restoration of miR-122 expression to hepatocellular carcinoma cells also 
increases their sensitivity to chemotherapeutics such as doxorubicin, adriamycin, and vincristine; 
this was also marked by miR-122-mediated reduction of cell cycle progression proteins, aiding in 
induction of cell cycle arrest (Fornari et al., 2009; Xu et al., 2011). miR-122 is believed to aid 
many chemotherapeutic agents in hepatocellular carcinoma by down-regulating the unfolded 
protein response, permitting therapeutic apoptosis that would otherwise be suppressed in cancer 
cells (Yang et al., 2011). The level of miR-122 in human serum is also being explored as a potential 
biomarker to detect hepatocellular carcinoma development and progression, as well as an indicator 
of other sources of liver damage (Bala et al., 2012; Bihrer et al., 2011; Cermelli et al., 2011; Chen 
et al., 2012; Ding et al., 2012; Farid et al., 2012; Hu et al., 2013; Laterza et al., 2009; Laterza et 
al., 2013; Starkey Lewis et al., 2011; van der Meer et al., 2013; Waidmann et al., 2012; Zhang et 
al., 2012). 
 
1.2.3 Role of microRNA-122 in the Hepatitis C Virus Life Cycle 
miR-122 has a unique relationship with Hepatitis C virus. By interacting with two binding sites 
in the 5´ UTR (Figure 1.2) of the viral RNA, it positively impacts viral RNA stability, translation, 
and RNA accumulation, which is entirely different from canonical miRNA activity. Furthermore, 
the interaction between HCV and miR-122 is unique in the known world of virus-host interactions, 
as well. Some viruses encode their own miRNAs (primarily DNA viruses) to directly manipulate 
host mRNAs, or produce decoy transcripts to “soak up” cellular miRNAs, while other viruses take 
a less-direct approach of inducing or suppressing select miRNAs to modify the host cell 
environment, and still other viruses take a broad-spectrum approach of hindering or altering global 
miRNA biogenesis by targeting pathway proteins like Dicer or Argonaute (Carnero et al., 2011; 
Green et al., 2014; Guo and Steitz, 2014; Haasnoot and Berkhout, 2011; Roby et al., 2014). In 
these instances, the purpose of the interaction between viral proteins or transcripts and miRNA(s) 
appears to have been to achieve the ideal host cell environment. In contrast, the direct interaction  
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miRNA-122 (blue) requires Ago2 (red) to facilitate its binding at two sites (S1 and S2) on the 
HCV 5´ UTR (black). 
  
Figure 1.2 miR-122 binding at the 5´ UTR of the Hepatitis C virus genome. 
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of the HCV genome with miR-122 has been deemed essential for efficient HCV RNA 
accumulation, and is considered a major determinant of the virus’ liver tropism. miR-122 was first 
identified as binding via 7 nt of its seed sequence to one site on the HCV 5´ UTR (now known as 
Site 1 or S1), 21 nt from the 5´ end of the viral RNA and just upstream of the virus’ IRES (Jopling 
et al., 2005). miR-122 was not originally detected to have any impact on translation, but did 
positively modulate accumulation of the viral RNA, as detected by northern blot. Abolition of its 
binding reduced RNA accumulation by 80% using an antagonist of cellular miR-122, or rendered 
it undetectable by mutating a single nucleotide in the predicted miR-122 binding sequence, and 
RNA accumulation was restored to wild-type levels in the binding site mutants by providing a 
synthetic miR-122 with the matching mutation that reinstated binding (Jopling et al., 2005). This 
mutational analysis also verified that it was a direct effect of miR-122 binding, rather than an 
indirect effect that miR-122 exerted on the cell. The same group later identified a second miR-122 
binding site just a few nt 3´ to the first, designated Site 2 or S2, and again showed that binding at 
this second site was also critical for detectable HCV RNA accumulation by generating point 
mutations in the binding site(s) that abolished RNA accumulation, and rescuing the mutants by 
supplying synthetic miR-122 with the concomitant mutation (Jopling et al., 2008). These seminal 
papers determined that binding of miR-122 at both S1 and S2 was required for detectable HCV 
RNA accumulation. Since this discovery, additional research has shown that binding of miR-122 
occurs outside the seed sequences as well, with the nucleotides 13-20 of miR-122 also interacting 
with the viral genome both between the two miR-122 binding sites, and also covering the very 5´ 
nucleotides of the viral genome, depicted in Figure 1.2 (Machlin et al., 2011; Mortimer and 
Doudna, 2013; Shimakami et al., 2012b). 
miR-122 has at least two other putative binding sites on the HCV genome, but these have not 
been as well-studied. Jopling et al. found a potential binding site in the 3´ UTR of the HCV genome 
that was conserved among viral genotypes, but abolition of this sequence by mutagenesis had no 
observable effect on viral replication or translation, indicating that this site does not interact 
functionally with miR-122 (Henke et al., 2008; Jopling et al., 2005; Nasheri et al., 2011). However, 
miR-122 has also been shown to bind to a seed sequence in the NS5b coding region of the viral 
RNA, with potential interactions between 3´ nucleotides on the miRNA and the genome similar to 
that found for binding at sites S1 and S2 (Nasheri et al., 2011). This interaction results in a 
reduction of HCV RNA accumulation – perhaps through translational suppression; such an 
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interaction has been proposed to reduce pathogenicity or immunogenicity of other chronic 
infections by reducing viral titres, but since this sequence is not conserved among all HCV 
genotypes, it is uncertain how large of a role it has in Hepatitis C virus infection (Mahajan et al., 
2009; Nasheri et al., 2011). 
Because the net effect of miR-122 on HCV RNA accumulation is contrary to typical miRNA 
functions, the precise mechanism(s) of this effect are uncertain. Further research comparing 
canonical miRNA functions to the effect of miR-122 on HCV has shown that the same biogenesis 
and RISC proteins involved in miRNA-mediated silencing are also involved in miR-122-mediated 
enhancement of HCV RNA accumulation. Particularly, Ago2 (and to a lesser extent, Ago1, 3, and 
4), GW182, and TRBP have been shown to be involved in the effect of miR-122 on HCV RNA 
accumulation, while Dicer has been implicated in aiding HCV RNA accumulation through 
mediating miR-122 biogenesis (Bukong et al., 2013; Conrad et al., 2013; Roberts et al., 2011; 
Roberts et al., 2014; Shimakami et al., 2012a; Thibault et al., 2013; Wilson et al., 2011). P-body 
components have also been implicated in aiding HCV RNA accumulation, both negatively (Xrn1) 
and positively (DDX6, LSm1, PatL1, ATX2, PABP1), although not all have been shown to be 
associated with the effect of miR-122, and some – like DDX6 – have been shown to impact HCV 
replication independently of miR-122 (Ariumi et al., 2011a; Huys et al., 2013; Li et al., 2013d; 
Pager et al., 2013; Roberts et al., 2014; Scheller et al., 2009). 
Since miRNAs are known to affect translation, other researchers revisited the possible effect 
of miR-122 on HCV IRES-driven translation, and found that miR-122 binding to the HCV genome 
did, in fact, increase the translation of the viral RNA by two to three-fold (Henke et al., 2008; Huys 
et al., 2013; Niepmann, 2009; Roberts et al., 2011; Wilson et al., 2011; Zhang et al., 2012). It was 
suggested that the sole function of miR-122 for the virus was to increase translation, resulting in a 
higher concentration of viral proteins that over time could increase replication efficiency and RNA 
accumulation, but evaluation of a viral translation mutant showed that the magnitude of the effect 
of increased translation could not account for the overall replication phenotype (Henke et al., 
2008). This was later verified by showing that a protein (Lsm1) involved in mediating the effect 
of miR-122 on translation had no impact on the ability of miR-122 to increase replication, 
emphasizing separate functions (Roberts et al., 2014). More recently, it has been suggested that 
the increase in translation is merely an indirect effect of stabilization of the viral RNA, with the 
implication being that when miR-122 binds, less viral RNA is degraded, which results in more 
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viral RNA available for translation (Conrad et al., 2013; Li et al., 2013d; Mortimer and Doudna, 
2013; Shimakami et al., 2012a; Shimakami et al., 2012b). The host 5´ to 3´ RNA exonuclease Xrn1 
has been implicated in this destabilization and degradation of the viral RNA; although early reports 
using siRNA to knock down Xrn1 showed no effect on HCV RNA accumulation, more in-depth 
analysis has shown that abolishing Xrn1 does permit increased HCV RNA accumulation (Jones et 
al., 2010b; Li et al., 2013d; Mortimer and Doudna, 2013). Most recently, miR-122 has been shown 
to be the mediator of protection from degradation by Xrn1 (see also Chapter 7), and has been 
shown to have no effect on translation in the absence of Xrn1, confirming that the increase in 
translation observed by adding miR-122 was due to stabilization and protection of the viral RNA 
from Xrn1 (Li et al., 2013d). However, just as the effect of miR-122 on translation was insufficient 
to explain the overall impact of miR-122 on HCV RNA accumulation, knockdown of Xrn1 was 
not able to rescue HCV RNA accumulation in the absence of miR-122, showing that miR-122 
must have an additional function in enhancing HCV RNA accumulation (see also Chapter 7) (Li 
et al., 2013d). There is an additional possibility, however; the substrate for Xrn1-mediated 
degradation is a 5´ monophosphate, but the HCV genome requires a 5´ tri-phosphate to replicate, 
which suggests that in order for the viral RNA to be susceptible to Xrn1 in the first place, it must 
first be modified by a host pyrophosphatase (Li et al., 2013c; Li et al., 2013d; Nagarajan et al., 
2013). The possibility that miR-122 also protects the HCV genome from a pyrophosphatase 
remains to be explored. 
miR-122 has also been suggested to act as a molecular switch for the viral RNA, where its 
binding defines whether the RNA is available for translation, or is instead being used as a template 
for RNA replication (Diaz-Toledano et al., 2009). Although structural studies suggest that miR-
122 binding does change the secondary RNA structure of the 5´ UTR – including the availability 
of the viral IRES – these proposed changes require additional sequences and structures in the core 
protein coding region of the genome (Diaz-Toledano et al., 2009; Mortimer and Doudna, 2013; 
Pang et al., 2012). However, sub-genomic HCV constructs respond to miR-122 binding similarly 
to full-length constructs, but they lack the core protein coding region suggested to be important in 
this switch, indicating that if miR-122 binding does act as a switch, this is not the mechanism 
involved (Thibault et al., 2013). 
It is possible that miR-122 directly affects replication of the viral RNA. This is the most 
challenging role to examine, because unlike other RNA viruses like polio, HCV requires all the 
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replicase components to be expressed in cis from the very RNA that is to be replicated, rendering 
it very difficult to separate translation from replication in vivo. Thus far, there is little evidence for 
or against miR-122 participating in replication. Mortimer and Doudna noted that miR-122 could 
still bind and stabilize HCV RNA in in vitro assays when point mutations were introduced to the 
miRNA that abolished its ability to affect replication, suggesting that the binding requirements for 
its effect on replication may be different than those for its effect on stability (Mortimer and 
Doudna, 2013). More directly, Norman et al. evaluated the synthesis of new viral RNA when the 
cells were treated with a miR-122 antagonist, but did not see a reduction in RNA synthesis (in fact, 
they observed a slight increase in RNA synthesis), while Villanueva et al. isolated replication 
complexes from cell culture before adding or antagonizing miR-122 and observed no change 
(Norman and Sarnow, 2010; Villanueva et al., 2010). With the replication complexes isolated from 
cells, the researchers could only evaluate the elongation phase of replication, and not initiation of 
the polymerase; however, they were also unable to detect miR-122 in these complexes, suggesting 
it may not be there at all (Villanueva et al., 2010). Thus, although the current consensus is that the 
role for miR-122 is not solely due to its function in stabilizing the viral RNA, it is still unclear 
what other mechanism miR-122 has for enhancing HCV RNA accumulation. 
 
1.2.4 Other miRNAs Binding to the HCV Genome 
At least four other miRNAs have been confirmed to interact with the Hepatitis C virus genome: 
miR-199a*, miR-196, let-7b, and miR-448 (Conrad and Niepmann, 2014; Singaravelu et al., 
2014). Unlike the overall impact of miR-122 binding to the HCV genome, each of these miRNAs 
impacts HCV in a more canonical manner, repressing translation of the viral genome and 
ultimately resulting in reduced replication (Cheng et al., 2012; Hou et al., 2010; Murakami et al., 
2009; Pedersen et al., 2007). These miRNAs may not only suppress translation but could also lead 
to cleavage and degradation of the viral genome; this was only investigated – and found to occur 
– with let-7b, and it is not known whether the others do so (Cheng et al., 2012). Since HCV has an 
error-prone polymerase, each of these sites would have been lost very quickly if they were 
detrimental. This suggests either that these miRNAs do not impact the virus in vivo, or that their 
suppressive effect benefits the virus – again, perhaps by reducing viral titres and limiting 
pathogenicity and immunogenicity (Mahajan et al., 2009). It is also important to note that 
knockdown of the proteins involved in miRNA-mediated translational suppression (such as Ago2) 
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has a net negative impact on HCV replication, indicating that the effect of these miRNAs on HCV 
RNA accumulation does not supersede the positive impact of miR-122 (Bukong et al., 2013; 
Conrad et al., 2013; Roberts et al., 2011; Shimakami et al., 2012a; Wilson et al., 2011). 
 
1.2.5 miR-122 in Other Viral Infections 
miR-122 has been implicated to play a role in at least two other viral infections in humans; 
surprisingly, only one of these is a liver disease. Hepatitis B virus (HBV) is a small, partially 
double-stranded DNA virus that is transmitted by blood and sexual contact, and causes a chronic 
liver infection in about 5% of adult acute infections, although the risk is much higher in children 
and infants (Kuo and Gish, 2012). One of the potential complications of HBV infection is the risk 
of accidental insertion of the viral DNA into the host’s genome, which could cause dysregulation 
of proliferation (for example) and lead to tumourigenesis (Kuo and Gish, 2012). Like an infection 
with Hepatitis C, HBV also causes long-term inflammation and damage that is associated with the 
development of liver cancer (Fallot et al., 2012; Kuo and Gish, 2012). Loss of miR-122 in Hepatitis 
B virus infection leads to increased viral replication; miR-122 directly suppresses CyclinG1 
expression, which results in the release of the antiviral and anti-tumour protein p53 (Wang et al., 
2012). Conversely, addition of miR-122 inhibited HBV replication, and was proposed to limit 
HBV-associated hepatocellular carcinoma by directly suppressing translation of NDRG3 (Fan et 
al., 2011). miR-122 has also been shown to directly bind to conserved HBV sequences, 
suppressing viral replication; in apparent response to this, the HBx viral protein inhibits miR-122 
expression by binding PPARγ, a transcriptional activator of miR-122 (Chen et al., 2011; Song et 
al., 2013). In addition, HBV appears to overproduce the targeted transcript to act as a miR-122 
sponge (Li et al., 2013b). 
The interaction between miR-122 and Borna disease virus (BDV) is less well-studied. BDV is 
a neurotropic virus, but it has been shown to have miR-122-complementary sequences, and 
functional assays have determined that miR-122 exerts a direct suppressive effect on both viral 
replication and translation (Qian et al., 2010). miR-122 also appears to indirectly impact viral 
replication by enhancing interferon signaling (Qian et al., 2010). 
Recently, several other Hepaciviruses have been discovered that bear putative miR-122 
binding sites, and it is possible that the miRNA may play a key role in the replication of these 
viruses too, although no functional assays have been published to determine this (Burbelo et al., 
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2012; Drexler et al., 2013; Kapoor et al., 2011; Kapoor et al., 2013; Lauck et al., 2013; Lyons et 
al., 2012). GB virus B is the closest relative to HCV that has an active culture system; it, too, bears 
two miR-122 binding sites in its 5´ UTR, and binding at these sites also positively modulates RNA 
accumulation of sub-genomic constructs of this virus (Sagan et al., 2013). Unfortunately, not 
enough is known about the origins of GB virus B to provide an explanation of its dependence on 
miR-122 and relation to Hepatitis C virus. The miR-122 sequence is highly conserved among 
mammals; since miR-122 is expressed at highest levels in the liver, and to a much lesser degree in 
other tissues such as nervous tissue, determining the infected tissues and developing culture 
models for these newly-discovered Hepaciviruses – and any others identified in the future – may 
provide some answers about the origins of Hepatitis C virus, and some explanations for its 
dependence on miR-122 and hepatotropism in humans (Chang et al., 2004; Jopling et al., 2005). 
 
1.3 Model Systems for Hepatitis C Virus 
1.3.1 Virus Constructs 
Early research in Hepatitis C virus was hindered by an inability to achieve the complete virus 
life cycle in a single system; workarounds included using bi-cistronic sub-genomic RNA 
constructs to assay replication and retroviral particles coated with HCV envelope proteins to study 
entry (Wang, 2013). In 2005, the first HCV isolate was identified that could complete the full viral 
life cycle, from entry and uncoating, translation and replication, and production of infectious virus 
particles, in a single system, and could further be used to infect animal models (Wakita et al., 
2005). This genotype 2a isolate was known as JFH-1 (for Japanese fulminant hepatitis), and was 
later modified through adaptive mutations to increase titers, and then by replacing the structural 
proteins with those from the J6 isolate, another genotype 2a virus (Date et al., 2004; Lindenbach 
et al., 2005). Additional chimeras have since been developed using the structural proteins from 
other genotypes to evaluate particle production and entry, but the JFH-1 isolate has been most-
heavily utilized as a base for evaluating the complete virus life cycle because it replicates to high 
levels in cell culture. Other isolates commonly used include the Con1 (Construct 1) and NC1 
genotype 1b constructs, the H77 (Hutchinson strain 77) genotype 1a construct, and a new genotype 
2a construct JFH-2 (Vieyres and Pietschmann, 2013). Although these isolates do not reach the 
same titers as the JFH-1-based constructs, they are still often used to understand genotype-specific 
aspects of the virus’ life cycle and verify pan-genotypic findings. 
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Many of the viral RNA constructs used in cell culture also bear reporter genes. There are three 
strategies for inserting a reporter gene in an HCV construct (depicted in Figure 1.3): the first is the 
generation of a bi-cistronic construct (Figure 1.3A), where the reporter is translated from the HCV 
IRES and has a functional stop codon, while the viral genome (either full-length or only the 
essential non-structural proteins) is translated from a second IRES – typically the 
encephalomyocarditis virus (EMCV) IRES (Lohmann et al., 1999; Sheehy et al., 2007; Vieyres 
and Pietschmann, 2013). This requires that the reporter gene have the first 39 nucleotides (13 
amino acids) of the Core protein fused to its N terminus, since the HCV IRES cannot initiate 
translation without them; this also then separates the translation of the viral non-structural proteins 
from the control of the HCV5´ UTR and IRES, which can be beneficial when attempting to 
separate translation and replication, but may introduce artefacts (Lohmann et al., 1999; Lu and 
Wimmer, 1996; Reynolds et al., 1995). The second strategy is to insert the reporter gene in frame 
with the virus polyprotein to produce a mono-cistronic construct (Figure 1.3B), utilizing the virus’ 
existing cleavage sequences to separate the C terminus of the preceding viral protein from the N 
terminus of the reporter, and then append a FMDV 2a slippage site in place of a stop codon (Jones 
et al., 2007a). This ensures that translation of the viral polyprotein continues uninterrupted after 
the reporter, but the slippage site separates the C terminus of the reporter protein from the N 
terminus of the following viral protein. In the most-commonly-used J6/JFH-1 chimeric genome, 
reporter genes such as Renilla or firefly luciferase, Gaussian (secretory) luciferase, neomycin 
phosphotransferase, and fluorescent proteins have been inserted between p7 and NS2 (Jones et al., 
2007a; Sheehy et al., 2007; Vieyres and Pietschmann, 2013). This is considered a less-artificial 
construct as it does not have the second IRES, but both the bi- and mono-cistronic constructs 
containing reporter genes are necessarily longer than the un-manipulated genome, which could 
affect replication efficiency. Finally, it is possible to insert a reporter or tag within the non-
structural coding region of either mono- or bi-cistronic constructs in the C-terminus of the NS5a 
coding region while maintaining the endogenous protease cleavage site between NS5a and NS5b; 
this has been particularly used to tag NS5a with green fluorescent protein or an immunological tag 
for intracellular tracking and pulldowns (Figure 1.3C) (Jones et al., 2007b; McCormick et al., 
2006; Moradpour et al., 2004; Wu et al., 2011). 
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A. General structure of HCV replicons containing a reporter gene or selection marker in the bi-
cistronic arrangement. Boxes represent open reading frames, while linear sections represent non-
coding RNA sequences. Top: Sub-genomic construct lacking structural genes. Bottom: Full-
genomic construct with all viral genes. Note that any gene product translated from the HCV IRES 
requires the first 39 nucleotides (13 amino acids) of the Core coding sequence for the IRES to 
function. B. General structure of HCV constructs containing excisable in-frame reporter gene or 
selection marker. The stop codon of the reporter is removed, and replaced with the short FMDV2a 
cleavage sequence that allows the reporter peptide to be cleaved from the following viral protein 
(e.g. NS2) without interrupting translation of the viral protein. C. General structure of HCV 
constructs with a reporter or tag within the non-structural proteins. The C-terminus of NS5a 
accommodates insertion without significant impairment of viral replication.  
Figure 1.3 HCV constructs containing reporter genes. 
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1.3.2 Cell Culture Models 
The first cell culture models for propagation of Hepatitis C virus made use of freshly-isolated 
human cells such as primary human hepatocytes, as standard lab cell lines were not amenable to 
HCV infection or replication – due in part, we now know, to their lack of miR-122 expression 
(Sheehy et al., 2007; Vieyres and Pietschmann, 2013). Huh7 was the first cell line identified to 
permit HCV replication and quickly became the key system for studying the HCV life cycle. 
Although culture methods for primary human hepatocytes have improved, rendering them useful 
for the study of serum-derived HCV, Huh7-derived cells hold an advantage over primary cell 
systems because they can be readily propagated and are relatively consistent from one experiment 
to the next (Lohmann and Bartenschlager, 2013; Lohmann et al., 2003; Lohmann et al., 1999; 
Molina et al., 2008; Nakabayashi et al., 1982). These cells are a polyclonal human hepatoma cell 
line, and are one of the few hepatoma cell lines that retained some miR-122 expression upon 
transformation and immortalization, which is likely why they were readily permissive to HCV 
replication when so many other cell lines tested were not (Jopling et al., 2005; Thibault et al., 2013; 
Varnholt et al., 2008). Since then, Huh7 cells have been selected and manipulated to a variety of 
ends by different research groups to analyze different aspects of the viral life cycle, whether 
selected for better permissiveness to HCV by maintenance of viral genomes expressing a neomycin 
resistance gene, or transduced by lentiviral vector to express a gene or shRNA to abolish 
expression of a particular gene (Jopling et al., 2005; Vieyres and Pietschmann, 2013). For example, 
Huh7.5 cell are a derivative of Huh7 cells generated by using a viral construct containing a 
neomycin resistance gene; cells were selected with G418 (an antibiotic antagonized by the 
neomycin resistance gene), such that those with greater permissiveness for replication would have 
greater resistance to G418 treatment (Blight et al., 2002). After several rounds of selection, clones 
were isolated and cured of the viral RNA by prolonged interferon treatment – much like a patient. 
The selected Huh7.5 clone was more permissive to HCV replication than the parent Huh7 cell line 
(Blight et al., 2002). In addition, a Huh7-derived reporter cell line was generated by selecting for 
lentiviral transduction with a construct bearing a fluorescent reporter tagged with a nuclear 
localization sequence and an NS3/4a cleavage site also found on the cellular IPS-1 protein (Jones 
et al., 2010a). When these cells are infected with HCV, NS3/4a cleaves the reporter construct, 
revealing the nuclear localization sequence and allowing the fluorescent marker to translocate from 
26 
 
the mitochondrial membrane to the nucleus; this translocation is the indicator of infection and can 
be read independent of active replication (Jones et al., 2010a). 
Huh7 cells and their derivatives originate from a 57-year-old Japanese man with hepatocellular 
carcinoma; recent publications have shown that other human hepatoma cell lines with diverse 
genetic backgrounds can be made to permit the complete virus life cycle as well, such as HepG2, 
Hep3B, and PLC/PRF-5 cells (Aden et al., 1979; Alexander et al., 1976; Date et al., 2004; Kambara 
et al., 2012; MacNab et al., 1976; Narbus et al., 2011; Sainz et al., 2012b; Thibault et al., 2013; 
Watashi et al., 2007; Windisch et al., 2005; Zhu et al., 2007). In particular, addition of miR-122 to 
HepG2 or Hep3B cells was necessary or aided in permitting efficient replication of Hepatitis C 
virus RNA (Kambara et al., 2012; Narbus et al., 2011; Thibault et al., 2013). Hep3B and HepG2 
cell lines transiently or stably expressing miR-122 have been touted as especially useful new 
culture systems because they can be polarized; since several of the HCV entry factors are tight 
junction proteins, fully understanding the entry process requires polarized cells (Mee et al., 2009; 
Narbus et al., 2011; Vieyres and Pietschmann, 2013; Zigmond et al., 2008).  
 In addition to this, since the identification of miR-122 as a key requirement for HCV RNA 
replication, many others have explored addition of miR-122 to non-liver and non-human cell lines 
in an attempt to develop more diverse models for the study of HCV. Non-liver human cell lines 
have been shown to permit low levels of HCV RNA replication with heavy selection and/or when 
miR-122 is supplemented: HeLa cells, HEK-293 cells, FU97 cells, and neuroepithelioma cells (Ali 
et al., 2004; Da Costa et al., 2012; Fletcher et al., 2010; Kato et al., 2005b; Shiokawa et al., 2014; 
Zhu et al., 2003). A wide array of murine liver and fibroblast cell lines have also been employed 
– with or without addition of miR-122 – in an attempt to study host requirements and restriction 
factors, and to develop a small animal model for the study of the HCV life cycle (see also Chapter 
3) (Chang et al., 2006; Frentzen et al., 2011; Frentzen et al., 2013; Lin et al., 2010; Long et al., 
2011; Thibault and Wilson, 2014; Uprichard et al., 2006; Vogt et al., 2013; Yeh et al., 2008; Zhu 
et al., 2003). Particularly, innate immune knockout mouse embryonic fibroblasts (MEFs) such as 
IRF-3 knockouts, or NCoA6 knockout MEFs – a gene in liver-X receptor signaling, unrelated to 
innate immune signaling – have been rendered permissive for transient sub-genomic HCV RNA 
replication upon supplementation with miR-122 (Lin et al., 2010; Thibault and Wilson, 2014). 
Since mammalian liver cells – such as the IPS-1, IRF-3, and IFNAR (interferon-α/β receptor) 
knockout mouse liver cells used by Frentzen et al. – have mature miR-122 that is identical to that 
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found in humans, mouse liver cell lines do not require supplementation with miR-122 unless 
transformation or immortalization results in loss of its expression (Chang et al., 2004; Frentzen et 
al., 2013).   
Primary cell lines, human embryonic stem cells and induced pleuripotent stem cells, liver slices 
and explants, and PBMCs still have important roles to play in our understanding of HCV infection 
(Lagaye et al., 2012; Molina et al., 2008; Roelandt et al., 2012; Schwartz et al., 2012; Vieyres and 
Pietschmann, 2013; Wu et al., 2012). They act as the bridge between the in vitro cell culture models 
and the in vivo animal models in understanding the pathology of the virus, as well as its molecular 
virology. For example, virus particles produced from cell lines discussed above do not have the 
same density profile nor lipoprotein content as serum-derived HCV particles, indicating that while 
secretion from these cells produces infectious virus particles, they are imperfect models for in vivo 
particle production (Lindenbach et al., 2006; Molina et al., 2008; Podevin et al., 2010; Vieyres and 
Pietschmann, 2013). In addition to this, more sophisticated culture methods have been employed 
to mimic the complete liver environment, including 3D culture, micropatterned co-cultures, and 
organoid cultures of both Huh7-derived cell lines and primary hepatocytes (Aly et al., 2009; 
Lohmann and Bartenschlager, 2013; Molina-Jimenez et al., 2012; Ploss et al., 2010; Sainz et al., 
2009). As might be expected, with some of these systems there are trade-offs in terms of viral 
RNA production and titer, but these ex vivo models provide another system to develop new avenues 
of research, as well as to verify or refute findings in cell culture that could otherwise prove to be 
artifactual (Steinmann and Pietschmann, 2013; Vieyres and Pietschmann, 2013).  
 
1.3.3 Animal Model Systems 
Chimpanzees were the first animal model to permit HCV infection, and were in fact 
instrumental to the discovery of the causative agent of non-A non-B Hepatitis (Choo et al., 1989; 
Houghton, 2009). To date, they are still the only demonstrated immunocompetent animal model 
for HCV infection for that analysis of the adaptive immune response and vaccine development 
(Bukh, 2012; Park and Rehermann, 2014). However, chimpanzees imperfectly mimic the disease 
course of HCV in humans, as a much smaller percentage of them progress from acute infection to 
chronic infection, and they do not show the fibrosis or cirrhosis observed in chronically-infected 
humans (Lanford et al., 2001). Additionally, chimpanzee research has always been expensive and 
fraught with ethical concerns, and most recently, it has all but been halted in most of the world due 
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to the ethical ramifications of using an endangered species for biomedical research (Harrington, 
2012; Mailly et al., 2013; Wadman, 2013). 
Much effort has gone into the development of a small animal model for HCV, particularly a 
mouse model because of the availability of genetic knockouts. One of the most successful models 
has been the human liver xenograft SCID (severe combined immune-deficient)-uPA mouse: this 
mouse is deficient in both B- and T-cells and therefore lacks an adaptive immune system, and is 
also transgenic for the urokinase-type plasminogen activator that caused degeneration of the 
mouse’s hepatocytes. This mouse is then implanted with human liver cells – because of its lack of 
an adaptive immune system, it cannot reject the xenograft – that take over the function of the 
mouse’s liver and can be infected with Hepatitis C virus (Mercer et al., 2001b). This mouse model, 
and another similar to it where mouse hepatocyte death is held off by a drug treatment until the 
time of xenografting, supports efficient infection with cell-culture and patient-derived viruses and 
demonstrates viremia similar to that in humans (Bissig et al., 2010; Mercer et al., 2001b). These 
mice have been valuable for the study of direct-acting antivirals and innate immune responses to 
the virus, along with the various stages of the virus’ life cycle in vitro; their major disadvantages 
are the heterogeneity of the human liver samples, and their lack of adaptive immune system that 
precludes the study of immunopathogenesis (Bukh, 2012; Meuleman and Leroux-Roels, 2008; 
Sandmann and Ploss, 2013).  
Other small animal models have been developed in an attempt to overcome these 
disadvantages: for example, the AFC7/huHSC-hep mice lack their own immune system, but are 
partially reconstituted with a human immune system (human hematopoeic stem cells), and human 
hepatocyte progenitors (Washburn et al., 2011). These mice do not produce detectable viremia, as 
human hepatocyte engraftment efficiency is quite low, but HCV infection has been confirmed, and 
these mice do reproduce cell-mediated responses, along with hepatitis and fibrosis associated with 
immunopathology of infection (Bukh, 2012; Washburn et al., 2011). Another interesting small 
animal model, the tree shrew (Tupaia belangeri), also mimics much of the pathogenesis of 
infection, including progression to chronicity, fibrosis and cirrhosis, and hepatocellular carcinoma 
(Amako et al., 2010; Bukh, 2012; Sandmann and Ploss, 2013). Viremia is low but detectable, and 
the animal is fully immunocompetent. However, immune responses and effects of antiviral therapy 
have not yet been examined in this model to validate it for all aspects of infection (Amako et al., 
2010; Xu et al., 2007). 
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Since the finding that mouse liver cells could permit replication of HCV RNA, a major 
remaining hurdle for an all-mouse model of HCV infection was the inability of the virus to use 
murine receptors – namely, CD81 and Occludin (Dorner et al., 2011; Frentzen et al., 2011; 
Frentzen et al., 2013; Ploss et al., 2009). Dorner et al. verified this by infecting mice with 
adenovirus expression vectors for CD81 and Occludin, and then infecting the mice with HCV 
(Dorner et al., 2011). While replication could not be detected in these mice, infection (that is, entry, 
uncoating, and translation) was detected using a reporter as described for Huh7 cells above, where 
infection causes NS3/4a-mediated cleavage of the IPS-1 sequence and translocation of 
fluorescence to the nucleus (Dorner et al., 2011). Transduction efficiency of liver cells with all 
receptors in the adenovirus-infected mice was very inefficient, and the adenovirus vectors 
themselves induced interferon responses that could have inhibited Hepatitis C virus, so these 
researchers then generated mice transgenic for the required entry receptors and verified their 
increased permissiveness for entry (Dorner et al., 2013b). By crossing these transgenic mice with 
Stat1-/- mice, they could be rendered susceptible to the complete virus life cycle, and infection was 
responsive to treatment with direct-acting antivirals (Dorner et al., 2013a). Although viral titers 
were very low in these mice, the infection persisted for 90 days in most mice before becoming 
undetectable; it is not yet clear whether the mice mounted a successful immune response to the 
virus and cleared it, or whether they are still deficient in some human factor the virus requires for 
chronic infection. These mice still have an adaptive immune system, but because the complete 
virus life cycle was best achieved by crossing with innate immune knockout mice, it is not yet 
known if these mice will truly recapitulate the immune responses and immunopathology of 
Hepatitis C virus infection in humans (Dorner et al., 2013a). 
 
1.4 Conclusions 
Systems to study the infection and life cycle of Hepatitis C virus have improved drastically in 
the last 10 years, and with them have come valuable advances in understanding virus-host 
interactions and the development of direct-acting antiviral drugs and early attempts at vaccines, as 
described above. These same drugs and vaccines also offer hope for eventual eradication of 
Hepatitis C virus infection. The identification of miR-122 as a required host factor for HCV 
replication has aided in development of both new cell culture systems and antiviral therapies, and 
has opened up a new avenue of investigation into the way a virus can hijack host pathways for its 
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own ends. Understanding the various functions of miR-122 in the HCV life cycle will provide 
more information on the relatively-unclear regulation and process of HCV RNA replication, and 
may also provide additional insight into mechanisms of miRNA functions in eukaryotic cells. The 
link between miR-122 and cancer may also be exploitable to understand HCV-associated 
hepatocellular carcinoma and prevention of carcinogenesis in chronically infected patients. As new 
relatives to Hepatitis C virus are discovered, the maintenance of one or both miR-122 binding sites 
may also provide clues as to the origin of HCV and other Hepaciviruses and their spread in their 
respective hosts.  
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2.0 Hypotheses and Objectives 
2.1 Rationale and Hypothesis 
microRNA-122 has been deemed crucial to the Hepatitis C virus life cycle through its binding 
to two sites on the 5´ UTR of the viral RNA, which has a drastic positive impact on HCV RNA 
accumulation. miR-122 is highly abundant in the liver, and found only at much lower levels in 
other body tissues, and has been implicated as a major determinant in Hepatitis C virus’ liver 
tropism. In addition, there are limited cell culture and animal model systems that permit the full 
Hepatitis C virus life cycle or infection. Thus, we set out to explore the possibility that we could 
exploit miR-122 to expand the tropism of HCV and broaden the repertoire of cell culture systems 
to study Hepatitis C virus. We further aimed to use our new system(s) to better understand the 
mechanism of the effect of miR-122 on the Hepatitis C virus life cycle. We hypothesized that 
addition of miR-122 to non-permissive non-human and human cell lines would render them 
permissive for part or all of the HCV life cycle, and we further hypothesized that these cell lines 
would be useful for providing new insights into how miR-122 promotes the Hepatitis C virus life 
cycle. 
 
2.2 Objectives 
i. Supplement wild-type and HCV restriction factor (PKR and NCoA6) gene knockout 
murine embryonic fibroblasts (MEFs) with miR-122 and test for permissiveness to sub-
genomic and full-length HCV replication. 
ii. Test hepatocytes from most-permissive knockout mice (PKR) for permissiveness to 
HCV replication. 
iii. Supplement Hep3B cells (a human hepatocellular carcinoma cell line) with miR-122 
and test for permissiveness to sub-genomic and full-length HCV replication. 
 
Based on results from experiments in Hep3B cells, additional objectives were defined: 
iv. Verify miR-122-independent replication of sub-genomic HCV RNA replication in 
Hep3B cells and Huh7.5 cells (Huh 7.5 cells are the widely-accepted model system to 
study the HCV life cycle). 
v. Examine the role of each miR-122 binding site in the known functions for miR-122 in 
the Hepatitis C virus life cycle. 
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3.1  Abstract 
Hepatitis C virus (HCV) is a serious global health problem, infecting almost 3% of the world’s 
population. The lack of model systems for studying this virus limit research options in vaccine and 
therapeutic development, as well as for studying the pathogenesis of chronic HCV infection. 
Herein we make use of the liver-specific microRNA miR-122 to render mouse cell lines permissive 
to HCV replication in an attempt to develop additional model systems for the identification of new 
features of the virus and its life cycle. We have determined that some wild-type and knockout 
mouse cell lines – NCoA6 and PKR knockout embryonic fibroblasts – can be rendered permissive 
to transient HCV sub-genomic RNA replication upon addition of miR-122, but we did not observe 
replication of full-length HCV RNA in these cells. However, other wild-type and knockout cell 
lines cannot be rendered permissive to HCV replication by addition of miR-122, and in fact, 
different NCoA6 and PKR knockout cell line passages and isolates from the same mice 
demonstrated varying permissiveness phenotypes and eventually complete loss of permissiveness. 
When we tested knockdown of NCoA6 and PKR in Huh7.5 cells, we saw no substantial impact in 
sub-genomic HCV replication, which we would expect if these genes were inhibitory to the virus’ 
life cycle. This leads us to conclude that along with the influence of specific gene knockouts there 
are additional factors within the cell lines that affect their permissiveness for HCV replication; we 
suggest that these may be epigenetically regulated, or modulated by cell line immortalization and 
transformation.  
 
3.2 Introduction 
Hepatitis C is a blood-borne viral disease prevalent worldwide; current estimates suggest 
approximately 150 million people are infected (WHO, 2012). Hepatitis C virus (HCV) becomes 
chronic in approximately 70% of acute infections, and can lead to the development of various 
cancers, liver steatosis, and numerous other complications throughout infection (Strader et al., 
2004). A member of the Flaviviridae family, HCV is an enveloped virus with a single-stranded 
RNA genome of positive orientation, and is a member of the genus Hepacivirus. The HCV genome 
is approximately 9.6kb in length, and consists of an uncapped 5´ un-translated region (UTR) 
containing significant secondary RNA structure deemed essential for viral RNA replication and 
an internal ribosomal entry site (IRES) essential for translation, followed by a single open reading 
frame (ORF) containing all the viral genes, and completed by a 3´ UTR with further secondary 
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RNA structures necessary for genome replication (Bartenschlager et al., 2004). The single ORF of 
the virus is translated as a polyprotein that is then cleaved into the individual viral proteins by both 
cellular and viral proteases (Bartenschlager et al., 2004).  
At least two aspects of the viral life cycle are major determinants of host range and cell 
specificity for Hepatitis C virus. Entry factors appear to define host range of the virus, as has been 
demonstrated both in vitro and in vivo: addition of human CD81 and human Occludin to murine 
cells permits entry of the virus, while generation of mice transgenic for these factors has permitted 
infection (Ploss et al., 2009; Vogt et al., 2013). However, these and other identified receptors – 
SR-B1, Claudin-1, TfR1, NPC1-L1, Syndecan-1, EGFR, and EphA2 – do not appear to define the 
liver specificity of HCV, as they can be found on and in many other human cell types as well 
(Dorner et al., 2013a; Dorner et al., 2013b; Evans et al., 2007; Lupberger et al., 2011; Martin and 
Uprichard, 2013; Pileri et al., 1998; Ploss et al., 2009; Sainz et al., 2012a; Scarselli et al., 2002; 
Shi et al., 2013; Vogt et al., 2013). ApoE expression (murine or human), which is liver-specific, 
does appear to be a requirement for production of infectious virions following infection, but is not 
required in the host cell for earlier stages of entry or RNA replication (Chang et al., 2007; Frentzen 
et al., 2013; Vogt et al., 2013). 
A host factor that likely influences liver-specificity of HCV replication is miR-122, a liver-
specific microRNA that binds to two sites on the 5´ UTR of the HCV genome (Jopling et al., 2006; 
Jopling et al., 2008; Jopling et al., 2005). This miRNA is highly abundant in the liver, accounting 
for approximately 70% of the small regulatory RNAs in hepatocytes; while its role in the liver is 
not yet completely defined, it does appear to regulate typical aspects of liver cell function such as 
cholesterol production and secretion, and it is also implicated as a tumour-suppressor microRNA 
(Bai et al., 2009; Esau et al., 2006; Norman and Sarnow, 2010; Xu et al., 2012). Interestingly, we 
and others have shown that expression of miR-122 in human liver cell lines previously considered 
refractory to HCV replication renders the cells permissive to HCV replication (Kambara et al., 
2012; Narbus et al., 2011; Thibault et al., 2013). This has also been demonstrated in other non-
human and non-liver cell lines, mostly through use of stable replicons rather than transient 
replication (Chang et al., 2008; Fukuhara et al., 2012; Lin et al., 2010).  
There is a need for more and better model systems in HCV research. Although we have recently 
begun adding other human and hepatocyte-derived cell culture systems to the predominant Huh7-
derived cell lines, non-human – particularly murine – cell lines remain a critical stepping-stone to 
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animal model development. A series of efforts using knockout mouse cells, selectable virus 
replicons, and human factor transduction has recently culminated in multiple research groups 
achieving the complete virus life cycle in mouse cells expressing the required entry and liver 
factors (Frentzen et al., 2013; Nandakumar et al., 2013; Vogt et al., 2013), but animal models of 
HCV infection are still limited (MacArthur et al., 2012). HCV mouse models relying on SCID-
uPA mice supporting xenografted human liver tissue can be infected, and virus-induced 
pathogenesis or drug response studied, but the mice have limited life spans, lack immune systems, 
and are expensive to produce (Mercer et al., 2001a). Similar mice have only recently been 
developed to contain a humanized immune system, but the expense of these animals, as well as 
the fact that their livers and immune systems come from humans and vary between each 
xenografted mouse, remains an obstacle for their widespread use in HCV studies (Bility et al., 
2012; Robinet and Baumert, 2011). Most recently, the human CD81/Occludin transgenic mouse 
model developed by Dorner et al. has been demonstrated to support the entire viral life cycle, but 
since it relies on innate immune gene knockouts such as Stat1 or IFNα/β, it is as yet unknown how 
much of the immune-mediated pathology will be recapitulated (Dorner et al., 2013a). The 
chimpanzee best represents the disease in humans, but they are currently not available for most 
research, and present both ethical and financial obstacles (MacArthur et al., 2012; Ploss and Rice, 
2009; Wadman, 2013). Tree shrews (Tupaia belangeri) have also been identified as a potential 
model for HCV chronicity and pathogenesis, but they have also not yet been evaluated for 
immunological aspects of the infection (Amako et al., 2010; Xie et al., 1998; Xu et al., 2007).  
Thus, we chose to examine mouse cell lines to identify other genetic knockouts that could 
render mouse cells, and potentially the mice of origin, permissive to HCV replication. We 
identified one wild-type and two knockout mouse embryonic fibroblast (MEF) cell lines, “GH” 
wild-type, and NCoA6 and PKR knockout cells, that were permissive to transient, unselected sub-
genomic HCV RNA replication when supplemented with miR-122. GH wild-type MEFs permitted 
only low levels of sub-genomic HCV RNA replication, while PKR MEFs initially supported high 
levels of sub-genomic RNA replication, but later passages, alternate isolates, and alternate sources 
of PKR knockout cells did not display a permissive phenotype. NCoA6 knockout cells also 
supported sub-genomic HCV RNA replication, although not to the levels seen in PKR MEFs, and 
HCV RNA replication in these cells also varied with cell passage. Since PKR and NCoA6 
knockdown in Huh7.5 cells had only a minor impact on sub-genomic RNA replication, we 
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conclude that the permissiveness of our mouse cell lines, while possibly modulated by the gene 
knockout, was also defined by other aspects of the cell. We speculate that cell line modifications 
induced by culturing, immortalization, transformation, or other epigenetic changes also impact 
permissiveness of cells to HCV replication. 
 
3.3 Results 
3.3.1 One wild-type MEF cell line is permissive to HCV replication when supplemented with miR-
122, while others are not. 
Wild-type MEFs from multiple sources were tested for permissiveness to HCV replication by 
electroporating cells with either wild-type (WT) or replication-incompetent (GND) sub-genomic 
HCV RNA, and supplementing the cells with either a control miRNA (miControl) or miR-122. 
Since the HCV RNA expresses a firefly luciferase reporter gene, replication was monitored by 
assaying firefly luciferase expression; firefly reporter luciferase expression from the wild-type 
viral RNA was compared to the non-replicating polymerase GND mutant to confirm replication, 
and electroporation efficiency was similar in all cases as determined by co-electroporation of a 
Renilla luciferase mRNA (data not shown). The MEFs depicted in Figure 3.1A were permissive 
to low levels of sub-genomic HCV RNA accumulation when electroporated with synthetic miR-
122; however, the raw luciferase expression was approximately a thousand-fold lower than is 
typical in Huh7.5 cells, which was reflected in our inability to detect RNA accumulation via 
northern blot (data not shown). In a different wild-type MEF cell line, sub-genomic HCV RNA 
was unable to replicate in any detectable manner regardless of miR-122 supplementation (Figure 
3.1B). In fact, of the five wild-type MEF cell lines we tested, as well as commonly-available NIH 
3T3 cells (data not shown), only those shown in Figure 3.1A demonstrated detectable HCV 
replication. We therefore conclude that some wild-type MEFs are permissive to low levels of 
transient sub-genomic HCV replication when supplemented with miR-122. As we later observed 
with other knockout mouse cell lines, permissiveness of these MEFs varied through passage, 
although not in a predictable manner. 
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Figure 3.1 Mouse cells with no known knockouts have varying permissiveness to HCV 
replication when supplemented with miR-122. 
A. Wild-type MEFs obtained from Gregory Hannon were electroporated with either wild-type 
(WT) or replication-incompetent (GND) sub-genomic HCV RNA and the indicated miRNA 
(miControl, or miR-122), and luciferase expression was monitored at the indicated time points as 
a measure of HCV replication. B. Wild-type MEFs obtained from Per Antonson were treated as 
indicated in (A). Results from (A) and (B) are displayed as mean and standard error of the mean 
(SEM) of three or more independent experiments. 
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3.3.2 PKR knockout MEFs are permissive to high levels of sub-genomic HCV RNA replication 
when supplemented with miR-122, but did not maintain their phenotype between passages and 
isolates. 
Protein kinase R (PKR) is a known anti-viral protein in mammalian cells (Dabo and Meurs, 
2012), and PKR knockout MEFs were reported to support colony formation with selectable sub-
genomic HCV more efficiently than wild-type MEFs (Chang et al., 2006; Vogt et al., 2013). Thus 
we hypothesized that PKR knockout MEFs would support efficient transient HCV replication if 
supplemented with miR-122. Upon electroporation of primary PKR knockout MEFs acquired from 
John Bell (Abraham et al., 1999) with sub-genomic HCV RNA and miR-122 (Figure 3.2A), we 
observed high levels of luciferase reporter expression, comparable to the levels achieved in Huh7.5 
cells, the most common cell line used for HCV research. Northern blot analysis confirmed sub-
genomic HCV RNA accumulation in these PKR knockout MEFs (Figure 3.2B), and levels were 
within 2-fold of those observed in Huh7.5 cells, which verified that luciferase expression 
accurately reflected HCV RNA accumulation (Figure 3.2C).  
These data were generated from two replicate experiments with a single isolate of primary 
PKR MEFs that we now believe to have been different from other PKR MEFs we tested. When 
further replicates were attempted with other isolates of PKR MEFs, we were unsuccessful in 
achieving detectable replication (data not shown), including PKR knockout MEFs obtained from 
Robert Silverman, which had been shown previously to support HCV replicon colony formation 
(Yang et al., 1995). Moreover, primary MEFs (Figure 3.2D) that we isolated from PKR knockout 
mice could support only low levels of HCV replication in the presence of miR-122, and primary 
PKR knockout hepatocytes did not support detectable HCV replication at all (Figure 3.2E and 
3.2F), despite efficient RNA transfection (based on luciferase expression 2 and 4 hours post-
transfection) by both electroporation (Figure 3.2E) and transfection (Figure 3.2F). Since PKR 
MEFs are visually distinct from Huh 7.5 cells, the only other cell line in use in our lab at the time, 
and our PKR MEFs did not replicate HCV in the absence of miR-122 (Figure 3.2A, WT + 
miControl), we omit contamination of the MEF cell line with Huh 7.5 cells as a possible 
explanation for positive results shown in Figure 3.2A. Therefore we show that a single isolate of 
PKR knockout MEFs was highly permissive for transient HCV RNA replication when 
supplemented with miR-122. 
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A. PKR knockout MEFs were treated as in Figure 3.1, and sub-genomic HCV replication was 
monitored at the indicated time points via luciferase expression. Results are shown with SEM, and 
are an average of two independent experiments. B. RNA from (A) was isolated from PKR 
knockout MEFs three days post-electroporation and probed for HCV RNA accumulation by 
northern blot, with GAPDH as a loading control. C. RNA from (A) was compared with RNA from 
Huh7.5 cells via northern blot. Bands from two independent experiments were quantified by 
densitometry, and normalized to GAPDH. Percentage HCV RNA +/- standard deviation is 
presented relative to Huh7.5 cells. D. Primary MEFs isolated from PKR knockout mice were 
treated as in Figure 3.1. Results are shown with SEM and are an average of nine independent 
experiments. E. Primary hepatocytes were isolated from PKR knockout mice and electroporated 
with sub-genomic RNA and miR-122. Luciferase expression was evaluated four hours post-
electroporation to assess RNA transfection efficiency and three days post-electroporation to detect 
sub-genomic RNA replication. Reporter activity above non-replicating (GND) levels was not 
detected. Results are an average of four experiments, shown with standard deviation. F. Primary 
hepatocytes isolated from PKR knockout mice were transfected via Lipofectamine 2000 with sub-
genomic RNA and miR-122, and evaluated as in (E). Reporter activity above non-replicating 
(GND) levels was not detected. Results are an average of six experiments, shown with SEM. G. 
Huh7.5 cells were first electroporated with the indicated siRNAs (siControl or siPKR), three days 
before a second electroporation (Day 0) with the indicated sub-genomic HCV RNA (wild-type 
(WT) or S1+S2:p3) and a second dose of siRNA. Results are an average of six independent 
experiments, shown with SEM. Experiments were analyzed with a two-way repeated measures 
ANOVA, and differences with siRNA treatment were not found to be statistically significant. H. 
The effect of PKR knockdown on HCV replication in Huh7.5 cells was evaluated by examining 
the fold-change in replication over siControl-treated cells that is caused by siPKR treatment. Error 
is shown as SEM. I. PKR knockdown in Huh7.5 cells was confirmed by qRT-PCR, and is shown 
as an average of three experiments with SEM. 
  
Figure 3.2 PKR knockout MEFs are permissive to sub-genomic HCV RNA replication when 
supplemented with miR-122. 
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To determine the influence of PKR on cell permissiveness for HCV, we tested the effects of 
PKR knockdown in Huh7.5 cells. Huh7.5 cells were electroporated with siRNA to PKR (siPKR) 
or to a control sequence (siControl) and allowed three days for the knockdown to take effect. The 
cells were then electroporated again with the indicated siRNA, as well as wild-type (WT) sub-
genomic HCV RNA or miR-122 binding site mutant (S1+S2:p3) sub-genomic RNA (Figure 3.2G). 
Because Huh7.5 cells already express miR-122, it was not added in this assay. The S1+S2:p3 RNA 
was tested because it is not responsive to miR-122, but is capable of replicating at low levels 
without miRNA supplementation, and so may be more sensitive to removal of anti-viral factors 
because the cell’s machinery is not saturated. Both wild-type and S1+S2:p3 sub-genomic 
luciferase reporter expression was increased between 1.2 and 1.5-fold by knockdown of PKR 
(Figure 3.2H), but this increase was not significant when tested by two-way ANOVA (Figure 
3.2G). Treatment of Huh7.5 cells with siPKR reduced PKR mRNA levels by 75% as measured by 
qRT-PCR (Figure 3.2I). Because knockdown of PKR in Huh7.5 cells has no significant impact on 
HCV RNA replication, we suggest that the permissive phenotype of the particular isolate of PKR 
knockout MEFs depicted in Figure 3.2A, B, and C may not be due to the genetic knockout, and 
may instead be due to other factors unique to that isolate. 
 
3.3.3 NCoA6 knockout MEFs are permissive to sub-genomic HCV RNA replication upon 
supplementation with miR-122, but do not maintain their phenotype between passages. 
Nuclear co-activator 6 (NCoA6, also known as RAP250, TRBP, NRC, ASC2, and PTIP) is a 
member of the nuclear receptor co-activator family, and aids in activation of the liver X receptor 
(LXRα) (Kim et al., 2003; Li et al., 2007; Mahajan and Samuels, 2005). This leads to transcription 
of genes involved in cholesterol metabolism and export, which may impact HCV replication and 
production of virus particles (Mahajan and Samuels, 2005). NCoA6 was also detected in a large-
scale siRNA screen to negatively impact HCV replication, but is not associated with major innate 
immune deficiencies (Tai et al., 2009). We therefore acquired NCoA6 knockout MEFs from Per 
Antonson to test this knockout for permissiveness to HCV replication (Antonson et al., 2003). 
When electroporated with sub-genomic HCV and miR-122, these cells demonstrated levels of 
luciferase (Figure 3.3A) and HCV RNA (Figure 3.3B) that, while robust, were not as high as those 
detected in PKR knockout MEFs, nor in Huh7.5 cells (data not shown). The knockout is 
embryonic-lethal, so we were unable to acquire mice and generate hepatocytes to test for additional 
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A. NCoA6 knockout MEFs were treated as in Figure 3.1, and sub-genomic HCV replication was 
monitored at the indicated time points via luciferase expression. Results are an average of four 
experiments, shown with SEM. B. RNA from (A) was isolated from NCoA6 knockout MEFs three 
days post-electroporation and evaluated for HCV RNA accumulation by northern blot, with 
GAPDH as a loading control. C. Huh7.5 cells were first electroporated with the indicated siRNAs 
(siControl or siNCoA6), three days before a second electroporation (Day 0) with the indicated sub-
genomic HCV RNA (Wild-type (WT) or S1+S2:p3) and a second dose of siRNA. Replication was 
evaluated by luciferase expression. Results are an average of five independent experiments, shown 
with SEM. Experiments were analyzed with a two-way repeated measures ANOVA, and 
differences with siRNA treatment were not found to be statistically significant. D. The effect of 
NCoA6 knockdown on HCV replication in Huh7.5 cells was evaluated by examining the fold-
change in replication over siControl-treated cells that is caused by siNCoA6 treatment, and are 
shown with SEM. E. NCoA6 knockdown in Huh7.5 cells was confirmed by qRT-PCR in an 
average of three independent experiments, and is shown with SEM.  
Figure 3.3 NCoA6 knockout MEFs are permissive to sub-genomic HCV RNA replication upon 
supplementation with miR-122. 
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permissiveness (Antonson et al., 2003). In addition, the NCoA6 knockout MEFs displayed varying 
levels of permissiveness to HCV RNA replication, with no clear correlation between isolate, 
passage number, or experiment date; data shown here is from strongly-permissive cells, and we 
did eventually exhaust our stocks of permissive cells. 
As we did for PKR, we also tested the NCoA6 knockdown phenotype in Huh7.5 cells via 
siRNA knockdown. Knockdown of NCoA6 increased luciferase expression from both miR-122-
dependent (WT) and miR-122-independent (S1+S2:p3) sub-genomic replicons (Figure 3.3C) 1.4 
to 1.8-fold at days 2 and 3 post-second electroporation (Figure 3.3D), but the effect of siNCoA6 
treatment was not statistically significant as determined by a two-way ANOVA. siNCoA6 
treatment of Huh7.5 cells resulted in a 68% reduction in NCoA6 mRNA levels in comparison to 
siControl treatment, relative to GAPDH mRNA (Figure 3.3E). As NCoA6 knockdown also has no 
significant impact on HCV RNA replication in Huh7.5 cells, we suggest that, as we found with 
the PKR knockout cells, the knockout of NCoA6 in the MEFs may not be responsible for the 
permissive phenotype of these cells. 
 
3.3.4 NCoA6 knockout MEFs are not permissive for full-length HCV RNA replication. 
To further investigate the possibility of using knockout MEFs as a model for HCV replication, 
we examined NCoA6 knockout cells’ permissiveness for full-length HCV RNA replication. The 
cells were electroporated with J6/JFH-1(p7-Rluc2a), a full-length mono-cistronic HCV RNA 
construct that bears the virus’ structural proteins and a Renilla luciferase reporter. Wild-type full-
length (FL WT) HCV RNA was electroporated with either miControl or miR-122 (Figure 3.4A). 
Although sub-genomic HCV RNA, included as a positive control, showed the cells to be 
permissive for replication of HCV RNA, and a firefly luciferase mRNA was included to confirm 
consistent electroporation efficiency (data not shown), full-length HCV RNA did not replicate 
detectably when supplemented with miR-122. In addition, when supernatant was collected from 
the MEFs on Day 5 and transferred to susceptible Huh7.5 cells, no infectious virus was detected 
(Figure 3.4B). In our hands, luciferase expression in reporter virus infected cells is sensitive 
enough to detect a single HCV focus-forming unit (FFU; data not shown), indicating that the full-
length RNA did not produce infectious virus in NCoA6 knockout MEFs. Therefore, NCoA6 cells, 
while competent for sub-genomic replication, do not permit replication of full-length HCV RNA 
or production of infectious virus particles. 
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Figure 3.4 NCoA6 knockout MEFs are not permissive for full-length HCV RNA replication. 
A. NCoA6 knockout MEFs were electroporated with full-length HCV RNA or sub-genomic HCV 
RNA and the indicated miRNA. Note that sub-genomic HCV RNA uses a firefly luciferase 
reporter, while full-length HCV RNA uses a Renilla luciferase reporter, and the relative light units 
measured (RLU) are not directly comparable. B. Supernatant from NCoA6 knockout MEFs 
electroporated with full-length HCV RNA was harvested five days post-electroporation and plated 
on Huh7.5 cells, which are permissive for HCV infection and replication without additional 
modification. Three days post-infection, the Huh7.5 cells were monitored for luciferase expression 
as an indication of replication. The luciferase levels indicated here are equivalent to background. 
Results in (A) and (B) are shown with SEM and are an average of three independent experiments.  
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3.3.5 Sub-genomic HCV RNA replication is unaffected by co-electroporated full-length RNA. 
One explanation for the inability of full-length HCV RNA to replicate in NCoA6 MEFs is that 
the full length RNA, or structural proteins expressed by it, activate murine innate immune sensors 
in the mouse cells, leading to induction of an anti-viral response. To test this we co-electroporated 
NCoA6 knockout MEFs with sub-genomic and full-length HCV RNA simultaneously, with the 
expectation that if the full length HCV genomic RNA was inducing an antiviral response in the 
host cell, then replication of the co-electroporated SGR RNA will be negatively influenced by the 
presence of full length HCV RNA. Because electroporation results in a >95% efficiency of RNA 
transfection in MEFs (data not shown), we were confident that the majority of cells would receive 
both viral RNAs, as well as the indicated miRNA. The sub-genomic construct encodes firefly 
luciferase (Figure 3.5A), while the full-length construct encodes Renilla luciferase (Figure 3.5B); 
each luciferase utilizes a different substrate, and so their expression can be evaluated separately 
within the same sample. There was no indication of trans-inhibition of SGR replication by full-
length HCV RNA, since replication of sub-genomic RNA was not impacted by addition of full-
length RNA (SGR + FL [miR-122], Figure 3.5A), and replication levels were similar to those seen 
in cells electroporated with SGR RNA alone (SGR [miR-122], Figure 3.5A). As expected, no sub-
genomic RNA reporter activity was identified in the sample that contained only full-length RNA 
(FL [miR-122]), and no sub-genomic replication was detected in cells given sub-genomic RNA 
without miR-122 (SGR [miControl]). This led us to conclude that the full-length RNA did not 
activate a trans-acting anti-viral response, nor cause any changes in the cell that could affect sub-
genomic RNA replication. Due to the design of the assay, when firefly (sub-genomic) luciferase 
levels are very high, some signal will bleed through into the Renilla (full-length) measurement 
even when no full-length RNA is present (SGR [miR-122], Figure 3.5B). No detectable full-length 
replication was observed in any of the samples (Figure 3.5B), showing that sub-genomic RNA was 
also unable to trans-complement full-length replication. In addition, tissue culture supernatant 
from these experiments demonstrated no detectable infectivity in Huh7.5 cells (Figure 3.5C), 
showing that the full-length RNA also did not produce sufficient levels of structural protein to 
trans-package the sub-genomic HCV RNA (Pacini et al., 2009).  
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Figure 3.5 The inability of full-length HCV RNA to replicate in NCoA6 knockout MEFs cannot 
be complemented by sub-genomic HCV RNA, and sub-genomic RNA is not packaged into 
particles when co-electroporated with full-length HCV RNA. 
NCoA6 knockout MEFs were electroporated with sub-genomic and/or full-length HCV RNA as 
indicated, and either miControl or miR-122. A. Sub-genomic HCV RNA encodes a firefly 
luciferase reporter that was monitored simultaneously with B. the full-length HCV RNA Renilla 
luciferase reporter in these cells at the indicated time points. C. Supernatant from the cells in (A, 
B) was collected three days post-electroporation and plated on permissive Huh7.5 cells to test for 
infectivity. Three days post-infection, Huh7.5 cells were monitored for both firefly (dark grey, 
Full-length) and Renilla luciferase (light grey, Sub-genomic) reporter activity to detect either 
production of infectious particles containing trans-packaged sub-genomic HCV RNA or full-
length HCV RNA respectively. Luciferase levels indicated here are equivalent to background. 
Results in (A), (B), and (C) are shown with SEM and are an average of five independent 
experiments.  
  
47 
 
3.4 Discussion 
Here we demonstrate that supplementing non-permissive mouse cells with miR-122 can render 
them permissive to transient sub-genomic HCV RNA replication; we bypass the human entry 
factor requirements by electroporating cells with viral RNA, rather than infecting them. miR-122 
is a liver-specific co-factor that is important for HCV RNA replication, and has thus been 
implicated in defining tissue tropism for the virus, and we confirm this as its addition renders 
murine embryonic fibroblasts permissive to HCV RNA replication. We identified wild-type and 
knockout (PKR and NCoA6) mouse embryonic fibroblasts that were permissive to detectable 
levels of HCV RNA replication when supplemented with miR-122. In general the gene knockouts 
increased the levels of HCV replication above that seen in wild-type MEFs and suggest that part 
of the permissive phenotype is mediated by the gene knockout as has been shown by others (Dorner 
et al., 2013a; Frentzen et al., 2013; Lin et al., 2010; Nandakumar et al., 2013; Vogt et al., 2013); 
however, we note that alternate isolates of wild-type and knockout MEFs were not permissive to 
HCV replication, and the permissiveness of each cell line further varied by passage and isolate. 
This variation was particularly observed with PKR knockout MEFs and hepatocytes from different 
isolates and multiple backgrounds (Figure 3.2), but was also observed with the wild-type and 
NCoA6 knockout MEFs through cell passage. In addition, when evaluating knockdown of either 
PKR or NCoA6 expression in the already-permissive Huh7.5 cells in the context of sub-genomic 
replication, we observed an insignificant pro-viral effect that we deemed unable to account for the 
permissiveness of the knockout in mouse cells, which leads us to suggest that at least part of the 
permissive phenotype of the knockout cell line is not directly due to the particular gene that is 
abolished. This, however, does not preclude the possibility that there are host and cell-type specific 
factors that may explain the lack of effect of knockdown in Huh7.5 cells. HCV, while adept at 
circumventing human host defense proteins such as PKR, could still be susceptible to murine PKR 
and this may be one of the reasons that the PKR knockout MEFs did originally permit high levels 
of replication. It is also possible that the absence of NCoA6 in non-hepatic cells (fibroblasts) had 
a more drastic effect than knockdown of NCoA6 in the liver-derived Huh7.5 cells, as modulation 
of lipids in liver-derived cells may be more nuanced or have more redundancies active than in 
fibroblasts; it is also possible that there is a species-specific effect of NCoA6 as we speculate with 
PKR. Ultimately, the loss of permissiveness indicates that there are factors other than the gene 
knockouts involved in permitting HCV replication in these cells. 
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Overall, we conclude that the permissiveness of a given MEF line may be influenced by both 
the targeted gene knockout, and genetic and/or epigenetic changes in the cell line that occur during 
transformation and/or immortalization. This is based on the varying permissiveness of different 
cell isolates and passages of the same knockout cell line, and our finding that the HCV permissive 
phenotype of an isolate of primary PKR knockout cells was not observed in other primary MEF 
isolates and hepatocytes. We concede that there may be some basic genetic differences in anti-
viral responses dependent upon the background of the mouse from which the MEFs were isolated, 
but the variability in permissiveness of immortalized MEFs over different passages suggests that 
this is not a key factor. Lohmann et al. noted that Huh7 cells themselves vary in permissiveness to 
HCV by up to 100-fold at different passages, so it is perhaps unsurprising to also observe this in 
other immortalized cell lines (Lohmann et al., 2003). Thus, we suggest that future research with 
HCV in immortalized knockout cell lines be undertaken with caution and effort to confirm the 
effect of the knockout on HCV replication in primary cells, and to develop a means of 
characterizing and retaining the susceptible phenotype of the cultured cells.  
Recently, Vogt et al. used drug selection to maintain sub-genomic and full-length HCV RNA 
replication in MEFs (Vogt et al., 2013). They also concluded that the use of antiviral gene 
knockouts increased the ability to select for stable cells. Based on these results we speculate that 
in both our study and in theirs that a subset of cells in each MEF population support HCV 
replication, and that their use of drug selection reinforced maintenance of the susceptible subset 
while eliminating cells that lost permissiveness through passage. Thus it is possible that in our 
studies, cells that support HCV replication were lost from the cell population. Unlike our study 
however, in the Vogt report and other previous reports, miR-122 was not required for stable HCV 
colony selection (Chang et al., 2008; Chang et al., 2006; Lin et al., 2010; Uprichard et al., 2006; 
Vogt et al., 2013; Zhu et al., 2003). This suggests that perhaps the knockout cells supported 
sufficient replication independent from miR-122 for selection (or generation of viral mutants that 
do not require miR-122), or that the selected cells could express miR-122 or other pro-viral factors. 
More recently, the same group has demonstrated the complete virus life cycle in entry-factor 
transgenic mice, although these mice also benefit from the same immune gene knockouts identified 
in stably selected MEFs (Dorner et al., 2013a; Vogt et al., 2013). Two other recent publications 
have shown replication of HCV in MEFs, primary murine hepatocytes, and murine hepatoma cells 
from innate immune knockout mice in the absence of selection (Frentzen et al., 2013; Nandakumar 
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et al., 2013); the wild-type and NCoA6 knockout cell lines we used here were immortalized 
through crisis, during which any number of changes may have occurred, and therefore we cannot 
directly compare them to the passage status and immortalization of the cell lines established by 
Frentzen et al. and Nandakumar et al. (personal communication).  
Our findings that NCoA6 knockout MEFs do not support detectable transient replication of 
full-length HCV RNA also require consideration. We originally considered these cells as a control 
knockout cell line until we determined that replication was higher in these cells than in the wild-
type MEFs;  we then hypothesized that a MEFs cell line could be made to support HCV replication 
through knockout of a host gene that does not affect innate immunity. However, the finding that 
NCoA6 knockout MEFs were not permissive for full-length HCV RNA replication limits their 
usefulness as models. Why the cells could not replicate full length HCV genomic RNA remains to 
be determined, but elements of the structural gene region may be involved since Aly et al. noted a 
difference in permissiveness of mouse cell lines for HCV replication that varied by the structural 
gene region of the construct used (Aly et al., 2011). In our hands, the full-length RNA did not 
appear to affect co-electroporated sub-genomic replication, arguing that whatever prevents full-
length replication in the cells does so in cis and is not, therefore, a dominant antiviral response 
triggered only by full-length HCV RNA. This is supported by others’ data that mouse cells do not 
restrict replication of HCV when fused with permissive human liver cells (Frentzen et al., 2011). 
Thus, neither expression of the structural proteins, nor structural protein gene regions of the RNA, 
promotes an antiviral state in the cells, since neither protein nor RNA adversely affected replication 
of sub-genomic HCV RNA in the same cell. This suggests another, non-immune limiting factor 
present in this particular cell line – and perhaps others – that could be exploited in place of innate 
immune knockouts.  
There are two major differences between the sub-genomic and full-length HCV RNAs that 
could affect replication in cis: the first is the structural protein coding region in the full-length 
RNA, while the second is the presence of the second (EMCV) IRES in the sub-genomic RNA 
construct. It is possible that the structural protein coding region contains cis-acting regulatory 
sequences that regulate HCV replication, and that a human specific host factor, absent from mouse 
cells, is required to activate this regulatory element. On the other hand, in the sub-genomic 
construct, the EMCV IRES drives expression of the non-structural proteins required for RNA 
replication instead of the HCV IRES. If the EMCV IRES drives translation more strongly than the 
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HCV IRES in mouse cells, then it may lead to more efficient expression of the viral non-structural 
proteins required for replication and this may overcome a host species barrier in the presence of 
miR-122. Finally, it may be a combination of these two factors, or the presence of the EMCV IRES 
may disrupt long-range cis regulatory elements in the non-structural genes in any host cell, 
permitting de-regulated replication of the sub-genomic RNA in any permissive environment.  
We therefore suggest that there are additional factors that need consideration when attempting 
to develop non-human cell culture models for HCV; the immortalization and subsequent 
maintenance regime of the cells may affect their permissiveness in addition to any knockout 
background, particularly when attempting unselected HCV RNA replication. Furthermore, the 
viral construct may also be important when attempting to identify permissive cell lines as was seen 
in the work by Aly et al. (Aly et al., 2011). Future work with new viral isolates may also advance 
the search for new murine models of Hepatitis C virus. 
 
3.5 Materials and Methods 
3.5.1 Ethics Statement.  
Mice were handled according to the guidelines provided by the Canadian Council on Animal 
Care and the University of Saskatchewan Policy on Care and Use of Animals in Research. 
Protocols for the collection of mouse cells were approved by the University of Saskatchewan’s 
Animal Research Ethics Board (Surgical Procedures 19940211). 
 
3.5.2 Cell Culture.  
Cell lines and primary mouse cells are adherent, and were maintained in complete Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1% 
Penicillin/Streptomycin, and 1% non-essential amino acids as described in (Thibault et al., 2013). 
Huh7.5 cells were provided by Charles Rice (New York, USA) (Blight et al., 2002). Wild-type 
mouse embryonic fibroblasts (MEFs) were obtained from Gregory Hannon (Cold Spring Harbor, 
USA), Robert Silverman (Yang et al., 1995), and Per Antonson (Huddinge, Sweden). NCoA6 
knockout MEFs (also known as RAP250 knockout MEFs) were also provided by Per Antonson 
(Antonson et al., 2003). PKR knockout MEFs and PKR knockout mice were provided by John 
Bell (Ottawa, Canada) (Abraham et al., 1999). We isolated primary PKR knockout MEFs from the 
mice as in (Lewis et al., 1992). Briefly, a 13 to 15-day pregnant mouse was euthanized with 
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isoflurane and embryos were extracted. Heads, appendages, and red matter were excised from the 
embryos, and the embryos were placed into a fresh dish. After chopping up the embryo tissue with 
scissors, it was incubated in trypsin for 1 hr at 37°C, before pelleting and plating in complete 
DMEM. PKR knockout hepatocytes were isolated as follows: a male 7 to 9 week-old PKR 
knockout mouse was euthanized with isoflurane, and the liver perfused from the vena cava with 
25 mL 37°C Krebs Ringer with glucose and 0.1mM EDTA. The liver was then digested with 
collagenase (12.6mg) in 25mL Krebs Ringer with glucose and 150 μM CaCl2 (Buffer 2). After 
digestion, the liver was removed from the body cavity and transferred to a petri dish, where it was 
punctured and resuspended in Buffer 2, and then filtered through a 70μM filter and washed twice 
with Buffer 2. Cells were then tested for viability with trypan blue, and, if greater than 80% viable, 
seeded at a density of 2.0 x 105 cells/well in collagen-coated 24-well dishes in complete DMEM.  
 
3.5.3 Viral plasmids and RNA.  
Plasmids pSGR JFH-1 Fluc WT and pSGR JFH-1 Fluc GND encode sub-genomic JFH-1-
derived HCV replicons with a firefly luciferase reporter; the GND contains an inactivating 
mutation in the viral polymerase (Kato et al., 2003; Kato et al., 2005a). Plasmids pSGR S1+S2:p3 
Fluc WT and pSGR S1+S2:p3 Fluc GND have C to G mutations at position 3 in both miR-122 
seed binding sites in the HCV 5´ UTR and were described in (Thibault et al., 2013). Plasmids 
pJ6/JFH-1(p7-Rluc2a) “FL WT” and pJ6/JFH-1(p7-Rluc2a) GNN “FL GNN” bear full-length 
viral sequences derived from the J6 (structural proteins) and JFH-1 (non-structural proteins) 
isolates of HCV, and a Renilla luciferase reporter, with the GNN having inactivating mutations in 
the viral polymerase (Jones et al., 2007a). Firefly luciferase control mRNA was transcribed from 
Luciferase T7 Control DNA plasmid (Promega; Nepean, ON, Canada), while Renilla luciferase 
control mRNA was transcribed from the pRL-TK plasmid (Promega). Plasmid templates for viral 
RNA and mRNA were prepared and in vitro transcribed with the MEGAScript T7 High Yield 
Transcription Kit and mMessage mMachine T7 Transcription Kit (Life Technologies; Burlington, 
ON, Canada), respectively, as described in (Thibault et al., 2013). 
 
3.5.4 microRNAs and silencing RNAs.  
miR-122: 5´-UGG AGU GUG ACA AUG GUG UUU GU-3´ and miR-122*: 5´-AAA CGC 
CAU UAU CAC ACU AAA UA-3´, annealed. miControl: 5´- GAA GGU CAC UCA GCU AAU 
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CAC and miControl*: 5´-GUG AUU AGC UGA CAG ACC UUC-3´, annealed (Wilson et al., 
2011). siPKR: 5´-GCG AGA AAC UAG ACA AAG U-3´. siNCoA6: 5´-CCA CAG AGC UGG 
ACA GUA AUU-3´. siControl: 5´- GAA GGU CAC UCA GCU AAU CAC dTTC-3´ (Wilson et 
al., 2003). All small RNAs were synthesized by ThermoScientific Dharmacon (Lafayette, CO, 
USA).  
 
3.5.5 Electroporation.  
Cells were electroporated using 4mm cuvettes at infinite resistance, and were prepared and 
plated as described in (Thibault et al., 2013). Briefly, cells were trypsinized, washed twice with 
cold Dulbecco’s PBS (D-PBS), then resuspended in D-PBS at a concentration of 1.5x107 cells/mL, 
with 400μL (6.0x106) cells used per sample. Mouse cell lines were electroporated with 10μg viral 
RNA, 1μg control Fluc or Rluc mRNA as transfection control, and 60pmol miRNA. Huh7.5 cells 
were electroporated with 5μg viral RNA and 1μg Rluc mRNA as transfection control. When used 
for knockdown, Huh7.5 cells were first electroporated with 60pmol siRNA and incubated for three 
days; they were then electroporated again with 60pmol siRNA, along with 5μg viral RNA and 1μg 
Rluc mRNA as transfection control. Electroporation conditions for MEFs were 400V, 250μF; for 
PKR knockout hepatocytes were 220V, 950μF; and for Huh7.5 cells were 270V, 950μF. Cells 
were then resuspended in 4mL DMEM, and 500μL cells were plated in 6-well dishes for luciferase 
harvests, or 2mL cells were plated into 10cm dishes for RNA harvests.  
 
3.5.6 Transfection.  
Briefly, media was replaced with Pen/Strep-free C-DMEM on PKR knockout hepatocytes one 
day post-extraction. Lipofectamine 2000 reaction mixture was assembled according to 
recommended protocol, with 0.4 μg viral RNA, 5.0 pmol miRNA, and 0.1 μg mRNA assembled 
with 1.5 μL Lipofectamine 2000 (approximately 3:1 ratio) in OptiMEM. Cells were transfected 
overnight, media was changed on Day 1 post-electroporation to C-DMEM, and luciferase was 
harvested as indicated. 
 
3.5.7 Luciferase Assays.  
Luciferase assays to monitor viral replication were carried out as described in (Thibault et al., 
2013). Briefly, cells were harvested by scraping in 100μL of passive lysis buffer. 10μL of lysate 
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was assayed for light production in 50μL of the appropriate assay buffer (luciferase substrate) for 
the type of luciferase in the sample, according to the associated protocol, and using a GLOMAX 
luminometer (Promega). 
 
3.5.8 Infections. 
Naive Huh7.5 cells were plated at 1.0x105 cells per well in a 6-well dish one day pre-infection. 
Supernatant from NCoA6 cells was collected at the indicated time, spun to pellet cell debris, and 
2mL was plated on naive Huh7.5 cells. Huh7.5 cell extracts were harvested as above at three days 
post-infection and assayed for luciferase expression to detect HCV infection. 
 
3.5.9 RNA collection.  
Total RNA was collected from cells three days post-electroporation into 1mL Trizol (Life 
Technologies) and isolated according to the manufacturer’s protocol. 
 
3.5.10 Northern blot.  
Northern blotting for HCV RNA was carried out as described in (Thibault et al., 2013). 
 
3.5.11 qRT-PCR.  
Total cellular RNA was reverse-transcribed using the iScript cDNA Synthesis Kit (BioRad; 
Mississauga, ON, Canada). qPCR reactions were carried out using the TaqMan kits 
Hs00169345_m1 (EIF2AK2, PKR), Hs01052843_m1 (NCoA6) and FAM-MGB 4352934-
0803022 (GAPDH); samples were amplified in triplicate with 2X TaqMan Master Mix (Life 
Technologies). All data was analyzed with the CFX Manager Software (BioRad). 
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4.0 Alternative Cell Culture Model Systems for Growth of Hepatitis C Virus 
We had hoped that our work presented in Chapter 3 would allow us to make progress on the 
development of a mouse model for HCV propagation, but for several reasons decided to pursue 
alternative cell lines as models.  Firstly, the murine cell lines described in Chapter 3 did not permit 
replication of the full-length virus, and hepatocytes isolated from the source mice were not 
permissive for HCV replication. This suggested to us that there were other impediments in our 
approach to developing cell lines or animals that could support the full HCV life cycle. Secondly, 
other researchers had recently developed an innate immune-deficient mouse model for Hepatitis 
C virus infection that supported virion entry, replication, and particle production (described in 
Chapter 1) (Dorner et al., 2013a; Vogt et al., 2013).  In addition, simultaneously with the work 
described in Chapter 3, we were exploring alternative human hepatoma cell lines that may be 
rendered permissive for replication of Hepatitis C virus through supplementation with miR-122 
and this seemed a path that would lead to interesting results in the laboratory focus. 
The experiments in Chapter 5 were carried out by PAT with assistance from PD, with the 
exception of those in Figure 5.5, which were performed by AH. Experiments were conceived by 
PAT, JAW, and AH. PAT, AH, and JAW analyzed the data. PAT and JAW wrote the paper. 
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5.1 Abstract 
The study of Hepatitis C virus (HCV) has benefitted from the use of the Huh7 cell culture 
system, but until recently there were no other widely-used alternatives to this cell line. Here we 
render another human hepatoma cell line, Hep3B, permissive to the complete virus life cycle by 
supplementation with the liver-specific microRNA miR-122, known to aid HCV RNA 
accumulation. When supplemented, Hep3B cells produce J6/JFH-1 virus titres indistinguishable 
from those produced by Huh7.5 cells. Interestingly, we were able to detect and characterize miR-
122-independent replication of bi-cistronic replicons in Hep3B cells. Further, we show that 
Argonaute-2 (Ago2) is required for miR-122-dependent replication, but dispensable for miR-122-
independent replication, confirming Ago2’s role in mediating the activity of miR-122. Thus 
Hep3B cells are a model system for the study of HCV, and miR-122 independent replication is a 
model to identify proteins involved in the function of miR-122. 
 
5.2 Introduction 
Hepatitis C is a blood-borne viral disease that naturally infects only humans and is prevalent 
worldwide. As of July 2012, the WHO estimates that 150 million people worldwide are infected 
with Hepatitis C virus (HCV) (WHO, 2012). HCV exposure leads to chronic liver infections in an 
estimated 70% of individuals, and can lead to the development of liver disease, steatosis, 
hepatocellular carcinoma, and other complications late in chronicity (Strader et al., 2004). 
Unfortunately, no preventative or therapeutic vaccine yet exists, and treatment options are limited. 
Current standard of care involves lengthy combination therapy with pegylated interferon-α (IFNα) 
and ribavirin. Recent approval of two new protease inhibitors, telaprevir and boceprevir, has 
improved treatment outcomes and when one or the other is added to the cocktail, approximately 
70% of genotype 1-infected patients (the most prevalent and difficult to treat) clear the infection 
(Myers et al., 2012). New direct-acting antiviral drugs currently under development should further 
improve the effectiveness of current treatment (Poordad and Dieterich, 2012).  
A member of the Flaviviridae family, HCV is an enveloped virus with a 9.6kb single-stranded 
positive-sense RNA genome. The uncapped 5´ un-translated region (UTR) of the viral genome 
bears an internal ribosomal entry site (IRES) that drives translation of the virus’ single open 
reading frame as a polyprotein. The polyprotein is co- and post-translationally cleaved by cellular 
and viral proteases to produce the structural (core, E1, E2) and non-structural (p7, NS2, NS3, NS4a 
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and 4b, NS5a and 5b) viral proteins. Both the 5´ and 3´ UTRs have significant secondary RNA 
structure that is essential for viral translation and replication (Bartenschlager et al., 2004). 
In 2005, Jopling et al. identified two binding sites for the liver-specific microRNA, miR-122, 
in the 5´ UTR of HCV; miR-122 binding enhances accumulation of HCV RNA in infected cells 
(Jopling et al., 2008; Jopling et al., 2005). MicroRNA-122 comprises about 70% of the small 
RNAs in the mammalian liver, and modulates expression of mRNAs involved in cholesterol 
biosynthesis, proliferation, and cell differentiation (Esau et al., 2006; Lagos-Quintana et al., 2002; 
Lin et al., 2008; Norman and Sarnow, 2010).  
miRNA expression is often dysregulated or abolished in cancer cells. Expression of miR-122 
is typically reduced or lost in liver cancers, but is more likely to be maintained in cases of HCV-
associated liver cancer (Coulouarn et al., 2009; Varnholt et al., 2008). Similarly, hepatocyte cell 
lines that were established from liver tumors also generally lack miR-122 expression. Huh7-
derived cell lines are the only human liver cell lines known to have significant endogenous 
expression of miR-122, and these were also the first cell line to robustly support replication of 
HCV (Jopling et al., 2005). While expression of the miRNA is considerably lower in these cells 
than in primary human hepatocytes, other liver cancer cell lines such as HepG2 and Hep3B cells 
have undetectable levels of miR-122 and are also non-permissive for HCV replication (Varnholt 
et al., 2008). This information led to the hypothesis that miR-122 plays a role in the host cell 
tropism of HCV, and this hypothesis is supported by several reports. Supplementation with miR-
122 of non-permissive mouse embryonic fibroblasts (MEF), HEK (human embryonic kidney), and 
HepG2 and Hep3B (human hepatoma) cells with miR-122 has rendered them permissive for 
transient replication of HCV RNAs derived from the JFH-1 isolate (Chang et al., 2008; Fukuhara 
et al., 2012; Kambara et al., 2012; Lin et al., 2010; Narbus et al., 2011). HepG2 and Hep3B cells 
were also capable of producing HCV particles. However, stable RNA replication of JFH-1-derived 
replicons has also been demonstrated in cells that do not express miR-122, such as murine 
embryonic fibroblasts (MEFs), through the use of selectable markers, suggesting that miR-122 is 
not essential for ongoing HCV replication (Chang et al., 2006; Uprichard et al., 2006). 
The mechanism of action of miR-122 in the HCV life cycle is unknown. The activity of miR-
122 in the replication of HCV is non-canonical, since it binds to the 5´ end of the viral genome 
and requires annealing of nucleotides outside of the miR-122 seed sequence (Machlin et al., 2011; 
Shimakami et al., 2012b). MicroRNAs normally bind to the 3´ ends of cellular mRNAs in a 
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sequence specific manner, within a complex with other proteins such as Argonaute-2 to form a 
RISC (RNA-induced silencing complex), and subsequently reduce mRNA translation and stability 
(Du and Zamore, 2005).  
Recent evidence suggests that miR-122 binding to the HCV genome stabilizes the viral RNA 
(Shimakami et al., 2012b). However, miR-122 has also been reported to enhance translation and 
augment RNA accumulation (Henke et al., 2008; Jangra et al., 2010a, b; Jopling et al., 2005; 
Machlin et al., 2011; Roberts et al., 2011; Villanueva et al., 2010). It is possible that the primary 
function of miR-122 is to stabilize viral RNA, and that the observed influences of miR-122 on 
HCV translation and replication stem from miR-122 modulation of HCV RNA stability, but this 
remains to be confirmed. To further tease these activities apart, researchers have begun to examine 
the cellular factors involved in miR-122-mediated enhancement of HCV RNA accumulation, the 
most obvious of which are the proteins in the microRNA biogenesis pathway and proteins that 
comprise the RISC. Thus far, research has shown that Dicer and TRBP, proteins involved in the 
biogenesis of microRNAs, are required for processing of miR-122, and that Argonaute-2 (Ago2) 
is required for miR-122 stabilization of HCV RNA, for efficient HCV RNA accumulation, and for 
miR-122 stimulation of HCV translation (Machlin et al., 2011; Shimakami et al., 2012a; 
Shimakami et al., 2012b; Wilson et al., 2011; Zhang et al., 2012).  
We, and others, have hypothesized that miR-122 is a limiting factor in HCV tissue tropism and 
cell culture models, and herein we have confirmed replication of the J6/JFH-1 viral RNA in Hep3B 
cells supplemented with miR-122, showing that these cells can produce virus particles to the same 
titres as Huh7.5 cells. Additionally, through use of Hep3B cells as a model system, we have 
identified and characterized miR-122-independent replication of two bi-cistronic HCV replicons, 
the sub-genomic JFH-1 replicon, and the full-genomic JFH-1 replicon. MicroRNA-122-
independent replication of HCV provides a model system in which to investigate the roles of 
cellular proteins in miR-122 processes, compared to their roles in HCV replication that are 
independent of miR-122. As proof of principle we evaluated the role of Argonaute-2 (Ago2) in 
replication of the sub-genomic replicon with and without miR-122, and determined that Ago2 
knockdown does not influence miR-122-independent replication, but has an effect on miR-122-
dependent replication. This confirms that Ago2 is involved in the activity of miR-122 as it 
promotes HCV RNA accumulation.  
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5.3 Results 
5.3.1 Supplementation with miR-122 renders Hep3B cells permissive to sub-genomic HCV RNA 
replication. 
Many human hepatomas have lost the ability to express the liver specific miRNA, miR-122 
(Coulouarn et al., 2009). Unlike commonly used human hepatoma cell lines such as Hep3B cells 
and HepG2 cells, Huh7-derived cells (such as Huh7.5) retained easily-detectable miR-122 
expression after transformation (Figure 5.1B, (Jopling et al., 2005)), and are also permissive to 
Hepatitis C virus replication. Because of this, and because miR-122 has been shown to impact 
HCV translation and replication, we hypothesized that miR-122 is a limiting factor in some non-
permissive cell lines, and that providing miR-122 will render them permissive for HCV replication 
and virion production. Electroporating Hep3B cells with synthetic mature miR-122 duplexed RNA 
permitted high levels of replication of the sub-genomic JFH-1 HCV replicon (SGR, depicted in 
Figure 5.1A), as measured by the firefly luciferase reporter gene in Figure 5.1C, and confirmed by 
northern blot analysis of viral RNA accumulation (Figure 5.1D). Replication-incompetent viral 
RNA (SGR GND) was used to establish basal levels of luciferase expression in the absence of 
replication. Both luciferase expression and accumulation of sub-genomic RNA in Hep3B cells 
were similar to that observed in Huh7.5 cells (data not shown). Transfection efficiency was 
determined by co-electroporation of a Renilla mRNA and analysis of Renilla luciferase expression 
levels two hours post-electroporation, and did not vary between samples (data not shown). Cell 
numbers were evaluated three days post-electroporation by WST-1 assay, and were consistent 
among samples in each experiment (data not shown). 
 
5.3.2 Full-length HCV RNA can replicate and generate infectious virus particles in Hep3B cells. 
Co-electroporation of J6/JFH-1 RNA (depicted in Figure 5.2A) and miR-122 also renders 
Hep3B cells permissive to replication of full-length HCV RNA (Figure 5.2B). Expression of the 
Renilla luciferase (Rluc) reporter confirmed replication of full length HCV RNA in Hep3B cells 
when co-electroporated with miR-122. In the absence of miR-122, the Rluc expression pattern 
overlapped that of the non-replicating GNN control (Figure 5.2B, compare WT + miControl and 
GNN + miR-122). Full-length HCV RNA accumulation by replication was confirmed by northern 
blot analysis (Figure 5.1D). Tissue culture supernatant was collected on day 3 post-electroporation  
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Figure 5.1 Replication of sub-genomic (SGR) HCV in Hep3B cells. 
A. Components of “SGR,” the bi-cistronic sub-genomic firefly luciferase reporter replicon based 
on the JFH-1 isolate. The replicon lacks the structural genes required to form particles, but has all 
the necessary non-structural genes required for replication, along with the 5´ and 3´ un-translated 
regions (UTRs). The firefly luciferase reporter gene is driven by the HCV IRES, while viral protein 
expression is driven by an EMCV IRES. B. miR-122 levels in human hepatoma cell lines were 
evaluated by TaqMan qRT-PCR. Levels are determined relative to a housekeeping small RNA, 
RNU6B, for comparison between cell lines. Huh7.5 cells are derived from Huh7 cells; HepG2 and 
Hep3B cells are of separate lineages. C. Cells were electroporated with the indicated SGR replicon 
RNA (wild-type, WT; or replication-incompetent, GND), and miRNA. Firefly luciferase 
expression was evaluated at the indicated time points. RLU are a measure of light produced by the 
luciferase enzyme extracted from cell lysates. All data shown is the average of three or more 
independent experiments, unless otherwise indicated, and error bars represent standard error. D. 
Total cellular RNA from (C) was collected three days post-electroporation and evaluated by 
northern blot. The blot shown is representative of three experiments. GAPDH is shown as a loading 
control. HCV (8.4 kb) refers to the size of the SGR replicon genome.  
  
61 
 
A. Representation of “J6/JFH-1 Rluc,” the mono-cistronic full-length J6/JFH-1 chimeric replicon, 
which bears all the viral genes, is capable of producing infectious particles in cell culture, and has 
a Renilla luciferase reporter gene. The HCV IRES drives translation of all the genes. B. Hep3B 
cells were electroporated with either wild-type (WT) or replication-incompetent (GNN) J6/JFH-1 
Rluc RNA, and the indicated microRNA. Luciferase expression levels were measured at the 
indicated times post-electroporation. C. Day 3 supernatant from Hep3B cells in (B) was used to 
infect naïve Huh7.5 cells; luciferase expression in the Huh7.5 cells three days post-infection 
indicated the presence of infectious HCV virions in the supernatant. Luciferase expression levels 
are shown on the axis in part (B). D. Northern blot of J6/JFH-1 RNA in Hep3B cells 3 days post-
electroporation, demonstrating HCV RNA replication in Hep3B cells supplemented with miR-
122. HCV (10.1 kb) refers to the size of the full-length replicon genome. E. Supernatant from both 
Hep3B and Huh7.5 cells three days post-electroporation were titrated for HCV focus-forming units 
(FFU). F. Northern blot comparing levels of J6/JFH-1 RNA in Huh7.5 cells, and in Hep3B cells 
supplemented with miR-122, three days post-electroporation. Bands are quantified by 
densitometry, and normalized to GAPDH. Percentages are an average of seven independent 
experiments, +/- standard deviation, and are presented relative to Huh7.5 cells. In all other panels, 
the data are presented as the average of three independent experiments and the error bars represent 
standard error of the mean. 
  
Figure 5.2 Replication of full-length (J6/JFH-1 Rluc) HCV in Hep3B cells. 
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and analyzed for the presence of HCV particles. When the supernatant was used to infect naïve 
Huh7.5 cells, luciferase expression in the newly infected cells (Figure 5.2C) indicated the presence 
of infectious HCV particles in the supernatant from Hep3B cells supplemented with miR-122. 
Focus-forming assays showed that infectious virus titres in the supernatant from miR-122-
supplemented Hep3B cells were similar to that from Huh7.5 cells (Figure 5.2E). Northern blot 
analysis of HCV RNA levels in miR-122 supplemented Hep3B cells compared with Huh7.5 cells 
(Figure 5.2F) indicates that at three days post-electroporation, Hep3B cells had similar levels of 
HCV RNA accumulation as that observed in Huh7.5 cells. 
 
5.3.3 Replication levels and virus particle production coincide with miR-122 levels in Hep3B cells. 
To determine how long Hep3B cells can support full-length viral replication when 
supplemented with synthetic mature miR-122 duplex RNA, we monitored HCV replication via 
luciferase expression, until none was detectable. By 15 days post-electroporation, little to no 
replication or infectious virus particle production was apparent in Hep3B cells (Figure 5.3A, B). 
We evaluated miR-122 levels by qRT-PCR at the same time points and determined that HCV 
replication paralleled the levels of exogenously supplied miR-122 (Figure 5.3C). At Day 6, miR-
122 levels were similar to that found in Huh7.5 cells, and by Day 9, miR-122 levels had dropped 
to 30% of miR-122 levels in Huh7.5 cells. The drop in miR-122 levels appears to correspond to 
the decline in HCV replication and particle production (as measured by luciferase). Thus, viral 
RNA replication and particle production coincide with miR-122 levels in Hep3B cells.  
 
5.3.4 Hep3B cells supplemented with miR-122 are permissive for HCV infection.  
Finally, we examined whether Hep3B cells can also support virus entry, and thus recapitulate 
a full round of infection in Hep3B cells when supplemented with miR-122. One day before 
infection, Hep3B cells were transfected via Lipofectamine 2000 (Figure 5.4A) with either miR-
122 or a control microRNA, and on day 0, were infected with J6/JFH-1 HCVcc (virus derived 
from Huh7.5 cells). Figure 5.4A shows luciferase expression from the infected cells at indicated 
time points post-infection. Hep3B cells supplemented with miR-122 show detectable luciferase 
expression post-infection. Furthermore, on Day 4 post-infection, supernatant from the infected 
cells was transferred to Huh7.5 cells for detection of infectious virus particle production. As can  
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Figure 5.3 Long-term replication of full-length HCV RNA in Hep3B cells. 
A. Luciferase levels representing replication of J6/JFH-1 Rluc HCV RNA in Hep3B cells were 
evaluated at the indicated time points post-electroporation. B. Luciferase levels representing 
infectious HCV particles in supernatants collected from ‘wild-type + miR-122’ in (A). Supernatant 
was collected at each time point and used to infect naive Huh7.5 cells; three days later, luciferase 
levels were analyzed to measure approximate supernatant infectivity. C. Relative miR-122 levels 
in Huh7.5 cells, un-electroporated Hep3B cells, and Hep3B cells electroporated with miR-122 
collected at the indicated times post-electroporation. miR-122 levels were determined by TaqMan 
qRT-PCR and normalized to RNU6B. Data represent the average of three independent experiments 
and bars represent standard error.  
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Figure 5.4 Infection of Hep3B cells with full-length J6/JFH-1 HCVcc. 
A. Hep3B cells were transfected via Lipofectamine 2000 with the indicated miRNA on Day -1, 
and infected with HCVcc (J6/JFH-1 particles derived from Huh7.5 cells) or mock-infected with 
media on Day 0. Luciferase was analyzed at the indicated time points to detect infection and 
subsequent replication. B. Supernatant was collected from the infected Hep3B cells in (A) on Day 
4, and was used to infect naïve Huh7.5 cell. Three days later, luciferase expression, in the same 
axis as in (A), was analyzed in the infected Huh7.5 cells to detect infection. Data are the average 
of three independent experiments and error bars represent standard error. C. Hep3B cells were 
electroporated with the indicated miRNA on Day -1, and infected with HCVcc (J6/JFH-1 particles 
derived from Huh7.5 cells) or mock-infected with media on Day 0. Luciferase was analyzed at the 
indicated time points to detect infection and subsequent replication. D. Supernatant was collected 
from the infected Hep3B cells in (C) on Day 4, and was used to infect naive Huh7.5 cells. Three 
days later, luciferase expression, on the same axis as in (C), was analyzed in the infected Huh7.5 
cells to detect infection. Data represent the average of three or more independent experiments and 
bars represent standard deviation. 
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be seen in Figure 5.4B, Hep3B cells bearing miR-122 prior to infection can carry out the viral life 
cycle and produce infectious virions, but at lower levels compared to cells electroporated with 
viral RNA, which suggests inefficient HCV entry into miR-122 transfected Hep3B cells. To ensure 
that the original virus HCVcc used to infect the cells could not contaminate the virus supernatants 
collected on Day 4, the Hep3B cells were washed and media was changed the day following the 
initial infection. Failure to detect virus in supernatant from Hep3B cells electroporated with 
miControl (grey) confirmed that there was no contaminating HCVcc remaining. We also tested 
whether electroporating the cells with miR-122 on Day -1 prior to infection would improve their 
uptake of miR-122 and thus, potentially, improve infectability, but this was not seen (Figure 5.4C 
and D). 
 
5.3.5 Sub-genomic HCV RNA can replicate in Hep3B cells un-supplemented with miR-122. 
Interestingly, luciferase expression levels in Hep3B cells electroporated with HCV sub-
genomic RNA (without miR-122) were greater than those of the replication incompetent GND 
control (Figure 5.1C, compare WT + miControl to GND + miControl). This suggested that SGR 
wild-type RNA was persisting longer than non-replicating RNA, even in the absence of miR-122 
supplementation. RNA levels from SGR in the absence of miR-122 were not initially detected by 
northern blot (Figure 5.1D), but higher than background luciferase expression was consistently 
seen. In addition, luciferase levels increased after day 1 post-electroporation, indicating that SGR 
RNA replicated in Hep3B cells even without miR-122 supplementation. We ruled out the 
possibility that the miControl synthetic RNA impacted sub-genomic replication by electroporating 
viral RNA with no accompanying microRNA into Hep3B cells, and found similar luciferase 
production as when miControl was provided (data not shown). We hypothesized that HCV RNA 
replication could be due to either low levels of active miR-122 within Hep3B cells, or alternatively, 
that sub-genomic RNA can replicate in Hep3B cells independent of the activity of miR-122.  
 
5.3.6 Hep3B cells lack functional endogenous miR-122. 
To rule out possible contribution of endogenous miR-122 on un-supplemented SGR replication 
in Hep3B cells, we analyzed the levels and activity of miR-122 in Hep3B cells. Real-time PCR 
analysis of miR-122 levels in Hep3B cells had indicated that Hep3B cells do not express 
consistently detectable amounts of miR-122 (Figure 5.1B). To analyze for functional miR-122 in  
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Figure 5.5 Hep3B cells lack functional miR-122. 
A. Reporters used in miRNA functional assays. Top: pLUC-122x2 encodes a firefly luciferase 
mRNA bearing miR-122 binding sites in its 3´ UTR; binding of miR-122 to these sites suppresses 
translation of the firefly luciferase reporter. Bottom: pRL-TK encodes a Renilla luciferase mRNA 
to be used as a transfection control. B. Hep3B cells were electroporated with the indicated miRNA 
or α-miR-122. Two days later, cells were transfected with two reporter plasmids that express the 
mRNAs shown in (B). One day post-transfection, cells were assayed for both luciferase reporters’ 
expression levels, and data was normalized to Renilla luciferase levels. Data are the average of 
three independent experiments and are shown as fold suppression compared to miControl by each 
miRNA. Bars represent standard error. C. Hep3B cells were electroporated with SGR RNA and 
the indicated miRNA dilutions. Luciferase was measured three days post-electroporation, and 
dilutions are shown relative to 60.0 pmol miControl. miR-122 dilutions are 1:1 (60.0 pmol), 1:10 
(6.0 pmol) and 1:100 (0.6 pmol). The GND mutant demonstrates non-replicating luciferase levels. 
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Hep3B cells we assayed for miR-122 suppression activity. In the assay, miR-122 suppression 
activity was monitored by using two plasmids (Figure 5.5A); one bears a firefly luciferase gene 
(Fluc) with HCV-derived miR-122 binding sites in the 3´UTR to measure miR-122 suppression, 
and the other bears a Renilla luciferase gene (Rluc) to control for transfection efficiency (Jopling 
et al., 2008; Machlin et al., 2011). If miR-122 is present in the co-electroporated cells, then 
expression of firefly luciferase will be reduced via the miRNA suppression pathway. If this is the 
case, then a miR-122 antagonist should relieve the suppression. When the reporter plasmids were 
electroporated alone or with the miR-122 antagonist, similar Fluc:Rluc ratios were observed, 
indicating no active miR-122 in Hep3B cells (Figure 5.5B). In control experiments, the miR-122 
antagonist was confirmed to be active since electroporation of synthetic miR-122 enhanced 
suppression activity, and the miR-122 antagonist completely abolished this enhancement (Figure 
5.5B, miR-122, and α-miR-122 + miR-122).  We also titrated amounts of miR-122 that can affect 
SGR by electroporating Hep3B cells with SGR RNA and ten-fold dilutions of miR-122 (Figure 
5.5C). Addition of 60 pmol of miR-122 appeared to saturate the systems involved in replication, 
as addition of greater amounts of miR-122 (5X, 300 pmol, and 10X, 600 pmol) did not further 
increase replication (data not shown). A ten-fold dilution of miR-122 (6.0 pmol) led to 
approximately ten-fold less luciferase expression on Day 3 post-electroporation, and when we 
supplemented with 0.6 pmol (a hundred-fold dilution) of miR-122 we saw a reduction in 
replication to levels no different than miControl-supplemented SGR RNA. Thus, a hundred-fold 
dilution (0.6 pmol) of miR-122 is below the threshold level required to augment HCV RNA 
accumulation. This dilution of miR-122 is easily and consistently detectable by qRT-PCR (Figure 
5.3C, and data not shown), and so we concluded that amounts of miR-122 not consistently 
detectable by qRT-PCR also do not affect HCV RNA accumulation, but we cannot rule out the 
existence of undetectable levels of miR-122 in Hep3B cells. 
 
5.3.7 HCV replication in Hep3B cells in the absence of miR-122 is not affected by a miR-122 
antagonist. 
To confirm that miR-122 un-supplemented sub-genomic HCV RNA replication in Hep3B cells 
was not dependent on miR-122, we tested whether it was affected by miR-122 antagonism. In 
transient HCV replication assays, un-supplemented sub-genomic RNA replication was unaffected 
by the addition of the miR-122 antagonist (Figure 5.6B, compare α-miR-122 to miControl and α-
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Con) or a mutant miRNA (miR-122/p3), while miR-122-supplemented sub-genomic RNA 
replication was reduced to un-supplemented levels by the antagonist (Figure 5.6B, compare miR-
122 and miR-122 + α-Con with miR-122 + α-122). RNA harvested on day 3 following 
electroporation was evaluated by northern blot in Figure 5.6D, and both miR-122-dependent (miR-
122) and miR-122-independent (miControl) HCV RNA accumulation was detectable upon 
overexposure of the blot. Thus, sub-genomic RNA can replicate independent of miR-122 to low 
levels in Hep3B cells.  
 
5.3.8 Replication of p3 SGR RNA in Hep3B and Huh 7.5 cells is not affected by miR-122 or α-
miR-122. 
If un-supplemented HCV replication in Hep3B cells is independent of miR-122, then sub-
genomic constructs that cannot bind to endogenous miR-122 should also be capable of replication. 
To test this hypothesis we generated sub-genomic constructs having various point mutations in 
both miR-122 binding sites (S1 and S2) in the 5´ UTR of the viral genome (Figure 5.6A). We and 
others have shown that point mutations in the miR-122 binding sites prevent interaction with miR-
122, and miR-122-mediated enhancement of HCV replication, and that introducing 
complementary mutations into an exogenously-provided miR-122 can restore this interaction, and 
restore replication of HCV (Henke et al., 2008; Jangra et al., 2010b; Machlin et al., 2011; Wilson 
et al., 2011). We first tested for miR-122-independent replication of a ‘p3-4’ sub-genomic RNA. 
The p3-4 mutant bears mutations at positions 3 and 4 of both miR-122 binding sites in the 5´UTR 
and has been used by our lab and others (Jopling et al., 2005; Wilson et al., 2011). When we 
evaluated the p3-4 sub-genomic construct in Hep3B cells there was no indication of miR-122-
independent replication (data not shown). However, even upon supplementation with a 
complementary miRNA, miR-122/p3-4, replication of the mutant could not be supplemented to 
wild-type levels (Wilson et al., 2011). Surmising that since these RNAs could not be fully 
complemented, they may be structurally flawed, we then evaluated two other constructs that each 
bore a single C to G point mutation in both miR-122 binding sites, one at position 5 of the miR-
122 seed sequence (p5) and one at position 3 (p3). The p5 SGR construct did not demonstrate 
replication without microRNA supplementation (data not shown), but the p3 construct did (Figure 
5.6C), and replicated in Hep3B cells to levels similar to that of the wild type construct (compare 
Figure 5.6B – miControl to Figure 5.6C – miControl). In addition, the p3 SGR was unresponsive 
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Figure 5.6 MicroRNA-122-independent replication of sub-genomic HCV. 
A. Left: Diagram of SGR construct. Right: Schematic of the miR-122 binding sites in the HCV 5´ 
UTR. Blue letters show miR-122 and black letters are HCV RNA. Bold indicates miR-122 seed 
sequences, while other complementary sequences between HCV and miR-122 are shown as 
aligned bases. The green arrows and bases indicate the p3 mutations in both seed sequences on the 
HCV genome (C to G), and the complementary changes found in the microRNA miR-122/p3 (G 
to C). B. Hep3B cells were electroporated with SGR RNA and the indicated microRNAs and/or 
miRNA antagonists (α-miR-122 and α-Control). Luciferase was assayed at the indicated time 
points. GND is the replication-incompetent mutant of SGR as in Figure 5.1C. C. Hep3B cells were 
electroporated with p3 SGR RNA, which bears a mutation in position 3 of the miR-122 binding 
sites S1 and S2 as depicted in (A), and otherwise treated as in (B). D. RNA collected from Hep3B 
cells three days post-electroporation was evaluated by northern blot to detect miR-122-dependent 
(miR-122) and miR-122-independent (miControl) replication. The top panel is overexposed in 
order to detect miR-122-independent replication. E. Huh7.5 cells were electroporated as in (B). F. 
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Huh7.5 cells were electroporated as in (C). G. RNA was collected from Huh7.5 cells and evaluated 
as in (D). Luciferase data are the average of three independent experiments; bars represent standard 
error. Blots are representative of two independent experiments. 
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to exogenously provided miR-122 (Figure 5.6C, compare miR-122 to miControl), and miR-122 
antagonist (Figure 5.6C, compare miControl to α-miR-122; α-Control also had no effect – data not 
shown) and could be complemented to near-wild-type levels by an exogenously provided miRNA, 
miR-122/p3, which bears a complementary sequence to the mutated construct (compare Figure 
5.6B - miR-122 to Figure 5.6C - miR-122/p3). Because the mutated miRNA did not affect the 
wild-type replicon (Figure 5.6B, miR-122/p3), and because the mutated replicon was not impacted 
by wild-type miR-122 nor its antagonist (Figure 5.6C, miR-122 and α-miR-122), we confirmed 
that the p3 mutation successfully abolished the effects of miR-122 binding on the replicon. This 
further confirms miR-122-independent replication of HCV SGR RNA.  
To ensure that miR-122-independent replication is not specific to some factor present only in 
Hep3B cells, we also examined miR-122-independent replication of SGR RNA in Huh7.5 cells. 
By use of α-miR-122 to antagonize the endogenous miR-122 in Huh7.5 cells, we were able to 
reduce replication of sub-genomic HCV RNA to levels similar to the miR-122-independent 
replication we observed in Hep3B cells (Figure 5.6E, α-miR-122; compare with Figure 5.6B, 
miControl). To substantiate miR-122-independent replication in Huh 7.5 cells, we analyzed 
replication of the p3 SGR construct in Huh 7.5 cells (Figure 5.6F). In Huh 7.5 cells, p3 SGR 
replication was unaffected by the miR-122 antagonist (Figure 5.6F, compare miControl and α-
miR-122; α-Control had no effect on p3 SGR replication – data not shown), confirming miR-122-
independent replication. The p3 SGR construct still responded to the complementary microRNA 
miR-122/p3. Evaluating Day 3 RNA from these experiments by northern blot (Figure 5.6G), miR-
122-dependent (“SGR WT” – SGR WT + miControl) and miR-122-independent (“p3 SGR” – p3 
SGR + miControl) RNA accumulation can both be detected upon overexposure of the blot. Huh7 
cells, the parent cells to the Huh7.5 line, also supported miR-122-independent replication of p3 
SGR (data not shown). Thus, we have detected unselected miR-122-independent replication of 
sub-genomic HCV RNA in three cell lines, and have verified that a mutation in the miR-122 
binding sites renders replication of the SGR construct independent of wild-type miR-122. 
 
5.3.9 miR-122-independent replication of a full length bi-cistronic replicon RNA. 
The miR-122-independent replication of HCV SGR RNA in Hep3B cells was not echoed by 
the J6/JFH-1 construct. Luciferase expression levels from full-length HCV RNA electroporated 
without miR-122 were indistinguishable from those of the non-replicative GNN control (compare  
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Figure 5.7 Replication of the bi-cistronic full-genome replicon (FGR) in Hep3B cells. 
A. Diagram representation of “FGR,” the bi-cistronic full-genomic firefly luciferase replicon 
which contains structural genes that permit infectious particle production; it is otherwise identical 
to the SGR. B. Hep3B cells were electroporated with FGR wild-type (WT) or replication-
incompetent (GNN) RNA and the indicated microRNA, and luciferase expression was measured 
at the indicated time points. C. Supernatants from cells in (B) were collected at Day 4 post-
electroporation, and were used to infect Huh7.5 cells. Three days after infection, luciferase levels, 
on the same axis as in (B), were evaluated in the Huh7.5 cells as an indication of the presence of 
infectious virus particles produced from Hep3B cells. Note the first two bars are both supernatants 
derived from WT + miControl electroporations; the solid black bar is the subset of supernatants 
that showed no virion production, while the checkered bar is the subset of supernatants that showed 
detectable virion production. Data are the average of more than three independent experiments, 
and error bars represent standard error of the mean.  
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Figure 5.1C and 5.2A, WT + miControl to GNN or GND). Thus we hypothesized that miR-122- 
independent replication may occur because of the bi-cistronic nature of the sub-genomic replicon. 
Alternatively, the increased length of the J6/JFH-1 genome could have impeded miR-122-
independent replication. In order to test both of these hypotheses, we evaluated the replication of 
the full-genomic replicon (FGR) in Hep3B cells. FGR is depicted in Figure 5.7A, and is a bi-
cistronic replicon RNA similar to SGR in that it contains an EMCV IRES that drives translation 
of the viral proteins, but is considerably longer since it also encodes the entire HCV polyprotein, 
including the viral structural proteins. Thus, if the bi-cistronic nature of the SGR replicon 
facilitates miR-122-independent replication of viral RNA, then the FGR replicon should also 
replicate independently of exogenous miR-122. However, if the genome length of the J6/JFH-1 
replicon is hindering miR-122-independent replication, FGR bears a longer sequence and should 
also exhibit no miR-122-independent replication.  
Our data indicates that FGR replicons can replicate independent of miR-122 since when we 
electroporated FGR RNA with a control miRNA we saw higher luciferase expression than was 
observed with the replication incompetent mutant (Figure 5.7B, WT + miControl vs. GNN), 
particularly at later time points. However, luciferase levels were very low. Thus, this construct 
does not appear to replicate as efficiently as either the SGR or J6/JFH-1 constructs in Hep3B and 
Huh7.5 cells (compare Figure 5.7A to Figure 5.1C and 5.2A; and data not shown). Evaluation of 
supernatant from Day 4 post-electroporation in Figure 5.7C shows limited production of infectious 
virus particles from miR-122-supplemented cells. We periodically observed production of 
infectious virus particles from miR-122-independent replication of FGR RNA in Hep3B cells 
(checkered bar), but we do not see this in every experiment. Thus, we believe that miR-122 un-
supplemented FGR replication in Hep3B cells can produce virus particles, but at very low levels. 
These results, however, suggest that the presence of a second IRES in the SGR and FGR replicons 
permits detectable replication of the viral RNA in the absence of miR-122.  
 
5.3.10 Argonaute-2 is not required for miR-122-independent replication of sub-genomic HCV 
RNA. 
We and others have shown that Argonaute-2 (Ago2), a key player in the microRNA 
suppression pathway, is required for the role that miR-122 plays in translation and stability of 
HCV RNA (Roberts et al., 2011; Shimakami et al., 2012a; Shimakami et al., 2012b; Wilson et al.,  
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Figure 5.8 Ago2 is not required for miR-122-independent replication of sub-genomic HCV. 
A. Hep3B cells were initially electroporated with either siAgo2 or siControl on Day -3; on Day 0, 
cells were electroporated again with the same siRNA, p3 SGR, and the indicated microRNA, along 
with a control Renilla mRNA. Luciferase was assayed at the indicated time-points post-second 
electroporation (Day 0) to detect RNA replication. B. Argonaute-2 knockdown in Hep3B cells 
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with p3 SGR. Left. Relative Hep3B cell numbers were assayed via the biochemical WST-1 assay 
to confirm that siRNA treatment did not affect cell growth. Right. On Day 3 post-second-
electroporation, RNA from all siControl-treated and all siAgo2-treated Hep3B samples was 
collected for qRT-PCR to confirm Ago2 knockdown. C. Hep3B cells were treated as in (A), but 
were electroporated with SGR WT and the indicated miRNA. D. Argonaute-2 knockdown in 
Hep3B cells with SGR WT, analyzed as in (B). E. Huh7.5 cells were treated as in (A); SGR RNA 
was used to represent miR-122-dependent replication, and p3 RNA was used to represent miR-
122-independent replication. F. Argonaute-2 knockdown in Huh7.5 cells, analyzed as in (C). Data 
represent the average of three or more independent experiments and bars represent standard 
deviation. 
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2011). Ago2 has also been implicated in the mechanism of miR-122 augmentation of HCV RNA 
accumulation through the use of Ago2 siRNA knockdown, but these assays could not rule out the 
possibility that Ago2 affected HCV replication through indirect modulation of other cellular 
functions (Wilson et al., 2011). To test the hypothesis that Ago2 promotes HCV replication due to 
its role in mediating the activity of miR-122, we assessed the influence of Ago2 knockdown on 
miR-122-independent SGR replication in Hep3B and Huh 7.5 cells (Figure 5.8). In Hep3B cells, 
Ago2 knockdown had no effect on miR-122/p3-independent replication of the p3 SGR and the 
wild-type SGR (Figure 5.8A and 5.8C, compare siAgo2 – miControl to siControl – miControl). 
However, Ago2 knockdown severely hampered the ability of miR-122/p3 to enhance p3 SGR 
luciferase expression (Figure 5.8A, compare siAgo2 – miR-122/p3 to siControl – miR-122/p3, and 
Figure 5.8C, compare siAgo2 – miR-122 to siControl – miR-122). Thus, the influence of Ago2 
knockdown on HCV replication is primarily via modulation of miR-122 activity. Evaluation of 
cell numbers confirmed that cell survival had no impact on our luciferase results, while we 
achieved 64% Ago2 mRNA knockdown as measured by qRT-PCR in both series of experiments 
(Figure 5.8B and 5.8D). We saw similar results in Huh7.5 cells. miR-122-independent replication 
of p3 SGR was unaffected by Ago2 knockdown (Figure 5.8E, compare siControl – p3 to siAgo2 
– p3), and miR-122-dependent replication of wild-type SGR RNA was reduced by Ago2 
knockdown (compare siControl – SGR to siAgo2 – SGR).  That Ago2 knockdown had a less severe 
effect on miR-122 dependent replication in Huh 7.5 cells than in Hep3B cells may have been due 
to less efficient Ago2 knockdown, 51%, in these cells. Huh7.5 cell numbers were also not affected 
by multiple electroporation (Figure 5.8F). Thus, while Ago2 plays a critical role in miR-122-
mediated enhancement of HCV RNA accumulation, we show here that its presence or absence 
does not appear to impact miR-122-independent replication of HCV, which suggests that the 
disruption of Ago2 activity outside of its role in supporting miR-122 does not significantly affect 
HCV replication following siRNA knockdown. 
 
5.4 Discussion 
We have demonstrated that Hep3B cells are a valuable model system for studying Hepatitis C 
virus. Hep3B cells can be rendered permissive for robust replication of sub-genomic (SGR), full-
genomic (FGR), and full-length (J6/JFH-1) replicons by supplementation with the liver-specific 
microRNA, miR-122. Supplementation with miR-122 allows us to recapitulate the complete virus 
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life cycle in Hep3B cells, from infection to production of new infectious virus particles, although 
HCV entry was inefficient in our experiments. Because Hep3B cells lack endogenous miR-122, 
we were also able to identify miR-122-independent replication of sub-genomic (SGR) and full-
genomic (FGR) bi-cistronic replicons. This enabled us to generate a sub-genomic mutant virus that 
can replicate independently of miR-122 in both Hep3B cells and Huh7-derived cells. 
The liver-specific microRNA, miR-122, augments replication of HCV RNA in Huh7-derived 
cells, and has been used to enhance replication of stable HCV replicons in non-liver cells such as 
HEK 293s and mouse MEFs (Chang et al., 2008; Fukuhara et al., 2012; Jopling et al., 2005; Lin 
et al., 2010). This led to the development of our hypothesis that miR-122 could be used to permit 
transient, unselected replication of HCV in other non-permissive cells. In the last year, two other 
labs have also published data on human liver cell lines supplemented with miR-122 to render them 
permissive to HCV replication (Kambara et al., 2012; Narbus et al., 2011). In our hands, and in 
the lab of Y. Matsuura, Hep3B cells can support levels of HCV replication and virus particle 
production similar to that found in Huh7-derived cells with no selection or adaptation (Kambara 
et al., 2012). Additionally, HCV RNA accumulation (Figure 5.2F) and virion production (Figure 
5.2E) in Hep3B cells were equivalent to that of Huh7.5 cells. However, contrary to a previous 
report in which Hep3B cells stably expressing miR-122 were highly infectable (Kambara et al., 
2012), we observed that Hep3B cells transfected with miR-122 were much less permissive to HCV 
entry (Figure 5.4A). Ploss et al. and Sainz et al. found Hep3B cells to be equally as permissive as 
Huh7 cells for entry by using lentiviral particles pseudotyped with HCV envelope proteins 
(HCVpp) as well as HCVcc (Ploss et al., 2009; Sainz et al., 2012). Observations by Shimakami et 
al. agreed with this using Hep3B cells stably expressing miR-122, which leads us to suspect that 
transient means of providing miR-122 reduced the infectability of Hep3B cells. However, Hep3B 
infection efficiency was not improved by electroporation of miR-122 (Figure 5.4Figure 5.4C and 
5.4D), thus poor infection may have been due to harmful effects of transfection (Figure 5.4) and 
electroporation, or perhaps to a different characteristic of the Hep3B cells used in our laboratory.  
High cellular levels of miR-122 coincide with efficient replication of the virus (as measured 
by luciferase) and production of infectious virus particles, and replication decreases as miR-122 
levels decrease over time (Figure 5.3). This suggests that miR-122 supports the continuing high 
levels of HCV RNA during the virus life cycle. This data agrees with other reports which showed 
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that miR-122 antagonism reduces HCV RNA levels in stable HCV cell lines (Jopling et al., 2005; 
Lee et al., 2012), and in HCV infected chimpanzees (Lanford et al., 2010).  
Interestingly, we have found that miR-122 is not essential for replication of bi-cistronic JFH-
1 sub-genomic (Figure 5.1C, Figure 5.6) and full-length (Figure 5.7) replicons in Hep3B or Huh7.5 
cells. By determining that Hep3B cells lack functional miR-122 (Figure 5.1B, 5.5, 5.6) we have 
shown that the basal replication of SGR and FGR in Figures 5.1, 5.6, and 5.7 occurs independently 
of miR-122, and have confirmed this through use of the mutant p3 SGR. Cells harbouring stably 
replicating HCV replicons have been established previously through antibiotic selection in cell 
lines that are not known to express miR-122, which indicated the possibility of miR-122-
independent replication, but the mechanism remained a mystery (Ali et al., 2004; Date et al., 2004; 
Kato et al., 2005b; Uprichard et al., 2006). In these instances, low levels of miR-122 expression in 
the cells, or the evolution of adaptive mutations in the 5´ UTR, had not been eliminated. Here, we 
have demonstrated transient miR-122-independent replication of HCV SGR RNA, confirming that 
miR-122 is not essential for replication of JFH-1 bi-cistronic constructs. Thus, HCV bi-cistronic 
replicons are capable of replicating independently of miR-122, while still being sensitive to 
supplementation with the microRNA.  
We have validated the usefulness of a mutant miR-122 binding site replicon, the p3 SGR, to 
study miR-122-dependent and -independent HCV replication. The p3 SGR replicon replicates to 
levels similar to those of wild-type SGR in the absence of miR-122, and is completely unaffected 
by the addition or removal of miR-122 (Figure 5.6C and E). However, when supplemented with 
miR-122/p3, which bears the complementary mutation in the miRNA sequence, replication of the 
p3 SGR is restored to levels that are within three-fold of wild-type SGR in the presence of miR-
122. By supplementing the p3 SGR RNA with exogenous miR-122 in Hep3B cells, and by using 
a miR-122 antagonist in Huh7.5 cells, we confirmed that it replicated entirely independent of miR-
122. Our data also suggests that a sub-genomic HCV mutant with p3-4 mutations at both miR-122 
binding sites exhibits impaired replication aside from lack of miR-122 binding (Wilson et al., 
2011). HCV SGR RNA carrying the p3-4 mutation could not replicate independently of miR-122 
(data not shown), and could not be complemented to within a log of wild-type through use of a 
complementary miR-122/p3-4 (Wilson et al., 2011). Interestingly, both p3 and p3-4 mutants have 
been shown to reach wild-type levels when complemented with the appropriate miRNAs in a sub-
genomic genotype 1a H77 replicon by Jopling et al., leading us to suspect that deficiencies in the 
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p3-4 mutant may be particular to JFH-1 or genotype 2a viruses (Jopling et al., 2005). Thus the p3 
mutation will be more useful than other miR-122 binding site mutants for studying replication of 
HCV JFH-1 in the presence and in the absence of miR-122, as it is fully complementable in 
multiple genotypes of virus.  
miR-122-independent replication is much less efficient than miR-122-dependent replication. 
Luciferase expression levels observed for miR-122-independent replication were approximately 
100-fold lower than for miR-122 augmented replication. In time-course experiments to compare 
luciferase expression kinetics of miR-122-dependent and -independent replication, the 100-fold 
difference was apparent by 1 day post-electroporation (Figure 5.1C, Figure 5.6). However, after 
day 1, the rate of increase in luciferase expression of miR-122-dependent and miR-122-
independent replication appears similar. Thus, we suspect that miR-122 is not essential for ongoing 
HCV RNA amplification per se, but appears to be required to establish and sustain high levels of 
HCV RNA inside the cell. This is consistent with the proposed role of miR-122 in promoting HCV 
RNA stability and suggests that a major role of miR-122 is to establish HCV replication at early 
stages in the life cycle (Machlin et al., 2011; Shimakami et al., 2012a; Villanueva et al., 2010). In 
addition, bi-cistronic, but not mono-cistronic HCV RNAs are capable of miR-122-independent 
replication. The SGR and FGR replicons are bi-cistronic constructs, with translation of the viral 
genes driven by an EMCV IRES and thus unaffected by miR-122. The HCV IRES only drives 
expression of the luciferase reporter genes, separating control of the replication machinery from 
normal HCV translation mechanisms. We propose that miR-122-independent replication relies on 
the presence of the EMCV IRES and possibly different translation regulation. It remains to be 
determined if full length JFH-1 is capable of miR-122 independent replication, and whether this 
phenomenon is relevant to the life cycle of HCV in infected patients. It is also unknown if bi-
cistronic replicons from other HCV isolates and genotypes will also demonstrate capacity for miR-
122-independent replication; however, we expect this may be difficult to detect in systems with 
replication levels lower than that of the JFH-1 isolate. However, miR-122 independent replication 
of JFH-1 SGR is a useful model to study the role of miR-122 in the life cycle of HCV in tissue 
culture. 
Analysis of genes that influence miR-122-dependent but not miR-122-independent replication 
provides a new screening tool for the identification of genes involved in the activity of miR-122. 
In the past, Ago2 has been implicated in the mechanism of miR-122 augmentation of HCV 
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replication based on data showing that Ago2 knockdown reduces HCV RNA accumulation in 
infected cells (Wilson et al., 2011). However, an indirect effect of Ago2 knockdown on HCV 
replication due to modulation of other miRNA regulated pathways could not be excluded in these 
experiments. In addition, conflicting reports of a role for Ago2 in an experiment in which miR-
122-induced augmentation of HCV RNA accumulation was measured suggest caution in 
interpreting data generated by using this method (Machlin et al., 2011; Wilson et al., 2011). Thus 
robust methods to confirm that Ago2 or other miRNA pathway proteins play a direct role in the 
mechanism miR-122 augmentation of HCV RNA accumulation were lacking. Using wild-type and 
p3 sub-genomic HCV replicons to analyse miR-122-dependent and -independent HCV replication 
in Hep3B and Huh 7.5 cells, we have shown that Ago2 knockdown does not affect miR-122-
independent replication, verifying that the role of Ago2 in the HCV life cycle lies in primarily in 
the activity of miR-122 (Figure 5.8). Examination of replication of the SGR and FGR constructs 
in a miR-122-free system such as Hep3B cells will allow us to analyze whether other components 
of the miRNA pathway involved in miR-122-mediated enhancement of HCV stability and/or 
replication may also act on HCV independently of miR-122.  
Ultimately, the development of a Hep3B-based cell line for studying the HCV life cycle will 
be useful for the field of HCV research. Nearly all HCV research is carried out in Huh7-derived 
cells, all of which will bear the same host genetics and polymorphisms, and the same or similar 
dysregulation of cellular pathways, potentially limiting the value of screens designed to discover 
virus-host interactions. Hep3B cells have already been useful in detecting and confirming miR-
122-independent viral replication, and are an alternative cell line in which to identify or confirm 
other virus-host interactions. 
 
5.5 Materials and Methods 
5.5.1 Cell Lines.  
Huh7.5 cells are a derivative cell line of Huh7 cells and were obtained from Charles Rice 
(Blight et al., 2002; Nakabayashi et al., 1982). Hep3B cells are a human hepatoma cell line (ATCC 
number HB-8064) containing an integrated Hepatitis B genome (Aden et al., 1979; Knowles et al., 
1980). HepG2 cells (ATCC number HB-8065) are also a human hepatoma cell line (Aden et al., 
1979). All cell lines were maintained as described previously (Wilson et al., 2011). 
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5.5.2 Plasmids and viral RNA. 
Plasmids pSGR JFH-1 Fluc WT and pSGR JFH-1 Fluc GND bear sub-genomic JFH-1-derived 
replicons with a firefly luciferase reporter (Kato et al., 2005a). Plasmids pJ6/JFH-1 FL Rluc WT 
and pJ6/JFH-1 FL Rluc GNN bear full-length viral sequences derived from the J6 (structural 
proteins) and JFH-1 (non-structural proteins) isolates of HCV, and a Renilla luciferase reporter 
(Jones et al., 2007). Plasmids pFGR Fluc JFH-1 WT and pFGR JFH-1 Fluc GNN bear full-
genomic bi-cistronic replicons of JFH-1, and a firefly luciferase reporter (Wakita et al., 2005). 
Plasmids pSGR p3 S1+S2 Fluc WT and pSGR p3 S1+S2 Fluc GND have C to G mutations at 
position 3 in the miR-122 seed binding sites S1 and S2 in the HCV 5´ UTR. The mutations were 
generated within the plasmid pSGR Fluc WT by using the QuikChange Site-Directed Mutagenesis 
kit (Agilent Technologies; Mississauga, ON, Canada) and the following primers: Site 1: 5´-ATA 
GGG GCG ACA CTG CGC CAT GAA TCA CTG-3´ and 5´-CAG TGA TTC ATG GCG CAG 
TGT CGC CCC TAT-3´. Site 2: 5´-CCA TGA ATC ACT GCC CTG TGA GGA AC-3´ and 5´-
GTT CCT CAC AGG GCA GTG ATT CAT GG-3´. “GNN” and “GND” mutants of each replicon 
bear the indicated inactivating mutations in the viral polymerase GDD motif. To make viral and 
sub-genomic RNA, all plasmid templates were linearized with XbaI and blunt-ended with mung 
bean nuclease (New England Biolabs; Pickering, ON, Canada), and then transcribed in vitro using 
the MEGAScript T7 High Yield Transcription Kit (Life Technologies; Burlington, ON, Canada) 
according to the accompanying protocol. Messenger RNA was transcribed in vitro using the 
mMessage mMachine T7 Kit (Life Technologies) according to the accompanying protocol. Firefly 
luciferase mRNA was transcribed from the Luciferase T7 Control DNA plasmid (Promega; 
Nepean, ON, Canada), linearized using XmnI, while Renilla luciferase mRNA was transcribed 
from the pRL-TK plasmid (Promega), linearized using BglII. pFluc122x2 is a plasmid coding for 
firefly luciferase followed by two repeats of the HCV miR-122 binding sites in the 3´ UTR of the 
reporter’s mRNA (Machlin et al., 2011). 
 
5.5.3 MicroRNAs and Anti-miR sequences.  
miR-122: UGG AGU GUG ACA AUG GUG UUU GU and miR-122*: AAA CGC CAU UAU 
CAC ACU AAA UA, annealed. miR-122/p3: UGC AGU GUG ACA AUG GUG UUU GU 
annealed to miR-122*. miControl: UAA UCA CAG ACA AUG GUG UUU GU annealed to miR-
122*. The miRIDIAN microRNA Hairpin Inhibitor, human hsa-miR-122a (proprietary sequence) 
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was used to inhibit miR-122 (α-miR-122), with miRIDIAN microRNA Hairpin Inhibitor Negative 
Control #1 (proprietary sequence) was used as a control (α-Control). siControl: AAG ACA CUG 
AGA CAC CAA UUG AC (Wilson et al., 2003). siAgo2: CAG ACU CCC GUG UGU CCU ATT 
(Wilson et al., 2011). All short RNAs were synthesized by ThermoScientific Dharmacon 
(Lafayette, CO, USA).  
 
5.5.4 Electroporations.  
All electroporations were carried out according to Lohmann et al. (2001) with some 
modifications: each sample contained 6.0x106 cells in 400 µL Dulbecco’s PBS for electroporation, 
cells were plated in culture media, and 500 µL of cells were seeded in 6 cm dishes for each time 
point. Cells were electroporated using 4 mm cuvettes at infinite resistance; optimized for the 
BioRad GenePulser XCell (BioRad; Mississauga, ON, Canada), Hep3B cells were electroporated 
at 225 V and 950 µF, while Huh7.5 cells were electroporated at 270 V and 950 µF. Where 
indicated, samples were electroporated with 10 µg viral RNA; 60 pmol microRNA and/or miR-
122 antagonist; and 2 µg messenger RNA coding for the luciferase reporter not found in the viral 
replicon. In dilution experiments, the indicated amount of microRNA was used instead. For Ago2 
knockdown experiments, 8.0x106 cells in 400 µL of Dulbecco’s PBS were first electroporated with 
60 pmol of the indicated siRNA to create Ago2 knockdown cells; two samples were pooled and 
plated in 15 cm dishes to recover. Three days post-first-electroporation, cells were again prepared 
as above (8.0x106 cells in 400 µL), and electroporated with 60 pmol of the same siRNA, plus viral 
RNA, microRNA, and mRNA as above. Cells were harvested at the indicated time points and 
indicated as time post-second electroporation. For 15-day experiments, cells were passaged 1/3 on 
Day 9 post-electroporation due to confluence. 
 
5.5.5 Transfections.  
For miR-122 suppression activity assays, Hep3B cells were electroporated with the indicated 
miRNA/miR-122 antagonist, and were plated in triplicate at 2.5x104 cells per well in 24-well 
dishes. Two days post-electroporation, each sample was transfected with 50 ng pRL-TK control 
plasmid and 50 ng pFluc122x2 in 1 µL Lipofectamine 2000 according to the suggested protocol 
(Life Technologies). Cell extracts were harvested and analyzed for luciferase expression one day 
post-transfection, to analyze miR-122 suppression activity. For miR-122 transfection to 
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supplement cells prior to HCV infection, Hep3B cells were plated at 1.0x105 cells per well in 6-
well dishes one day before transfection. Cells were transfected according to the Lipofectamine 
2000 protocol with 100 pmol microRNA one day prior to infection. 
 
5.5.6 Infections. 
To evaluate HCV infectious virus production, naїve Huh7.5 cells were plated at 1.0x105 cells 
per well in a 6-well dish one day pre-infection. Hep3B supernatant was collected at the indicated 
time, spun to pellet cell debris, and 2 mL was plated on the naїve Huh7.5 cells. Cell extracts were 
harvested as above three days post-infection and assayed for luciferase expression to monitor HCV 
infection. To evaluate Hep3B infectability, HCV infectious supernatant from Huh7.5 cells 
(described below, approximately 104 FFU/mL) was plated on Hep3B cells at the indicated time 
post-Hep3B-electroporation or transfection. 2 mL of supernatant was added to approximately 
1x105 Hep3B cells per well of a 6-well dish. Cell extracts were harvested at the indicated time 
points post-infection to detect infection of Hep3B cells by using luciferase assays. 
 
5.5.7 HCV Titration.  
HCV titre was evaluated by focus-forming assay. One day pre-infection, naїve Huh7.5 cells 
were plated on a chamber slide such that they would be 90% confluent in four days. Cells were 
infected on Day 0, and fixed with acetone three days post-infection. 1:200 mouse-anti-HCV Core 
(C7-50, Abcam; Cambridge, MA, USA) in 5% BSA was used to detect foci of infection, and 1:100 
goat-anti-mouse IgG Alexa-fluor 488 (Life Technologies) in PBS was used for visualization. 
Results are reported as focus-forming units per mL of supernatant. 
 
5.5.8 Luciferase Assays. 
For replication assays, 500 µL electroporated cells were plated with 4mL media in a 6cm dish 
and incubated for 1-5 days, and cell extracts were harvested in 100 µL of the appropriate lysis 
buffer. For suppression assays, cells were plated as indicated for transfection, and were harvested 
in 100 µL passive lysis buffer. The Dual Luciferase Assay Reporter Kit (Promega) was used for 
all samples analyzed for both Renilla and firefly luciferase activity. The Renilla Luciferase Assay 
Reporter System (Promega) was used for all samples analyzed solely for Renilla luciferase 
activity, and the Luciferase Assay System (Promega) was used for all samples analyzed solely for 
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firefly luciferase activity. Harvests and assays were carried out according to the kits’ protocols; 
results were read in the GLOMAX luminometer (Promega) with a 2-second delay and 10-second 
reading.  
 
5.5.9 Total RNA. 
Total RNA was harvested and isolated using Trizol reagent (Life Technologies) and the 
associated protocol. Untreated cells were plated at 107-108 cells per 10 cm tissue culture dish and 
were harvested into 1 mL Trizol at least 24 hours later. Total RNA samples collected after HCV 
RNA electroporation were plated at 1.5x106 cells (2 mL) on a 10 cm dish and harvested 3 days 
post-electroporation into 1 mL Trizol. 
 
5.5.10 qRT-PCR. 
miRNA qRT-PCR: miRNAs were reverse-transcribed using the TaqMan MicroRNA Reverse 
Transcription Kit (Life Technologies) according to the provided protocol, with RT primers from 
the hsa-miR-122 (002245) and RNU6B (001093) TaqMan MicroRNA Assay kits (Life 
Technologies). miRNA qPCR reactions were assembled according to the TaqMan Small RNA 
Assay protocol with 2X TaqMan Master Mix (Life Technologies) and probes for hsa-miR-122 and 
RNU6B TaqMan MicroRNA Assay kits described above. Quantitative amplification was carried 
out with samples in triplicate in a 96-well plate in the CFX96 real-time PCR system (BioRad) 
according to kit protocol. Ago2 qRT-PCR: total cellular RNA was reverse-transcribed using the 
iScript cDNA Synthesis Kit (BioRad). qPCR reactions were carried out using the TaqMan kits 
Hs00293044_m1 (Ago2) and FAM-MGB 4352934-0803022 (GAPDH); samples were amplified 
in triplicate as for miRNA qPCR. All data was analyzed with the CFX Manager Software 
(BioRad). 
 
5.5.11 Northern blot. 
Protocol was carried out as described in (Wilson et al., 2011). Bands were imaged and 
quantified using a Molecular Imager (BioRad) and the QuantityOne software (BioRad). 
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5.5.12 Relative cell numbers. 
20 µL of cells immediately post-electroporation were plated in triplicate in a 96-well plate. 
Three days post-electroporation, WST-1 reagent (Roche Diagnostics; Laval, QC, Canada) was 
added to the cells according to the manufacturer’s protocol. Colourimetric reactions based on 
mitochondrial activity were measured one to two hours post-treatment on a SpectraMax 340 
PC384 Microplate Spectrophotometer (Sunnyvale, CA, USA). Cell numbers were based on a 
standard curve of ten-fold dilutions of the appropriate cell type. 
 
5.5.13 Data Analysis. 
All data is displayed as a mean of three or more independent experiments (except where 
indicated) and bars indicate standard error of the mean. 
 
5.6 Acknowledgements 
We thank Charlie Rice, Peter Sarnow, and Takaji Wakita for reagents.  P.A.T. held a CGS-M 
scholarship from NSERC and is currently a scholarship recipient from the National CIHR Training 
Program in Hepatitis C. The study was supported by funds from the University of Saskatchewan, 
Saskatchewan Health Research Foundation (establishment, 10156; and team grant, RAPID, 1927), 
National Sciences and Engineering Research Council (discovery grant G9631), and the Canadian 
Foundation for Innovation (18622). 
  
86 
 
6.0 miR-122-Independent Replication as a Tool for Understanding HCV and miR-122 
Having characterized and validated Hep3B cells and the p3 sub-genomic mutant HCV RNA 
as tools for understanding the role of miR-122 in the Hepatitis C virus life cycle (Chapter 5), we 
next set out to use these tools to better understand the mechanism of miR-122-mediated 
augmentation of HCV RNA accumulation. A recent publication provided evidence that one of the 
functions of miR-122 was to protect the viral RNA from degradation, mediated by the host 
cytoplasmic 5´ to 3´ RNA exonuclease, Xrn1 (Li et al., 2013d). We considered our miR-122-
independent HCV replication system an ideal context in which to verify that miR-122 protects the 
viral RNA from Xrn1. Further, we considered this model system and its derivatives ideal to further 
characterize the mechanism of miR-122-mediated protection by understanding the role of binding 
at each miR-122 binding site on the viral 5´ UTR.  
The experiments in Chapter 7 were conceived by PAT, AH, JG, DP, and JAW, and were 
carried out primarily by PAT with assistance from JG and DP. PAT, AH, and JAW analyzed the 
data, and PAT and JAW wrote the paper. 
  
87 
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7.1 Abstract 
miR-122 is a liver-specific miRNA that plays a critical role in the HCV life cycle by binding 
to two sites (S1 and S2) on the 5´ UTR of the viral RNA. It positively affects viral RNA stability, 
translation, and replication, but the mechanism for these functions is not well-understood. To 
unravel the role in the virus life cycle of miR-122 binding at each miR-122 binding site, we 
employed Hep3B cells, which do not express miR-122, miR-122 binding site mutant viral RNAs, 
and complementation with either miR-122 or a mutant miRNA that binds to the mutated sites. We 
found that miR-122 binding at either site alone increased replication equally, while binding at both 
sites had a moderately co-operative effect. miR-122 is known to protect HCV RNA from Xrn1, a 
cytoplasmic 5´ to 3´ exoribonuclease. Xrn1 depletion rescued miR-122-unbound full-length RNA 
replication to detectable levels, but not to miR-122-bound levels, confirming that miR-122 has 
additional functions beyond protection from Xrn1. In cells depleted of Xrn1, replication of S1-
bound HCV RNA was greater than S2-bound, suggesting unequal contributions of each binding 
site to HCV replication when the need for protection from Xrn1 is reduced. miR-122 binding at 
S1 or S2 also increased translation, but when Xrn1 was knocked down, miR-122 binding at either 
site no longer had an effect, suggesting that the influence of miR-122 on HCV translation reflects 
protection from Xrn1 degradation. Our results show that both miR-122 binding sites contribute to 
protection of the viral RNA from Xrn1, but binding at S2 does so more than binding at S1. We 
also suggest then that miR-122 binding at S1 is more important for the additional function(s) of 
miR-122 in augmentation of viral RNA replication. 
 
7.2 Introduction 
Hepatitis C virus is a hepatotropic virus that infects an estimated 150 million humans 
worldwide, a significant portion of whom do not know their status due to the largely asymptomatic 
nature of the infection (WHO, 2012). The virus is transmitted by blood to blood contact, and 
humans are the only known reservoir. Chronic infection occurs in approximately 70% of cases, 
and can lead to sequelae such as metabolic disease, steatosis, hepatocellular carcinoma, and 
decompensated liver disease late in infection (Strader et al., 2004).  
One of the major determinants of the virus’ hepatotropism is its requirement for the liver-
specific, liver-abundant microRNA, miR-122 (Thibault et al., 2013; Thibault and Wilson, 2014). 
miR-122 binds to two sites at the 5´ end of the virus’ positive sense RNA genome, and has been 
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shown to directly enhance viral RNA accumulation, since mutation of the miR-122 binding sites 
abolish RNA accumulation and provision of exogenous miR-122 sequences having compensatory 
mutations that restore binding reinstate RNA accumulation (Huys et al., 2013; Jangra et al., 2010b; 
Jopling et al., 2008; Machlin et al., 2011; Norman and Sarnow, 2010; Shimakami et al., 2012b; 
Thibault et al., 2013). We, and others have also ruled out any significant indirect influence of miR-
122 on HCV in cell culture models (Jopling et al., 2008; Norman and Sarnow, 2010; Thibault et 
al., 2013). Argonaute-2, one of the key effector proteins in the microRNA pathway, is required for 
miR-122 to increase HCV replication, while several other proteins in the microRNA pathway and 
RNA-induced silencing complex (RISC) have been implicated in either biogenesis or the direct 
interaction of miR-122 with HCV (Huys et al., 2013; Roberts et al., 2011; Shimakami et al., 2012a; 
Wilson et al., 2011; Zhang et al., 2012). Although miR-122 uses canonical microRNA seed 
sequence binding and RISC components when interacting with the HCV genome, it also binds to 
HCV nucleotides outside the seed sequence, creating a double stranded RNA/protein structure that 
overhangs the very 5´ end of the viral genome, and also interacts with the “spacer” sequence 
located between miR-122 binding sites S1 and S2 on the HCV 5´ UTR (Machlin et al., 2011; 
Shimakami et al., 2012a).  
While interaction between miR-122 and the HCV 5´ UTR causes an increase in HCV RNA 
accumulation, evidence suggests that there are multiple mechanisms involved. miR-122 modestly 
increases translation of the viral RNA, but this has recently been attributed to simply increasing 
stability of the viral RNA, allowing more viral RNA to be translated (Henke et al., 2008; Jangra et 
al., 2010b; Roberts et al., 2011; Shimakami et al., 2012a). In particular, miR-122 has been 
implicated in shielding the 5´ end of the viral RNA from degradation by Xrn1, the major 
cytoplasmic 5´ to 3´ exoribonuclease that normally functions to degrade decapped host mRNAs 
and other Flavivirus RNAs (Jones et al., 2010b; Li et al., 2013d; Nagarajan et al., 2013; Roby et 
al., 2014). Ultimately, though, the increase in translation and stability is considered insufficient to 
explain the increase in HCV RNA accumulation mediated by miR-122, and other mechanisms 
require exploration (Jangra et al., 2010b; Li et al., 2013d; Shimakami et al., 2012a). 
Here we verify that miR-122 protects the 5´ end of the viral genome from Xrn1, and that each 
of the miR-122 binding sites plays a role in this. We also show that knockdown of Xrn1 positively 
impacts translation, and that the function of miR-122 in promoting translation is primarily through 
protection from Xrn1. However, our results also indicate that protection from Xrn1 is not the only 
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function of miR-122 in the viral life cycle and that miR-122 must have additional functions. 
Finally, we found that binding of miR-122 at each site contributes equally to replication, while 
binding at both sites demonstrates a co-operative effect. However, in the absence of Xrn1, binding 
at S1 increased replication more than binding at S2, suggesting that S1 binding contributes more 
to the additional functions of miR-122 in HCV. 
 
7.3 Results 
7.3.1 Impact of Xrn1 on HCV RNA replication.  
7.3.1.1 Xrn1 knockdown affects miR-122-unbound sub-genomic HCV replication more than miR-
122-bound sub-genomic replication. 
Xrn1, a host cytoplasmic 5´ to 3´ RNA exonuclease, has been shown to target the 5´ end of 
HCV RNA for degradation; miR-122 has been implicated to have a role in protecting the viral 
RNA from Xrn1 (Li et al., 2013d). In spite of this relationship, in a previous report, Xrn1 
knockdown did not restore any detectible replication of an HCV genome to which miR-122 
binding had been abolished; this finding was deemed evidence that protection from Xrn1 was not 
the only function for miR-122 during the HCV life cycle. We believed that our previously-
characterized system of miR-122-independent replication of HCV RNA would be ideal to further 
test whether knockdown of Xrn1 can restore or improve HCV replication in the absence of miR-
122 binding and verify whether miR-122 plays a key role in abolishing the impact of Xrn1 on 
HCV RNA (Thibault et al., 2013). To test this, we used siRNAs to knock down Xrn1 in Hep3B 
cells, and after waiting for three days to allow knockdown to occur, we electroporated the cells 
again with siRNA and miRNA as indicated, along with transfection control Renilla luciferase 
reporter mRNA and sub-genomic viral RNA. We have previously shown that sub-genomic JFH-1 
HCV RNA (SGR WT, a bi-cistronic construct that expresses a firefly luciferase reporter gene) can 
replicate at low levels without miR-122 binding to the 5´ UTR, and that Hep3B cells are an ideal 
system to study miR-122-independent replication because they do not express detectable miR-122. 
We can therefore test miR-122-independent replication of wild-type HCV RNAs, instead of using 
constructs with miR-122 binding site mutations (Thibault et al., 2013). We hypothesized that if 
miR-122 functioned to protect the 5´ end of the viral RNA from degradation by Xrn1, then 
abolition of Xrn1-mediated degradation of the viral RNA by Xrn1 knockdown should enhance 
miR-122-independent HCV replication. If protection from Xrn1 is the primary role for miR-122, 
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then Xrn1 knockdown should restore replication in the absence of miR-122 binding to levels 
similar to replication with miR-122 binding.  
Our results (Figure 7.1A) show that while knockdown of Xrn1 increased miR-122-unbound 
replication levels by up to 22-fold (compare siControl [Unbound] to siXrn1 [Unbound]), it did not 
reach the same levels of replication as miR-122-bound replication (compare siXrn1 [Unbound] to 
siControl [Bound]). We verified that the siXrn1 treatment reduced Xrn1 mRNA by 62% in Hep3B 
cells (Figure 7.1C). We also ensured that knockdown of Xrn1 or other treatments did not affect 
Hep3B cell growth three days post-second electroporation (data not shown) and that transfection 
efficiency was similar for all samples as measured by Renilla luciferase expression from the 
control mRNA two hours post-second electroporation (data not shown). Thus Xrn1 knockdown 
can augment but cannot restore replication of miR-122-unbound HCV RNA, which suggests that 
protection from Xrn1 is not the only function for miR-122 in promoting HCV replication. Similar 
to the finding of Li et al. we observed that Xrn1 knockdown also enhanced replication levels of 
miR-122-bound HCV RNA, suggesting that if miR-122 protects the RNA from degradation by 
Xrn1, that protection is not complete (Li et al., 2013d).  
If miR-122 functions to shield the viral RNA from Xrn1, then knockdown of Xrn1 would have 
a greater impact on HCV replication without miR-122 binding than with miR-122 binding. 
Conversely, if miR-122 did not play a role in shielding the viral RNA from Xrn1, then knockdown 
of Xrn1 would have the same impact on replication with and without miR-122 binding. To test 
this, we compared the effect of Xrn1 knockdown on miR-122-bound and miR-122-unbound 
replication (Figure 7.1B). We confirmed others’ observations that knockdown of Xrn1 had a 
positive impact on viral replication when miR-122 was bound, increasing replication 5-fold by 
three days post-second electroporation. However, we also demonstrated that knockdown of Xrn1 
had a greater impact on replication of miR-122-unbound SGR WT RNA and increased it by 22-
fold on Day 2, and 16-fold on Day 3, considerably more than the impact of knockdown on miR-
122-bound replication. Ultimately, this supports a model where miR-122 binding plays a role in 
protecting the HCV genome from Xrn1, but the protection is incomplete. 
Huh7-derived cells are the most-commonly used cell lineage when studying Hepatitis C virus 
in vitro, and so we also verified our conclusions in Huh7.5 cells. However, because Huh7.5 cells 
express miR-122, in order to test miR-122-unbound replication we made use of a miR-122 binding 
site mutant sub-genomic RNA, SGR S1+S2:p3 (Thibault et al., 2013) that has already been shown  
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Figure 7.1 Impact of Xrn1 knockdown on miR-122-bound and miR-122-unbound rsub-genomic 
JFH-1 HCV replication in Hep3B cells. 
A. Hep3B cells were electroporated with siXrn1 or siControl for pre-knockdown, and three days 
later (Day 0) cells were electroporated again with the indicated siRNA, wild-type sub-genomic 
HCV RNA (SGR) containing a firefly luciferase reporter gene, a Renilla messenger RNA to 
control for transfection efficiency, and miR-122 (Bound) or miControl (Unbound). Replication 
was measured by evaluating luciferase production at the indicated time points post-second 
electroporation. B. The effect of Xrn1 knockdown on miR-122-bound and miR-122-unbound sub-
genomic HCV RNA replication was determined by measuring the fold increase in luciferase 
expression with siXrn1 treatment over luciferase expression with no knockdown (siControl), using 
luciferase data from (A) at the indicated time points. Significance was determined by paired 
parametric t-test. C. The effectiveness of siXrn1 at knocking down Xrn1 mRNA levels in Hep3B 
cells was determined by RT-qPCR of RNA collected three days post-second electroporation, 
shown here as fold mRNA reduction normalized to host GAPDH mRNA levels. D. Huh7.5 cells 
were treated as in (A), but no miRNA was added since Huh7.5 cells already express endogenous 
miR-122. “Bound” samples were electroporated with wild-type SGR RNA, while “Unbound” 
samples were electroporated with the miR-122 binding site-mutant SGR S1+S2:p3 RNA described 
in Thibault et. al. (Thibault et al., 2013), which does not respond to miR-122. E. The effect of Xrn1 
knockdown on miR-122-bound and miR-122-unbound sub-genomic HCV RNA replication was 
determined as in (B). Significance was determined by unpaired parametric t-test. F. The effect of 
siXrn1 treatment on Xrn1 mRNA levels in Huh7.5 cells was evaluated as in (C).  
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to be unresponsive to miR-122. SGR S1+S2:p3 contains a C to G mutation at position 3 in both 
miR-122 binding sites (S1 and S2) that abolishes miR-122 binding, and replicates to similar levels 
as miR-122-unbound SGR WT. We again observed that knockdown of Xrn1 increased replication 
of both miR-122-bound and miR-122-unbound SGR (Figure 7.1D), that Xrn1 knockdown did not 
restore miR-122-unbound replication to miR-122-bound levels (Figure 7.1D), and that miR-122-
unbound replication increased to a much greater degree (12-fold) than miR-122-bound replication 
(2.5-fold, Figure 7.1E). We also observed that siXrn1 treatment reduced Xrn1 mRNA levels by 
63% in Huh7.5 cells (Figure 7.1F), Xrn1 knockdown did not affect Huh7.5 cell growth, and 
transfection efficiency was similar in all samples (data not shown). Thus, we show here that Xrn1 
knockdown has a positive impact on HCV replication, and that it has a greater effect on HCV 
replication when miR-122 is not bound to the viral 5´ UTR, suggesting a specific role for miR-122 
in protecting the viral RNA from Xrn1. 
 
7.3.1.2 The greater impact of Xrn1 knockdown on miR-122-unbound sub-genomic HCV RNA 
replication is not due to resource limitations for miR-122-bound replication. 
To exclude the possibility that the difference in effects of Xrn1 knockdown on miR-122-
dependent and miR-122-independent replication was impacted by the different levels of replication 
observed and the host cell’s capacity to support HCV replication, we repeated our experiments 
using dilutions of viral RNA that would establish miR-122-bound replication levels similar to miR-
122-unbound replication. To do this we electroporated Huh7.5 cells with 1000-fold less SGR WT 
RNA than S1+S2:p3 RNA (Figure 7.2A, compare siControl [p3, Unbound] to siControl [WT 
1:1000]). In all cases, knockdown of Xrn1 still increased replication (Figure 7.2A). However, in 
both miR-122-bound samples (WT 1:1 and WT 1:1000, Figure 7.2B), Xrn1 knockdown increased 
replication by 2 to 4-fold with no significant difference between dilutions, while miR-122-unbound 
replication (p3 1:1) was increased 17-fold. Cell numbers were not affected by the differing 
amounts of viral replication, and transfection efficiency was likewise unaffected (data not shown). 
Thus, the effect of Xrn1 knockdown on miR-122-unbound replication is miR-122-specific, and is 
not an artefact of reaching the replication capacity of the host system. 
  
94 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 The greater impact of Xrn1 knockdown on miR-122-unbound sub-genomic HCV 
RNA replication is not due to resource limitations for miR-122-bound replication. 
A. Huh7.5 cells were electroporated as described in Figure 7.1D. “WT, Bound” samples used 5µg 
of wild-type SGR RNA, “p3, Unbound” samples used 5µg of mutant SGR S1+S2:p3 RNA, and 
“WT 1:1000” samples used 5ng of wild-type SGR RNA. B. The effect of Xrn1 knockdown on 
bound, unbound, and diluted bound replication was evaluated as in Figure 7.1E. Significance was 
determined by paired parametric t-test.  
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7.3.1.3 Knockdown of Xrn2 has a similar effect on both miR-122-unbound sub-genomic HCV 
replication and miR-122-bound sub-genomic HCV replication. 
Xrn2 is another major host 5´ to 3´ RNA exonuclease, but is normally found in the nucleus 
(Nagarajan et al., 2013). We hypothesized that since Xrn1 knockdown did not fully restore miR-
122-unbound replication to miR-122-bound levels, miR-122 may also protect HCV RNA from 
Xrn2, and so we tested miR-122-bound and miR-122-unbound replication with and without Xrn2 
knockdown as we had with Xrn1. In Hep3B cells, as expected, knockdown of Xrn2 led to increased 
replication of both miR-122-bound and miR-122-unbound SGR WT RNA (Figure 7.3A), but the 
difference in the impact of Xrn2 knockdown on bound (2-fold) and unbound (4-fold) replication 
(Figure 7.3B) was not as great as had been observed for Xrn1 knockdown in Figure 7.1. siRNA 
treatment achieved a 90% reduction in Xrn2 mRNA in Hep3B cells (Figure 7.3C) but did not affect 
Hep3B cell numbers, and transfection efficiency was similar among all samples (data not shown). 
When tested in Huh7.5 cells, the results were similar: knockdown of Xrn2 led to increased miR-
122-bound and miR-122-unbound replication of SGR WT (Figure 7.3D), but the difference in 
increase between bound (1.4-fold) and unbound (3-fold) replication (Figure 7.3E) was again not 
as dramatic as it had been with Xrn1. As with Hep3B cells, siRNA treatment resulted in an 86% 
reduction in Xrn2 mRNA levels in Huh7.5 cells (Figure 7.3F), but did not affect Huh7.5 cell 
numbers, and translation was similar in all samples (data not shown). Because the effects of Xrn2 
knockdown on miR-122 bound and miR-122-unbound replication were similar in both Hep3B and 
Huh7.5 cells, we conclude that Xrn2 may restrict HCV RNA replication to a small degree, and 
miR-122 may function to protect HCV from Xrn2, but its contribution to miR-122-mediated 
augmentation of the HCV life cycle is minimal.  
 
7.3.1.4 Knockdown of Xrn1 enhances full-length viral RNA replication and permits detectable 
replication of full-length RNA in the absence of miR-122 binding. 
The JFH-1 sub-genomic replicon has been valuable in allowing us to work with HCV RNA 
replication in the absence of miR-122, but it lacks the structural proteins and coding regions of the 
virus, and also contains an additional IRES derived from the encephalomyocarditis virus that 
drives translation of the viral non-structural proteins. Thus, we next set out to test the effect of 
Xrn1 on replication of the full-length J6/JFH-1 mono-cistronic viral RNA (FL WT) with and 
without miR-122 binding. We had previously been unable to detect replication of this construct in  
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Figure 7.3 Impact of Xrn2 knockdown on miR-122-bound and  miR-122-unbound sub-genomic 
HCV replication. 
A. Hep3B cells were electroporated with siXrn2 or siControl for pre-knockdown, and three days 
later (Day 0) were electroporated again with the indicated siRNAs, miRNAs, mRNAs, and viral 
RNAs as described in Figure 7.1A. “Bound” samples were electroporated with miR-122, while 
“Unbound” samples were electroporated with miControl. B. The effect of Xrn2 knockdown on 
miR-122-bound and unbound replication was evaluated as in Figure 7.1B. Significance was 
determined by unpaired parametric t-test. C. The effectiveness of siXrn2 treatment on Xrn2 levels 
in Hep3B cells was evaluated by RT-qPCR as in Figure 7.1C. D. Huh7.5 cells were treated with 
siXrn2 as described in Figure 7.1D. “Bound” samples were electroporated with wild-type SGR 
RNA, while “Unbound” samples were electroporated with mutant SGR S1+S2:p3 viral RNA, 
which does not respond to miR-122. E. The effect of Xrn2 knockdown on miR-122-bound and 
unbound replication was evaluated as in Figure 7.1E. Significance was determined by paired 
parametric t-test. F. The effect of siXrn2 treatment on Xrn2 mRNA levels in Huh7.5 cells was 
evaluated as in Figure 7.1F. 
  
97 
 
 
98 
 
Figure 7.4 Knockdown of Xrn1 enhances full-length J6/JFH-1 viral RNA (FL WT) replication 
and permits detectable replication of full-length RNA in the absence of miR-122 binding. 
A. Hep3B cells were electroporated with siXrn1 as described in Figure 7.1A, but the wild-type 
full-length J6/JFH-1 viral RNA “FL WT” which encodes an in-frame Renilla luciferase reporter 
was used, and firefly messenger RNA was used as a transfection control. “Bound” samples were 
electroporated with miR-122, while “Unbound” samples were electroporated with miControl. B. 
The effect of Xrn1 knockdown on wild-type full-length HCV RNA replication was evaluated as 
described in Figure 7.1B. Significance was determined by unpaired parametric t-test. C. Hep3B 
cells were electroporated with siXrn1 as in Figure 7.1A, but replication was evaluated using the 
miR-122 binding site-mutant full-length J6/JFH-1 viral RNA “FL S1+S2:p3,” a full-length mimic 
of the SGR S1+S2:p3 mutant that does not respond to wild-type miR-122, but does respond to 
miR-122/p3, a miR-122 mimic bearing the G to C mutation at position 3 that matches the C to G 
mutation in the miR-122 binding sites on the viral RNA. “Bound” samples were electroporated 
with miR-122/p3, while “Unbound” samples were electroporated with miControl. D. The effect of 
siXrn1 on FL S1+S2:p3 miR-122-bound and unbound replication were evaluated as in Figure 
7.1B. Significance was determined by unpaired parametric t-test. E. Huh7.5 cells were 
electroporated with siXrn1 as described in Figure 7.1D, but with full-length J6/JFH-1 viral RNA 
“FL S1+S2:p3,” which does not respond to miR-122 endogenous to Huh7.5 cells. “Bound” 
samples were electroporated with miR-122/p3 and “Unbound” samples were electroporated with 
miControl as in (C). F. The effect of Xrn1 knockdown on the miR-122 binding site mutant full 
length HCV RNA replication was evaluated as described for Figure 7.1E. Significance was 
determined by unpaired parametric t-test. 
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the absence of miR-122 binding, despite the construct expressing the highly sensitive Renilla 
luciferase as a reporter, since we could not detect luciferase expression above the background 
levels expressed from a polymerase-inactivated mutant, FL GNN (Thibault et al., 2013). We 
observed that knockdown of Xrn1 in Hep3B cells led to increased levels of replication of miR-
122-bound FL WT RNA as expected (Figure 7.4A), but we also observed that Xrn1 knockdown 
allowed detectable replication of miR-122-unbound FL WT RNA, which had not been reported 
previously (compare siXrn1[Unbound] to GNN and siControl [Unbound]). Detectable replication 
continues at low levels for four and five days post-electroporation (data not shown), but does not 
increase further, perhaps due to cell confluence. This suggests to us that FL WT RNA can replicate 
in the absence of miR-122, but without knockdown of Xrn1, this replication is occurring at levels 
below our limit of detection as defined by luciferase expression from the GNN mutant.  
When we quantified the effect of Xrn1 knockdown on miR-122-bound and unbound 
replication (Figure 7.4B) we noted that the impact of Xrn1 knockdown appeared to have no 
significant difference in increasing replication (2.5-fold and 3-fold). However, we speculate that 
the actual increase in unbound full-length viral replication due to Xrn1 is greater than our 
calculated values, since miR-122-unbound replication levels were equivalent to background 
(Figure 7.4B, compare siControl [Unbound] to GNN) and thus probably occurring below the limit 
of detection.  
We also tested miR-122 binding site mutant full-length HCV RNA (FL S1+S2:p3) for the 
effect of Xrn1 on bound and unbound replication to confirm the phenotype using HCV RNAs 
having miR-122 point mutations (Figure 7.4C). As with SGR S1+S2:p3, FL S1+S2:p3 has two C 
to G mutations at position 3 in both miR-122 binding sites (S1 and S2), but is otherwise identical 
to FL WT. FL S1+S2:p3 replicates to similar levels as FL WT when complemented with miR-
122/p3, a synthetic miR-122 that bears the G to C mutation at position 3 to complement the p3 
mutation in the viral construct. Knockdown of Xrn1 increased both miR-122-bound and miR-122-
unbound replication of FL S1+S2:p3 by 6-fold (Figure 7.4D), similar to what was observed with 
FL WT, and like we observed with FL WT, unbound FL S1+S2:p3 replication levels were 
undetectable in siControl treated cells (compare siControl [Unbound] to GNN), but Xrn1 
knockdown increased replication of FL RNA, and permitted detectible, but low level, replication 
in the absence of miR-122 binding.  
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We also verified our findings in the more-commonly used Huh7.5 cell culture system, which 
required us to use the full-length miR-122 binding site mutant (FL S1+S2:p3) to test for the effect 
of Xrn1 on bound and unbound replication as was done in Hep3B cells. Like in Hep3B cells, we 
were unable to detect FL S1+S2:p3 replication without miR-122 binding in Huh7.5 cells (Figure 
7.4E, compare siControl [Unbound] to GNN). Knockdown of Xrn1 led to a 3-fold increase in 
replication of bound FL S1+S2:p3 (Figure 7.4F), and also permitted replication of miR-122-
unbound FL S1+S2:p3 (Figure 7.4E, compare siXrn1 [Unbound] to siControl [Unbound] or GNN). 
Similar to our observations in Hep3B cells, the effect of Xrn1 knockdown on miR122-unbound 
replication was not significantly different than its effect on miR-122-bound replication (Figure 
7.4B and 7.4D), but as we noted previously, this comparison is not accurate because we do not 
have a true baseline for miR-122-unbound replication in the presence of Xrn1 since it is likely 
below the limit of detection. We show here that Xrn1 knockdown can also positively impact full-
length HCV RNA replication, and can relieve Xrn1-mediated suppression of miR-122-unbound 
replication of the full-length construct such that it can be detected. 
 
7.3.2 Roles of miR-122 binding at site S1 and S2 in HCV RNA accumulation. 
In the interest of further evaluating the role of miR-122 binding in HCV replication, we 
examined the possibility that each miR-122 binding site has a different function, or contributes to 
the effect of miR-122 differently. In order to evaluate this, we generated full length and sub-
genomic constructs bearing the p3 mutation in either miR-122 binding site S1 or S2 (SGR S1:p3, 
SGR S2:p3, FL S1:p2, and FL S2:p3), meaning that the un-mutated site would still be able to use 
wild-type miR-122, but that the mutated site would require supplementation with the mutant 
miRNA, miR-122/p3. 
 
7.3.2.1 miR-122 binding at each site contributes equally to SGR RNA replication in Huh7.5 cells, 
and binding at both sites exerts a co-operative effect. 
To characterize the contribution of each site to sub-genomic HCV RNA replication, we 
examined replication of each mutant in the presence of miR-122 endogenous to Huh7.5 cells. 
When only S2 was occupied, SGR S1:p3 (Figure 7.5A, S1:p3 [S2 Bound]) replication levels were 
11-fold higher than S1+S2:p3 [Unbound], where neither site was occupied (Figure 7.5F), and 36-
fold lower than when both sites were occupied. Similarly, when only S1 was occupied, SGR S2:p3  
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Figure 7.5 Replication of sub-genomic HCV RNA bearing p3 mutations in miR-122 binding 
sites S1 or S2 under various binding conditions in Huh7.5 cells. 
A-D. Huh7.5 cells were electroporated with the indicated sub-genomic viral RNA and miRNA, 
along with a transfection control Renilla mRNA. SGR WT [S1+S2 Bound] was electroporated 
with miControl, since Huh7.5 cells express endogenous miR-122. SGR S1+S2:p3 was 
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electroporated with either miR-122/p3 [S1+S2 Bound] or miControl [S1+S2 Unbound]. SGR 
S1:p3 RNA contains a p3 mutation only in miR-122 binding site S1, leaving S2 intact; it was 
electroporated with miR-122/p3 [S1+S2 Bound], miControl [S2 Bound], or additional miR-122 
[S2 Bound + miR-122]. SGR S2:p3 RNA contains the p3 mutation only in miR-122 binding site 
S2, leaving S1 intact. It was electroporated with miR-122/p3 [S1+S2 Bound], miControl [S1 
Bound], or additional miR-122 [S1 Bound + miR-122]. SGR GND RNA contains an inactivating 
GDD to GND mutation in the viral polymerase, rendering it replication-incompetent. Viral 
replication was measured by evaluating firefly luciferase viral reporter expression at the indicated 
time points. E. The effect of binding at miR-122 sites S1 or S2 on replication are shown relative 
to replication of unbound sub-genomic viral RNA, “S1+S2:p3 [S1+S2 Unbound],” at three days 
post-electroporation.   
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replication levels were similar to those of SGR S1:p3 (Figure 7.5A) – 12-fold higher than 
S1+S2:p3 [S1+S2 Unbound] (Figure 7.5F) and 31-fold lower than S2:p3 [S1+S2 Bound]. Since 
binding at S1 increased replication by 12-fold, and binding at S2 increased replication by 11-fold, 
we would expect that binding at both sites would increase replication by a total of approximately 
130-fold if the effects were merely multiplicative. However, binding at both sites increased 
replication by 200-fold over unbound replication (Figure 7.5F). Thus, each miR-122 binding site 
contributes equally to replication of HCV SGR RNA and binding to both sites has a moderately 
co-operative effect on replication over the binding at each individual site. 
We tested SGR S1:p3 and SGR S2:p3 to confirm that their replication capacity had not be 
altered by the point mutations in any way other than in their ability to bind miR-122 (Figure 7.5B). 
This was confirmed by our finding that both SGR S1:p3 and SGR S2:p3 replicated to levels similar 
to the SGR WT when binding to the mutant site was restored through the addition of miR-122/p3. 
Similarly, replication of SGR S1+S2:p3 was also near wild type levels when miR-122 binding was 
restored by miR-122/p3. Thus, the S1 and S2 mutations did not affect the replication capacity of 
the construct in the presence of miR-122 binding.  
 
7.3.2.2 miR-122 binding to sub-genomic RNA is saturated at S2 but not S1 by endogenous miR-
122 in Huh7.5 cells. 
We also supplemented the cells with synthetic miR-122 to analyse the impact of increased 
levels of miR-122 available for binding at each site. Supplementing Huh7.5 cells with additional 
synthetic miR-122 (which is able to bind at S2) did not further increase replication of SGR S1:p3 
(Figure 7.5B, S1:p3 [S2 Bound + miR-122]), indicating that maximum replication capacity was 
achieved in Huh 7.5 cells with endogenous miR-122 levels. However, supplementing SGR S2:p3 
with additional miR-122 (which is able to bind to S1) increased replication a further 4.6-fold 
(Figure 7.5C, S2:p3 [S1 Bound + miR-122]), indicating that the effect of miR-122 binding at S1 
is not saturated in Huh 7.5 cells and greater levels of miR-122 binding enhances replication.  
 
7.3.2.3 In Huh7.5 cells, binding at S2 appears to be more important than binding at S1 for full-
length HCV RNA replication. 
We chose to further examine the role of each miR-122 binding site on replication of the full-
length viral RNA using full-length constructs bearing the p3 mutation in either S1 or S2 (FL S1:p2 
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and FL S2:p3), where the un-mutated site can still bind endogenous miR-122 present in Huh 7.5 
cells, while the mutated site is unoccupied unless the experiment is supplemented with miR-
122/p3. These constructs were tested in Huh 7.5 cells using conditions similar to those used to test 
SGR RNAs in Figure 7.5. Similar to the results seen using sub-genomic mutants, FL S1:p3 (where 
S2 is occupied by endogenous miR-122) showed intermediate replication (Figure 7.6A, S1:p3 [S1 
Bound]). However, converse to the sub-genomic mutants, FL S2:p3 (where S1 is occupied by 
endogenous miR-122) did not demonstrate detectable replication (Figure 7.6A, compare S2:p3 [S1 
Bound] to GNN). This suggests an unequal contribution to full-length replication by each miR-
122 binding site. Replication of FL S2:p3 was restored to wild-type levels when both miR-122 
binding sites were occupied (Figure 7.6B), as was replication of FL S1:p3, confirming that 
replication of the miR-122 binding site mutants was not impaired when both miR-122 binding 
sites were occupied. Since the FL S2:p3 mutant does not replicate at detectable levels when only 
S1 is bound, while the FL S1:p3 mutant does replicate at detectable levels when only S2 is bound, 
it appears that binding at S2 is more important for full-length HCV RNA replication in Huh7.5 
cell than binding at S1. 
 
7.3.2.4 Additional miR-122 binding to full-length HCV RNA at S1 increases replication more 
than added miR-122 binding at S2 in Huh7.5 cells. 
Using the SGR RNA we found that S1 but not S2 responded to a greater abundance of miR-
122 (Figure 7.5C and 7.5D). We also tested the effects of miR-122 supplementation on FL S1:p3 
and FL S2:p3 and observed similar results. Both FL S1:p3 and S2:p3 responded to the addition of 
exogenous miR-122 (Figure 7.6C, S1:p3 [S2 Bound + miR-122] and Figure 7.6D, S2:p3 [S1 
Bound + miR-122]; Figure 7.6F), but the response of FL S2:p3 was greater (8.8-fold increase, 
compare FL S2:p3 [S1 Bound] with FL S2:p3 [S1 Bound + miR-122]) and statistically significant, 
while the response of FL S1:p3 (3.8-fold increase, compare FL S1:p3 [S2 Bound] to FL S1:p3 [S2 
Bound + miR-122]) was smaller and not significant, supporting our findings using the SGR that 
the response to miR-122 binding at S1 requires greater levels of miR-122 to become saturated. In 
fact, supplementation of S2:p3 with exogenous miR-122 was required for detectable levels of 
replication (Figure 7.6D, S2:p3 [S1 Bound + miR-122]), but it still did not replicate to the same 
level as S1:p3 [S2 Bound] (Figure 7.6E, 7.6F). Thus, S2 binding appears to be more important 
than S1 based on these results.  
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Figure 7.6 Replication of full-length HCV RNA bearing p3 mutations in miR-122 binding sites 
S1 or S2 under various binding conditions in Huh7.5 cells. 
A-E. Huh7.5 cells were electroporated with the indicated full-length viral RNA and miRNA, along 
with a transfection control firefly mRNA, as described in Figure 7.6. Viral replication was 
measured by evaluating Renilla luciferase viral reporter expression at the indicated time points. F. 
The effect of binding at miR-122 sites S1 or S2 on replication are shown relative to replication of 
unbound full-length viral RNA, “S1+S2:p3 [S1+S2 Unbound],” at three days post-electroporation. 
Significance for relevant comparisons was determined by unpaired parametric t-test.  
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7.3.2.5 Binding at either S1 or S2 increases replication to the same degree within FL S1:p3 or 
FL S2:p3 RNA in Hep3B cells. 
Results from Huh 7.5 cells using S1:p3 and S2:p3 suggested that abolishing binding to S2 has 
a more potent effect on HCV RNA replication than binding to S1. However, we cannot exclude 
the possibility that the phenotype was due to the S2:p3 point mutation itself, and not simply due 
to S2 being unoccupied by miR-122. This cannot be tested in Huh7.5 cells because they express 
endogenous miR-122, but Hep3B cells, which do not express endogenous miR-122, are an ideal 
system to evaluate the contribution of each miR-122 binding site to replication of individual HCV 
RNA constructs, and thus can be used to identify possible impacts of the p3 mutations on each 
HCV RNA. We evaluated the relative contribution of binding at each site in FL S1:p3 (Figure 
7.7A) and FL S2:p3 (Figure 7.7B) RNA in Hep3B cells by supplementing each construct with 
either miR-122 or miR-122/p3. For FL S1:p3 (Figure 7.7A), we compared the effect of binding at 
S1 (adding miR-122/p3) to the effect of binding at S2 (adding miR-122), relative to unbound 
(miControl) replication and S1+S2 bound (adding miR-122 + miR-122/p3) replication. 
Replication of S1:p3 was almost identical when only S1 or only S2 was bound (Figure 7.7A, S1:p3 
[S1 Bound] and S1:p3 [S2 Bound]; Figure 7.7E). FL S2:p3 (Figure 7.7B) was evaluated the same 
way, but binding to S1 was assessed using miR-122, and binding to S2 was assessed using miR-
122/p3; again, binding at either site impacted replication of the FL S2:p3 construct equally 
(compare Figure 7.7B, S2:p3 [S1 Bound] to S2:p3 [S2 Bound]; see Figure 7.7E). Thus, within a 
given construct, binding of miR-122 at either S1 or S2 has an equal impact on full-length HCV 
replication.  
 
7.3.2.6 FL S2:p3 replication is impaired in comparison to FL S1:p3 when only one site is 
occupied. 
Interestingly, replication of FL S2:p3 with only one site bound was significantly lower than 
replication of FL S1:p3 with only one site bound, regardless of which site was bound (compare 
Figure 7.7A S1:p3 [S1 Bound] or S1:p3 [S2 Bound] to Figure 7.7B, S2:p3 [S1 Bound] or S2:p3 
[S2 Bound]; see also Figure 7.7E). In fact, replication of FL S2:p3 was near the lower limit of 
detection when only one site was bound (Figure 7.7B, compare S2:p3 [S1 Bound] and S2:p3 [S2 
Bound] to S2:p3 [S1+S2 Unbound] and GNN). However, when both sites were bound, FL S2:p3 
replicated at wild-type levels, as did FL S1:p3 (Figure 7.7C), as had been observed in Huh7.5 cells.  
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Thus, FL S2:p3 appears to have become severely dependent on miR-122 binding at both sites for 
replication. This construct therefore may be a useful model to study the influence of miR-122 on 
HCV by comparing replication of S2:p3 with wild type RNA, and identify the sequences that 
mediate the extreme dependence on miR-122. That the phenotype was only observed with the FL 
S2:p3 mutant and not with the SGR S2:p3 mutant suggests that this impairment may involve an 
interaction between the miR-122 binding sites and the structural coding region that is absent in the 
SGR constructs, or perhaps is influenced by the presence of a second IRES in the SGR construct. 
This also suggests that our observation that FL S2:p3 [S1 Bound] had lower replication levels in 
Huh7.5 cells (Figure 7.6A) was due to a phenotype of the mutant construct, rather than a function 
of binding at S1, and does not support our previous conclusion that S2 was more important for FL 
HCV RNA replication, and instead suggests that each miR-122 binding site has an equivalent 
contribution in magnitude to full-length HCV replication.  
 
7.3.2.7 miR-122 binding at both S1 and S2 together exerts a co-operative effect in increasing 
replication of full-length HCV RNA in Hep3B cells. 
The full-length S1 and S2 mutants also provide evidence that miR-122 binding at both sites 
co-operatively increases replication (Figure 7.7E). In FL S1:p3, binding at S1 increased replication 
16.5-fold, and binding at S2 increased replication 18.3-fold over unbound “replication,” although 
it is important to note that we cannot detect unbound replication and so we are comparing this 
increase to the limit of detection of our luciferase assay (GNN). If the virus’ response to binding 
at both sites were multiplicative, S1+S2 binding would increase replication approximately 300-
fold over unbound, but instead replication is increased 775-fold, demonstrating that S1 and S2 
have a co-operative effect on binding. In FL S2:p3, the effect is much more drastic: S1 binding 
increased replication 2.1-fold, S2 binding increased replication 1.6-fold, and together they 
increased replication 440-fold, rather than 3.3-fold, which would be indicative of a multiplicative 
effect. A caveat to our interpretation is that in both instances, we cannot compare an increase in 
replication directly with miR-122-unbound replication of either construct, since – if it is occurring 
– it is at levels below the ability of our assay to detect. 
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Figure 7.7 Replication of full-length HCV RNA bearing p3 mutations in miR-122 binding sites 
S1 or S2 under various binding conditions in Hep3B cells. 
A-D. Hep3B cells were electroporated with the indicated full-length viral RNA and miRNA, along 
with a transfection control firefly mRNA. FL WT [S1+S2 Bound] was electroporated with miR-
122, since Hep3B cells do not express endogenous miR-122. FL S1+S2:p3 was electroporated 
with either miR-122/p3 [S1+S2 Bound] or miControl [S1+S2 Unbound]. FL S1:p3 RNA contains 
a p3 mutation only in miR-122 binding site S1, leaving S2 intact; it was electroporated with miR-
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122/p3 [S1 Bound], miR-122 [S2 Bound], both miR-122/p3 and miR-122 [S1+S2 Bound], or 
miControl [S1+S2 Unbound]. FL S2:p3 RNA contains a p3 mutation only in miR-122 binding site 
S2, leaving S1 intact; it was electroporated with miR-122 [S1 Bound], miR-122/p3 [S2 Bound], 
both miR-122 and miR-122/p3 [S1+S2 Bound], or miControl [S1+S2 Unbound]. FL GNN RNA 
contains an inactivating GDD to GNN mutation in the viral polymerase, rendering it replication-
incompetent. Viral replication was measured by evaluating Renilla luciferase viral reporter 
expression at the indicated time points. E. The effect of binding at miR-122 sites S1 or S2 on 
replication are shown relative to replication of unbound full-length viral RNA, “S1+S2:p3 [S1+S2 
Unbound],” at three days post-electroporation. Significance for relevant groups was determined 
by unpaired parametric t-test.  
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7.3.2.8 Binding at S1 increases FL RNA replication more than binding at S2 when Xrn1 is 
knocked down in Hep3B cells. 
We have confirmed that one of the functions of miR-122 binding at the HCV 5´ UTR is to 
protect the viral RNA from the effects of Xrn1. Further, we have established that protection from 
degradation by Xrn1 is not the only role for miR-122. Thus, we propose that by evaluating the 
impact on viral replication of miR-122 binding to each binding site in the context of Xrn1 
knockdown, we can determine their individual contributions to the Xrn1-independent miR-122 
function. We compared the effect of binding at both sites, neither site, and either S1 or S2, in the 
context of Xrn1 knockdown on FL S1:p3 and FL S2:p3 replication (Figure 7.8A and 7.8C, 
respectively). Despite our earlier observation that under normal cellular conditions, S1 and S2 
contribute to FL replication to an equal degree (Figure 7.7; see also Figure 7.8B and 7.8D), we 
observed that when Xrn1 was knocked down, S1 bound replication was significantly higher than 
S2 bound replication (Figure 7.8A and 7.8C, Figure 7.8E). Particularly, when Xrn1 was knocked 
down, binding at S1 increased replication 23-fold (FL S1:p3) and 18-fold (FL S2:p3) over unbound 
replication on Day 3, while binding at S2 only increased replication 15-fold (FL S1:p3) and 5.1-
fold (FL S2:p3) over unbound replication on Day 3 (Figure 7.8E). This is in comparison to our 
previous observations with both SGR and FL constructs under normal (no knockdown) conditions, 
that binding at either S1 or S2 has equal impact on replication. These findings show that binding 
to S1 has a greater impact on the Xrn1-independent function(s) of miR-122, suggesting that S1 is 
more important for the Xrn1-independent functions of miR-122 binding, and by inference that 
binding at S2 may be more important in protection from Xrn1 during replication. In addition our 
data show that the Xrn1-independent role for miR-122 still functions co-operatively: with Xrn1 
knockdown, binding at each site separately in FL S1:p3 increased replication by 18- and 23-fold, 
but binding at both sites increased replication 670-fold (data not shown), and binding to each site 
separately in FL S2:p3 increased replication 18-fold and 5.1-fold but together increased replication 
by 1620-fold (data not shown).  
 
7.3.2.9 Binding at S2 is more important for protection from Xrn1 than binding at S1, but both 
sites protect from Xrn1. 
We also used the data presented in Figure 7.8A-D to analyze the impact of Xrn1 on replication 
of HCV RNA when miR-122 occupied each individual binding site by calculating the increase in 
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Hep3B cells were electroporated with A. siXrn1 or B. siControl for pre-knockdown, and three 
days later (Day 0) were electroporated again with the indicated siRNAs, miRNAs, a transfection 
Figure 7.8 Binding at S1 increases replication of FL S1:p3 RNA more than binding at S2 when 
Xrn1 is knocked down. 
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control firefly luciferase mRNA, and FL S1:p3 viral RNA. Viral RNA was supplemented with 
miR-122/p3 (S1 Bound), miR-122 (S2 Bound), miR-122/p3 and miR-122 (S1+S2 Bound), or 
miControl (S1+S2 Unbound), and replication was measured by evaluating reporter Renilla 
luciferase expression at the indicated time points. Results are an average of four independent 
experiments. C. siXrn1 and D. siControl-treated Hep3B cells were treated as in (A) and (B), 
respectively, but were electroporated with FL S2:p3 RNA. Results are an average of two 
independent experiments. E. The fold increase in replication of FL S1:p3 RNA (light grey, left) 
and FL S2:p3 RNA (dark grey, right) when either S1 or S2 is bound over unbound replication is 
shown in the context of siXrn1-treated cells. Significance was determined using paired parametric 
t-test. F. The effect of Xrn1 knockdown on FL S1:p3 with one, both, or neither binding site 
unoccupied is shown by comparing the fold increase in replication with Xrn1 knockdown from 
(A) to replication with siControl treatment from (B), no knockdown. The dotted line indicates 1-
fold, or no increase in replication due to knockdown. Significance was tested using ordinary one-
way ANOVA and Tukey’s multiple comparisons post-test with pooled variance, and no group was 
found significantly different. G. The effect of Xrn1 knockdown on FL S2:p3 with one, both, or 
neither binding site unoccupied is shown by comparing the fold increase in replication with Xrn1 
knockdown from (C) to replication with siControl treatment from (D), no knockdown. The dotted 
line indicates 1-fold, or no increase in replication due to knockdown. Significance was tested using 
repeated measures one-way ANOVA and Tukey’s multiple comparisons post-test with individual 
variances, and no group was found significantly different.  
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replication when Xrn1 is knocked down compared to replication in the presence of Xrn1 
(siXrn1/siControl) for each miR-122 binding condition: S1+S2 Bound, S1 Unbound, S2 Unbound, 
and S2+S2 Unbound (Figure 7.8F and 7.8G). We propose that the extent to which replication is 
enhanced by Xrn1 knockdown when a particular site is unprotected (unbound) is proportional to 
the contribution of that site to protection from Xrn1. For example, if a site is important for 
protection from Xrn1, when it is unbound, knockdown of Xrn1 will increase replication (relieve 
suppression) more than if that site is not important for protection from Xrn1. Our calculations 
showed that RNA without binding at S2 was more vulnerable to Xrn1 (Xrn1 knockdown had a 
greater enhancing effect) than when S1 was unbound, or when both sites were bound, although 
due to experimental variability these differences are not statistically significant. This indicates that 
binding at S2 serves to protect the viral RNA from Xrn1 more-so than binding at S1, and taken in 
conjunction with the results in Figures 7.5-7.7 and Figure 7.8D-F, S1 may play a different role in 
the viral life cycle. However, since Xrn1 knockdown also increased replication of RNA with miR-
122 bound at both sites, this protection is not complete. Additionally, because Xrn1 knockdown 
could not rescue miR-122-unbound replication of FL S2:p3, we further conclude that the 
impairment of the S2:p3 construct when only one binding site is occupied is not related to 
susceptibility to Xrn1. 
  
7.3.2.10 miR-122 binding at either S1 or S2 does not impact FL S1:p3 RNA translation when Xrn1 
is knocked down in Hep3B cells.  
One of the challenges in studying the role of miR-122 in the HCV life cycle is the difficulty in 
isolating effects on translation from effects on replication. Although we observe an impact of Xrn1 
on replication, it is possible that it is instead actually affecting translation, and over the course of 
our three-day experiments this effect compounds to impact replication. Thus we chose to examine 
the effect of miR-122 binding in each combination in the context of Xrn1 knockdown, using FL 
S1:p3 GNN, which is incapable of replication. When cells were treated with siControl (Figure 
7.9A), we observed that binding at S1+S2 increased translation over unbound translation up to 1.9-
fold over the 12-hour time period, which is within range of others’ observations (Henke et al., 
2008; Huys et al., 2013; Jangra et al., 2010b; Shimakami et al., 2012a; Wilson et al., 2011). We 
also observed that binding at either S1 or S2 had a lesser, but still-discernible impact on translation,  
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Figure 7.9 Knockdown of Xrn1 increases FL S1:p3 RNA translation overall, but also reduces 
the contribution miR-122 binding makes to viral translation, particularly with binding at S1. 
Hep3B cells were electroporated with siXrn1 or siControl for pre-knockdown. Three days later, 
cells were electroporated with FL S1:p3 GNN (replication-incompetent S1 miR-122 binding 
mutant) viral RNA, transfection control firefly mRNA, and the indicated miRNAs as described in 
Figure 7.7. Because the viral RNA is replication-incompetent, measuring luciferase at the indicated 
3, 6, 9, and 12 hours post-second electroporation only measures viral translation. Viral translation 
was normalized to transfection control mRNA firefly luciferase expression levels measured at 3 
hours post-second electroporation. The effect on translation of FL S1:p3 GNN viral RNA by 
miRNA binding at S1, S2, or both sites was compared to translation when neither site was bound 
in A. siControl-treated cells or B. siXrn1-treated cells, where the dotted line represents 1-fold or 
no increase in translation. C. Stimulation of translation by Xrn1 was determined by comparing 
normalized viral translation in siXrn1-treated cells to viral translation in siControl-treated cells. 
The dotted line indicates 1-fold, or no stimulation of viral translation. Significance for all figures 
was determined using two-way ANOVA with Tukey’s multiple comparisons test. Only significant 
differences are indicated; all other comparisons were not significant.  
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and that there was no significant difference between the impact of S1 or S2 binding, suggesting 
that binding at each site plays an equivalent role in the effect of miR-122 on translation. However, 
when Xrn1 was knocked down (Figure 7.9B), binding at either S1 or S2 alone did not increase 
translation at all, and binding at both sites had a much weaker impact on translation (1.4-fold at 
most). This suggests that most, or all of the apparent impact of miR-122 on translation is due to 
protection from Xrn1; we suggest that the remaining impact of binding at both sites (S1+S2) when 
Xrn1 is knocked down is due to minimal amounts of Xrn1 remaining in the cell, rather than to a 
direct impact on translation independent of protection from Xrn1. Knockdown of Xrn1 increased 
overall viral RNA translation considerably (Figure 7.9C) and also positively impacted mRNA 
translation (data not shown). Particularly, knockdown of Xrn1 had a greater impact on maximal 
S1+S2 Unbound translation (4.8-fold) than it did on either S1 Bound (2.9-fold), S2 Bound (3.6-
fold), or S1+S2 Bound (3.6-fold) translation, providing further evidence that binding at these sites 
protects from Xrn1. 
 
7.4 Discussion 
We have shown that miR-122 has a specific function in shielding the 5´ un-translated region 
of the Hepatitis C virus RNA from the host RNA exonuclease Xrn1 (Figures 7.1, 7.2, and 7.4), but 
not Xrn2 (Figure 7.3). We have also demonstrated that replication of full-length HCV RNA in the 
absence of miR-122 can be detected following knockdown of Xrn1, and we speculate that full 
length HCV RNA replicates in the absence of miR-122 binding, but that this replication is too low 
to be detected using current methods (Figures 7.5 and 7.6), unless we first remove restriction by 
Xrn1 (Figures 7.4 and 7.8). Because knockdown of Xrn1 does not allow miR-122-un-
supplemented replication to reach miR-122-supplemented levels, we conclude that miR-122 has 
additional functions in viral replication above that of protecting the viral RNA from Xrn1.  
We quantified the relative contribution of miR-122 binding at each of the two 5´ miR-122 
binding sites to HCV replication, showing that each site contributes with equal magnitude to 
enhancing replication of the virus, and that binding at both sites increases replication co-
operatively (Figures 7.5-7.7). We also evaluated the effect of miR-122 binding at either S1 or S2 
in the context of Xrn1 knockdown to assess the impact of miR-122 on its Xrn1-independent role 
in full-length viral replication (Figure 7.8). We found that when Xrn1 was knocked down, binding 
at S1 caused a greater increase in replication than binding at S2; to analyze this differently, 
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knockdown of Xrn1 enhanced replication more when S1 was bound than when S2 was bound. 
Since Xrn1 is an HCV restriction factor, the greater the increase in replication observed by removal 
(knockdown) of Xrn1, the more Xrn1 was suppressing replication under those conditions. By 
inference, this suggests that binding at S2 more strongly protects from Xrn1 and binding to S1 
more strongly affects Xrn1-independent functions of miR-122, but our observations also suggest 
that binding at both sites contributes to both Xrn1-dependent and Xrn1-independent functions.  
In both sub-genomic and full-length RNAs, each miRNA binding site appeared to require a 
different amount of miR-122 to saturate the effects of binding. Providing greater amounts of miR-
122 exogenously to Huh7.5 cells enhanced both sub-genomic (Figure 7.5D) and full-length (Figure 
7.6D) RNA replication when binding at S1, suggesting that S1 binding is not saturated in Huh 7.5 
cells. By contrast, exogenous addition of miR-122 for binding at S2 did not augment replication 
of sub-genomic RNA (Figure 7.5C), and increased full-length RNA replication only slightly 
(Figure 7.6C), suggesting S2 is already saturated in Huh 7.5 cells. This data may reflect the 
enhanced binding strength of miR-122 to S2 proposed by Mortimer et al (Mortimer and Doudna, 
2013). This also has implications for many earlier explorations of the functions of miR-122, where 
Huh7.5 cells were supplemented with additional miR-122; these researchers may have been 
measuring only the effects of S1, since binding at S2 may have already been saturated (Cox et al., 
2013; Henke et al., 2008; Huys et al., 2013; Jangra et al., 2010a, b; Shimakami et al., 2012a). 
When we evaluated translation, we found that under normal conditions, S1 and S2 binding 
contributed similarly to stimulation of HCV translation, and binding at both sites together 
increased translation more than either site alone (Figure 7.9A). However, when Xrn1 was knocked 
down, binding at S1 or S2 did not increase translation (Figure 7.9B), and binding at both sites 
together had only a small effect. This suggests that the effect of miR-122 on translation is mostly 
or solely due to protection from Xrn1.  
Other researchers have also found that miR-122 functions to increase HCV translation (Henke 
et al., 2008; Huys et al., 2013; Jangra et al., 2010b; Niepmann, 2009; Roberts et al., 2011; Roberts 
et al., 2014; Shimakami et al., 2012a; Wilson et al., 2011; Zhang et al., 2012), and when the effect 
is compared to that of miR-122 on replication, it is most likely that miR-122 has a separate, 
additional role in replication (Jangra et al., 2010b; Roberts et al., 2014; Shimakami et al., 2012a). 
More recently, researchers have been exploring whether the effect of miR-122 on viral translation 
is merely a stabilization of the viral RNA that leaves more copies available for translation (Conrad 
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et al., 2013; Li et al., 2013d; Mortimer and Doudna, 2013; Shimakami et al., 2012a; Shimakami et 
al., 2012b). In particular, Xrn1 has been implicated as the major host factor de-stabilizing and 
degrading the viral RNA (Jones et al., 2010b; Li et al., 2013d; Mortimer and Doudna, 2013), 
although not all screens involving Xrn1 knockdown show that it has an effect on HCV (Ariumi et 
al., 2011a; Jones et al., 2010b; Pager et al., 2013; Scheller et al., 2009). Our evidence (Figure 7.9) 
combined with others’ suggests that the main impact that miR-122 has on translation is indeed due 
to protecting the viral RNA from degradation by Xrn1, leaving more copies of the RNA to be 
translated. Although we did observe an apparent slight increase in translation of viral RNA after 
Xrn1 knockdown when both miR-122 binding sites are occupied (Figure 7.9B), this could be due 
to the fact that we cannot eliminate 100% of Xrn1 through knockdown, and that miR-122 could 
be shielding the viral RNA from the small percentage of Xrn1 remaining in the cell. Interestingly, 
others show that the effect of miR-122 on stability does not actually require active replication or 
translation of the viral RNA (Mortimer and Doudna, 2013; Shimakami et al., 2012a). 
We and others hypothesized that miR-122 binding to S1 creates a double stranded RNA 
structure that protects the 5´ end of the viral RNA from degradation, and the specific impact of 
Xrn1 knockdown on miR-122-unbound replication supports this hypothesis (Li et al., 2013c; Li et 
al., 2013d). Our results support a role for protection from Xrn1 in miR-122 augmentation of HCV 
replication; we also found that binding of miR-122 at both sites contributes to protection from 
Xrn1, but Xrn1 knockdown impacts S1-unbound replication less than S2-unbound replication; this 
means that Xrn1 is better able to suppress replication when S2 is unprotected, than when S1 is 
unprotected. Thus we suggest that the mechanism by which miR-122 protects viral RNA from 
Xrn1 is not mediated by the overlap created by binding to S1, but that the miR-122/Ago2/RISC 
complex formed by binding at each site, and the concomitant protein/RNA structure protects the 
HCV RNA from Xrn1 (Machlin et al., 2011; Shimakami et al., 2012a; Shimakami et al., 2012b; 
Wilson et al., 2011). We further suggest that binding of miR-122/Ago2/RISC at S2 changes 
conformation of the viral RNA in such a way as to prevent Xrn1-mediated suppression of HCV 
replication. 
Our observations that knockdown of Xrn1 did not eliminate the requirement for miR-122 on 
viral replication in any context tested (Figures 7.1, 7.2, 7.4, and 7.8) also supports the conclusion 
that protection from Xrn1 (and thus, increased stability) is not sufficient to account for the effect 
of miR-122 on HCV RNA accumulation, although we cannot rule out the possibility that 
118 
 
incomplete knockdown of Xrn1 could be responsible for the remaining difference (Jangra et al., 
2010b; Roberts et al., 2014; Shimakami et al., 2012a). One possibility is that miR-122 protects the 
viral RNA from an as-yet unidentified pyrophosphatase that removes the 5´ triphosphate (Li et al., 
2013c; Wilson and Sagan, 2014). HCV requires a 5´ triphosphate for efficient replication, but Xrn1 
is much more effective against monophosphate 5´ ends – such as those produced by de-capping of 
mRNAs – so degradation of the HCV genome by Xrn1 may require enzymes to generate a 5´ 
monophosphate substrate on the 5´ end of the viral RNA, and miR-122 may also protect the RNA 
from the putative pyrophosphatase (Garcia-Sastre and Evans, 2013; Li et al., 2013c; Li et al., 
2013d). This may explain why Xrn1 knockdown alone is insufficient to restore replication to miR-
122-bound levels in the absence of miR-122 (Li et al., 2013c; Li et al., 2013d; Nagarajan et al., 
2013). Alternatively, miR-122 may have an additional function un-related to end-protection, such 
as in viral life cycle stages following translation like the switch from translation to replication, or 
aiding in initiation of replication. In vitro work suggests that miR-122 is not involved in elongation 
by the virus’ RNA-dependent RNA polymerase, NS5b, but a role in initiation of replication has 
not been thoroughly examined, nor has a role in polymerase elongation been studied in vivo 
(Norman and Sarnow, 2010; Villanueva et al., 2010).  
The relative contributions of miR-122 binding at S1 and S2 to the viral life cycle are not yet 
fully explained, as different researchers reach different conclusions, and all use Huh7-derived cell 
lines that express endogenous miR-122. The original discoverers of the two miR-122 binding sites 
in the 5´ UTR first determined that binding at both sites was required for HCV RNA to accumulate 
to detectable levels; this was characterized using H77-derived virus constructs (genotype 1a) 
whose replication was detected solely by northern blot, and was verified by making mutations at 
positions p3, p3-4, and p6 of S1, S2, or both miR-122 binding sites, all of which abolished 
detectable replication unless the complementary microRNA was provided (Jopling et al., 2008; 
Jopling et al., 2005). Later analyses using more sensitive methods like detection of particle 
production showed that constructs with mutations in either S1 or S2 can replicate (to varying 
degrees) without compensatory miR-122 binding (Li et al., 2011a; Shimakami et al., 2012b).  
Our results show that replication with either S1 bound or S2 bound occurs at similar levels, but 
others’ results indicate that binding at S1 has an overall greater effect on replication (Jangra et al., 
2010b; Li et al., 2011a; Shimakami et al., 2012b). Analysis of the roles of each miR-122 binding 
site by Li et al. using a JFH-1-derived genotype 2a virus concluded that binding at S2 was 
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unimportant for HCV replication, because when binding at S1 was abolished (either by insertion 
of a host hairpin RNA sequence, or by point mutations in the binding site), the construct did not 
respond to a miR-122 antagonist (Li et al., 2011a). However, both the hairpin insertion construct 
and the S1 binding site point mutants that failed to respond to the antagonist were severely 
impaired for replication at the time points indicated, suggesting that a failure to respond to the 
antagonist may have been due to an inability to detect a significant response due to poor overall 
replication. The authors of this paper separately made a point mutation in S2 and noted that 
replication was affected by the miR-122 antagonist to the same degree as if the mutation was not 
there; however, the mutation they used (p6, A to G) was already present in genotype 4, and could 
theoretically retain miR-122 binding via G-U base pairing. Structural data and in vitro analysis of 
miR-122 binding affinities also suggests that the binding at S2 is stronger and less-sensitive to 
binding site mutations (Mortimer and Doudna, 2013). Therefore, this mutation may not have 
abolished binding at S2, which would explain why the S2 mutant appeared to be as responsive to 
a miR-122 antagonist as the wild-type construct (Li et al., 2011a). 
In experiments by the Lemon group measuring particle production and luciferase reporter 
levels, it was found that abolishing binding at S1 (S1:p6, A to U) had a greater impact on 
replication than abolishing binding at S2 (S2:p6, A to U) using a JFH-1-derived genotype 2a virus, 
and thus they suggest that binding at S1 is overall more important than binding at S2 (Jangra et al., 
2010b; Shimakami et al., 2012b). In contrast, we found that binding at either S1 or S2 in full-
length JFH-1-derived genotype 2a viruses (Figure 7.7) had an equal impact on replication when 
evaluated within the same construct but using the p3 C to G mutation instead of p6, A to U. We 
also observed differences between S1 and S2 binding mutants, but because we were able to use 
the Hep3B system that lacks endogenous miR-122, we were able to show that the differences were 
not because of miR-122 binding at those sites, but because of the point mutation itself; thus, the 
different findings may stem from differential effects of the p3 and p6 mutations. Interestingly, this 
group also found that supplementation of additional wild-type miR-122 (above that endogenous 
to Huh7.5 cells) had a greater impact on the S2:p6 mutant where it could bind to S1 than on S1:p6 
where it could bind to S2, and support our findings that replication is more responsive to increased 
binding at S1 and relatively non-responsive to increased binding at S2 (Jangra et al., 2010b; 
Shimakami et al., 2012b).  
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We propose that the FL S2:p3 mutant is impaired for replication in some way that is only 
compensated for by miR-122 binding at both sites (Figure 7.6 and 7.7). Binding at just one site 
does not compensate for this impairment (Figure 7.7), nor does knockdown of Xrn1 (Figure 7.8C 
and 7.8B), and Xrn1 knockdown cannot rescue miR-122 unbound replication of FL S2:p3 to 
detectable levels (Figure 7.8C), but miR-122 binding at both sites reinstates wild-type levels of 
replication. Since the miR-122-unbound replication of the FL S1+S2:p3 mutant is rescuable by 
knockdown of Xrn1 (Figure 7.4), the severely impaired phenotype is only displayed when the 
RNA has the p3 mutation at S2 alone. In addition, since SGR S2:p3 does not demonstrate any 
impairment (Figure 7.5), we suggest that the alternative translation regulation or absence of the 
structural gene coding region in SGR can overcome this impairment. Overall the FL S2:p3 mutant 
appears to be severely dependent upon miR-122 for its replication, and characterization of this 
dependency – particularly through comparison of the RNA structures within the 5´ UTR of S2:p3 
and sequence-specific interactions with other cis viral RNA structures in the mutant with viral 
RNAs that do not exhibit the impaired phenotype such as wild-type, S2:p6, S1:p3, S1+S2:p3, and 
the SGR S2:p3 – may provide further insight into mechanisms of miR-122’s interaction with the 
HCV life cycle. 
Overall, our efforts add to the growing picture that the function of miR-122 in the Hepatitis C 
virus life cycle is nuanced and complicated. We find that miR-122 binding does protect the viral 
RNA from Xrn1 during replication and translation, but that it must have additional functions in 
the HCV life cycle. We also provide evidence to suggest that replication of full-length HCV RNA 
can occur in the absence of miR-122 binding since detectible replication can be rescued by 
relieving suppression by Xrn1. We further determine that binding of miR-122 at both S1 and S2 
contribute equally to replication, and that their effects are co-operative when both sites are bound, 
but that when we remove the need to protect the viral RNA from Xrn1 (by Xrn1 knockdown), S1 
binding increases replication more than S2 binding does, indicating that binding at each site 
contributes differentially to the various functions of miR-122. Finally, we have also validated the 
Hep3B cell culture system, which allows for identification of effects of point mutations in the miR-
122 binding sites on virus replication that permit more accurate analysis of virus life-cycle 
processes in the presence and absence of miR-122 binding, and characterization of the roles of the 
different binding sites in the same HCV RNA construct. Further characterization of the effects of 
specific binding-site point mutations may also shed light on the various functions of miR-122. By 
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exploring the functions of miR-122 on the Hepatitis C virus life cycle in this system, we have 
provided insight into both others’ results with respect to the roles of miR-122 binding to the HCV 
genome and future avenues of exploration to further understand the mechanisms of miR-122’s 
interaction with Hepatitis C virus. 
 
7.5 Materials and Methods 
7.5.1 Cell Lines.  
Huh7.5 and Hep3B cells were grown and maintained as described in Thibault et al. (Thibault 
et al., 2013). 
 
7.5.2 Plasmids and Viral RNA.  
Plasmids pSGR JFH-1 Fluc WT and pSGR JFH-1 Fluc GND contain bi-cistronic JFH-1-
derived sub-genomic replicons with a firefly luciferase reporter; the GDD to GND mutation 
renders the viral polymerase non-functional (Kato et al., 2005a). pSGR JFH-1 S1:p3 Fluc WT, 
pSGR JFH-1 S2:p3 Fluc WT, and pSGR JFH-1 S1+S2:p3 Fluc WT contain C to G mutations at 
position 3 of miR-122 binding site 1, site 2, or sites 1 and 2, respectively, generated as described 
in Thibault et al. (Thibault et al., 2013). Plasmids pJ6/JFH-1 FL Rluc WT and pJ6/JFH-1 FL Rluc 
GNN contain mono-cistronic chimeric replicons with J6-derived structural proteins and JFH-1-
derived un-translated regions and non-structural proteins, along with an in-frame Renilla luciferase 
reporter; the GDD to GNN mutation renders the polymerase non-functional (Jones et al., 2007a). 
pJ6/JFH-1 FL S1:p3 Rluc WT, pJ6/JFH-1 FL S2:p3 Rluc WT, and pJ6/JFH-1 FL S1+S2:p3 Rluc 
WT contain C to G mutations as described for the concomitant S1:p3, S2:p3, and S1+S2:p3 SGR 
mutants. These were generated by replacing the 177bp EcoRI to AgeI fragment from J6/JFH-1 
with the fragment from the appropriate miR-122-binding site mutant SGR plasmid. Plasmids pT7 
luciferase (containing firefly luciferase, Promega; Nepean, ON, Canada) and pRL-TK (containing 
Renilla luciferase, Promega) were used as templates for production of mRNA. Viral RNA and 
mRNA were in vitro transcribed from these plasmids as described in Thibault et al. (Thibault et 
al., 2013). 
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7.5.3 MicroRNAs and siRNAs.  
miR-122, miR-122/p3, and miControl are described previously (Thibault et al., 2013). siXrn1 
(s29015: 5´ – GAG AGU AUA UUG ACU AUG Att–), siXrn2 (s22412: 5´ – GGA AAG UUG 
UGC AGU CGU Att – 3´), siControl (5´ – GAA GGU CAC UCA GCU AAU CAC ttc – 3´). All 
small RNAs were synthesized by ThermoScientific Dharmacon (Lafayette, CO, USA). 
 
7.5.4 Electroporation of Hep3B and Huh7.5 cells.  
Electroporations were carried out as described in Thibault et al. (Thibault et al., 2013). Both 
Hep3B and Huh7.5 cells were electroporated using the following conditions: 225V, 950µF, 4mm, 
and ∞Ω. 
 
7.5.5 Transient HCV Replication Assays Without Knockdown.  
On Day 0, 6.0x106 cells in 400µL Dulbecco’s PBS were electroporated with 1µg mRNA, 
60pmol miRNA, and 5µg (Huh7.5) or 10µg (Hep3B) in vitro-transcribed viral RNA. After 
electroporation, cells were resuspended in 4mL cell culture media. 500µL of cells were incubated 
in microfuge tubes at 37°C for 2 hours, then harvested for luciferase analysis. For all other 
luciferase analysis, 500µL cells per well were plated in 6-well dishes and incubated at 37°C to be 
harvested at the indicated time points. 2mL cells were plated in a 4mm tissue culture dish to be 
collected for RNA analysis three days post-electroporation.  
 
7.5.6 Transient HCV Replication Assays With Pre-Knockdown.  
Three days before Day 0, 6.0x106 cells in 400µL Dulbecco’s PBS were electroporated with 
60pmol siRNA for pre-knockdown, and were plated in 15cm tissue culture dishes, two cuvettes 
per dish. siRNA-treated cells were incubated for three days at 37°C. On Day 0, cells were collected 
from the dishes, prepared as described for electroporation (two cuvettes’ worth from each dish), 
and then electroporated and plated as described above. 
 
7.5.7 HCV Translation Assays With Pre-Knockdown.  
Cells were electroporated for pre-knockdown as above. Three days later, cells were prepared 
as above and electroporated again with 5µg viral RNA, 1µg mRNA, and 60pmol miRNA, and 
recovered in 4mL culture media. 500µL of cells were incubated at 37°C in microfuge tubes for 
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three hours before collecting for luciferase analysis; 500µL cells per well were plated in 6-well 
dishes for the six, nine, and twelve-hour luciferase samples. 2mL of cells per well were plated in 
6-well dishes for total RNA collection at three hours post-electroporation.  
 
7.5.8 Luciferase Assays.  
Each sample was harvested for luciferase by first washing with Dulbecco’s PBS, and then 
scraping into 100µL 1X Passive Lysis Buffer (Promega). Samples were assayed using the Dual 
Luciferase Assay Kit, Luciferase Assay Kit, or Renilla Luciferase Assay Kit (Promega) according 
to the manufacturer’s protocol, and using the GLOMAX luminometer (Promega) with a 2-second 
delay and 10-second reading. 
 
7.5.9 Total RNA Extraction.  
Each sample for RNA analysis was washed with Dulbecco’s PBS and collected into 500µL 
Trizol (Life Technologies; Burlington, ON, Canada). RNA was isolated by following the 
manufacturer’s protocol. 
 
7.5.10 RTq-PCR.  
1 µg of total cellular RNA was reverse-transcribed using the iScript cDNA Synthesis Kit 
(BioRad; Mississauga, ON, Canada). qPCR reactions were carried out using the TaqMan kits (Life 
Technologies) FAM-MGB Hs00404871_m1 (Xrn1), FAM-MGB Hs01071302_m1 (Xrn2), and 
FAM-MGB 4352934-0803022 (GAPDH); samples were amplified in triplicate in a 96-well plate 
in the CFX96 real-time PCR system according to kit protocol (BioRad). All data was analyzed 
with the CFX Manager 2.0 Software (BioRad). 
 
7.5.11 Data Analysis. 
All experiments are shown as an average of at least three independent experiments (unless 
otherwise noted) with error bars indicating standard error of the mean (SEM). Statistical analyses 
were performed using GraphPad Prism 6.0.4; statistical significance was determined by the tests 
indicated in the figure legend.  * p≤0.05; ** p≤0.01; *** p≤0.001; **** p≤0.0001; n.s. = not 
significant (p˃0.05).  
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8.0 Conclusions and Discussion 
8.1 General Conclusions 
o Supplementation of miR-122 to non-permissive cells can render them permissive to 
HCV RNA replication 
o Mouse embryonic fibroblasts can permit sub-genomic HCV RNA replication 
o miR-122 is not sufficient to overcome some barriers to HCV replication in 
transformed and immortalized cells 
o Passage and culture conditions can affect cell culture permissiveness to HCV RNA 
replication 
o Replication of full-length, mono-cistronic HCV RNA is subject to greater constraints 
than replication of sub-genomic, bi-cistronic HCV RNA 
o Hep3B human hepatoma cells lack only miR-122 to be able to support the entire 
HCV life cycle 
o Hep3B cells produce infectious virus to the same titers as the specialized Huh7.5 
cells, but did not undergo adaptation to generate their permissiveness 
o Sub-genomic bi-cistronic HCV RNA can replicate in the absence of miR-122 binding 
o C-to-G mutations at position p3 in both miR-122 binding sites on the viral 5´ UTR 
abolish miR-122 binding, but do not affect the miR-122-independent replication of 
sub-genomic HCV RNA, nor do they affect miR-122-dependent replication when the 
sites are bound by the matching mutant miRNA, miR-122/p3 
o miR-122-independent replication is also independent of the requirement for 
Argonaute-2 
o Binding of miR-122 at both sites (S1 and S2) in the 5´ UTR contribute equally in 
magnitude to sub-genomic and full-length HCV RNA replication 
o Binding of miR-122 at both sites exerts a co-operative effect on HCV RNA 
replication, rather than merely a multiplicative effect 
o Full-length HCV RNA bearing a p3 C-to-G mutation at miR-122 binding site S2 is 
impaired for replication when only one (or neither) miR-122 binding site is occupied, 
but replicates at wild-type levels when both sites are occupied 
o miR-122 functions to protect the 5´ end of HCV RNA from the host cytoplasmic 5´ 
to 3´ RNA exonuclease, Xrn1, but also has additional functions in the HCV life cycle 
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o Binding of miR-122 at site S2 functions to protect HCV RNA from Xrn1 during 
replication more than binding at site S1 
o Binding of miR-122 at site S1 is important for an alternate function of miR-122, and 
binding at S2 may also contribute to these alternate functions 
o The effect of miR-122 on translation is mostly or entirely accounted for by protection 
from Xrn1 
 
8.2 Discussion and Future Directions 
Our results in Chapters 3 and 5 with both mouse embryonic fibroblasts and human hepatoma 
cells show that miR-122 is a major determinant of tissue tropism for Hepatitis C virus, since 
supplementation of a given cell line with miR-122 was sufficient to permit replication of viral 
RNA. This idea has interesting implications for the development of culture systems for the newly-
discovered non-primate Hepaciviruses, as well as for understanding their origins, since all the 
sequences isolated thus far show putative miR-122 binding sites at S1, but lack a putative S2, while 
GBV-B has been shown to use miR-122 binding at two sites much like HCV (Burbelo et al., 2012; 
Drexler et al., 2013; Kapoor et al., 2011; Kapoor et al., 2013; Lauck et al., 2013; Lyons et al., 
2012; Sagan et al., 2013). However, particularly with mouse cells, we noted that merely 
supplementing with miR-122 was not necessarily sufficient to permit RNA replication, as not all 
mouse cell lines supplemented with miR-122 were permissive, and some cell lines lost their 
permissiveness over time despite addition of miR-122. It is not surprising that more than just miR-
122 is required to permit HCV RNA replication in cell culture models; we found that MEFs bearing 
a knockout for the host antiviral sensor PKR, as well as MEFs bearing a knockout for the liver-X 
receptor-interacting protein NCoA6, permitted replication of viral RNA better than wild-type 
MEFs, suggesting that the knockouts also aided in rendering the cells permissive to HCV. 
However, these cells later lost permissiveness, and when we tested knockdown of these factors in 
the already-permissive Huh7.5 cell line, we observed no significant increase in viral RNA 
replication, which calls into question whether it was the knockouts, or another unique property of 
each cell line acquired through transformation, which rendered them permissive in the first place. 
It is still possible that HCV already has mechanisms to prevent restriction by human PKR and 
NCoA6 such that knockdown of these in Huh7.5 cells had no effect, while removing these 
restriction factors in a mouse setting was beneficial to the virus, but since the wild-type MEFs also 
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lost permissiveness for replication, we were unable to test knockdown of the murine factors 
directly to verify the roles of PKR and NCoA6 in mouse cells.  
Others have shown that cell culture conditions and passage of well-established cell lines can 
change their properties, so it is not surprising that less-characterized and “fresher” cell lines also 
changed in permissiveness to HCV over time and through passage (Calles et al., 2006; Jensen and 
Norrild, 2000; Lohmann et al., 2003; Richards et al., 2010; Siissalo et al., 2007). The PKR 
knockout cell line appeared to have gone through crisis when we first started working with them, 
which may have involved a genetic or epigenetic change that rendered them highly permissive for 
sub-genomic HCV RNA replication; however, as the cell line was not immortalized, the cells soon 
became senescent, and other isolates from the same source never experienced the same crisis. It is 
also useful to note at this point that primary hepatocytes isolated from the PKR knockout mice 
were not permissive for RNA replication, regardless of supplementation with miR-122, but 
primary hepatocytes do not grow in culture, and others have shown that HCV replication benefits 
from a growing and dividing host cell; thus, it is again not certain whether the PKR knockout 
would have benefited HCV RNA replication (Nelson and Tang, 2006). The wild-type and NCoA6 
cells were already immortalized, and were permissive to low and intermediate levels of replication, 
respectively; it is possible that some event in the lab triggered their loss of permissiveness, but 
since this occurred at vastly different points in time for the two cell lines, we propose that it was 
unrelated epigenetic changes that affected the ability of the two cell lines to support sub-genomic 
HCV RNA replication.  
Based on our findings, acquiring other currently-permissive mouse cell lines and monitoring 
them for changing permissiveness could lead to identification of murine-specific HCV restriction 
factors such as the ones that we hypothesize affected our murine cell lines. Some of these – 
particularly any with no known involvement in innate or adaptive immunity – would be candidates 
for development of knockout mouse model systems. While the most recent mouse model actually 
achieves infection in the mouse liver, as opposed to a human liver tissue xenograft, it is still 
impaired for interferon signaling since it is a Stat1-/- mouse and is therefore not ideal for vaccine 
and immunopathogenesis studies (Dorner et al., 2013a). Developing a similar mouse in a non-
immunity-related restriction factor knockout background would finally permit an 
immunocompetent mouse model of infection that could be used for vaccine development and other 
studies that involve innate and adaptive immunity. 
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We observed that in both mouse cells and Hep3B cells, sub-genomic HCV RNA behaved 
differently than full-length HCV RNA. In mouse cells, only sub-genomic HCV RNA would 
replicate when supplemented with miR-122; full-length HCV RNA would not. In Hep3B cells, we 
were able to easily detect miR-122-independent replication of sub-genomic HCV RNA, but could 
not detect miR-122-independent replication of full-length HCV RNA unless we first knocked 
down the host restriction factor Xrn1. This suggests that there is some additional requirement for 
or restriction on replication of the full-length genome that is not present for the sub-genomic RNA. 
There are a plethora of differences between these two constructs: the sub-genomic construct lacks 
the viral structural proteins and their coding regions, and also has an additional IRES – which adds 
both secondary RNA structure and a separation of translation from replication – while the full-
length construct has an additional protein (Renilla luciferase) within the viral polyprotein. We have 
begun work in characterizing the differences between these two viral RNA constructs, with the 
aim of discovering what permits easily-detectable miR-122-independent replication of sub-
genomic HCV RNA. Preliminary results using a series of mono-cistronic constructs sequentially 
deleted for structural and scaffolding proteins (data not shown) suggest that the presence of the p7 
coding region may be the key difference between sub-genomic and full-length miR-122-
independent replication. Because co-electroporation experiments of full-length and sub-genomic 
HCV RNA together in Hep3B cells (data not shown) show no impairment of miR-122-independent 
sub-genomic replication when full-length RNA is also translating and replicating, we do not 
believe it is the p7 protein itself. However, the full-genomic replicon used in Chapter 5 is bi-
cistronic, and does express the p7 protein (thus containing the p7 coding region), yet it does show 
miR-122-independent replication. We hypothesize that the p7 coding region is involved in some 
regulatory long-range RNA-RNA interactions with other portions of the genome – which may in 
turn be regulated by miR-122 – and these interactions are impaired by the second IRES present in 
the full-genomic replicon. 
It is also possible that the difference between replication of sub-genomic and full-length RNA 
in mouse cells and in Hep3B cells occurs through two separate mechanisms, particularly since we 
did not detect miR-122-independent replication of the sub-genomic replicon even in the highly-
permissive PKR knockout MEFs. In mouse cells, the impairment of the full-length HCV RNA 
may be due to restriction factor binding in the structural coding region, rather than viral cis-RNA-
RNA interactions; inability to detect miR-122-independent replication may have been a function 
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of higher levels of Xrn1 or a similar ribonuclease from which miR-122 functions to protein the 
viral RNA. Since much of the experiments described above involve characterization of 
requirements for miR-122, it is likely that identification of the driving force behind the observed 
differences between sub-genomic and full-length replication will also provide further insight into 
the mechanisms of miR-122-mediated enhancement of HCV RNA accumulation, such as 
regulation of potential RNA-RNA interactions that affect the virus life cycle. As we have shown, 
there is much work remaining to understand the role of miR-122 in the HCV life cycle. 
At the time that miR-122 was first identified as a major requirement for the Hepatitis C virus 
life cycle, JFH-1-derived full-length constructs were replacing sub-genomic replicons of various 
origins in the literature, since the full-length constructs were both more biologically relevant and 
more useful for studying all the stages of the viral life cycle (Vieyres et al., 2013). The sub-genomic 
replicon based from the high-capacity JFH-1 isolate was not studied in detail by many researchers 
in the field in favour of the full-length genome, including those attempting to develop new cell 
culture and animal models for the virus. Due to the poor replication capacity of the other sub-
genomic replicons at the time, it is likely that miR-122-independent replication would only have 
been detectable with the JFH-1 sub-genomic replicon (Vieyres et al., 2013). Additionally, while 
others had shown selectable replication of various isolates in cells unlikely to express miR-122, 
most of this work had been done before the finding that miR-122 was a requirement for HCV 
replication, and so the absence of miR-122 in these cell lines had never been established (Ali et 
al., 2004; Chang et al., 2006; Kato et al., 2005b; Uprichard et al., 2006; Zhu et al., 2003). Thus, it 
was not surprising that others did not identify the capability of the sub-genomic replicon to 
replicate at low levels in the absence of miR-122 without selective pressure.  
The value in having a system where replication occurs completely independent of miR-122 is 
clear, since it is a key control in any experiment done to understand the role of miR-122. 
Researchers have made use of miR-122 antagonists such as that described in Chapter 5, or have 
added more miR-122 to systems that already express miR-122. However, the antagonist may not 
reach 100% of the cells that have viral RNA, or may not sequester 100% of the miR-122 in the 
cells it does reach, and thus cannot be used to achieve a miR-122-free system in Huh7-derived 
cells, which are still the cell culture model most used for HCV. Addition of miR-122 to a system 
like the Huh7.5 cell line comes with its own potential pitfalls as well, since the dynamic range of 
both miR-122 availability and HCV replication is considerably reduced. For example, using the 
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electroporation conditions we have established in our lab, addition of five or ten-fold more miR-
122 to Huh 7.5 cells had only a limited impact on HCV RNA replication (two- to four-fold 
increase, data not shown), indicating that the amount of miR-122 available in Huh7.5 cells or 
typically provided exogenously is nearly saturating, and either the cells or the virus cannot support 
much higher levels of replication than are observed under normal conditions. By contrast, addition 
of miR-122 to Hep3B cells covers replication ranging from conditions with no miR-122 to 
saturating amounts of miR-122, and we determined that replication increased in proportion to 
amount of miR-122 added, such that a 1/10 dilution of miR-122 resulted in an approximate 1/10 
reduction in replication over a 10,000-fold range. Thus, the practice of adding more miR-122 to 
Huh 7.5 cells to attempt to observe requirement for a particular host factor (or restriction by a 
particular host factor) in mediating the effect of miR-122 may not yield relevant results (Cox et 
al., 2013; Henke et al., 2008; Huys et al., 2013; Jangra et al., 2010a, b; Shimakami et al., 2012a; 
Wilson et al., 2011). We also observed that binding of miR-122 at site S2 is saturated or nearly-
saturated under typical conditions; combined with our observation that each miR-122 binding site 
contributes more to different functions of the miRNA, experiments where additional miR-122 is 
added to systems that already contain nearly-saturating levels of miR-122 are likely to only 
evaluate the effect of miR-122 on functions associated with site S1, which does not appear to be 
saturated under normal conditions in our experiments. Thus, Hep3B cells provide a valuable miR-
122-null background in which to study the mechanisms of action of miR-122.   
Finally, researchers have circumvented the requirement for specific binding of miR-122 by 
mutating single nucleotides in the miR-122 binding sites to abolish binding, and supplementing 
with a mutant miRNA that is based on miR-122 but bears the complementary point mutation(s) to 
restore binding (Jopling et al., 2008; Jopling et al., 2005). Particularly, this experiment and others 
like it have been used to demonstrate a direct interaction between the miRNA and the viral RNA 
and rule out any systematic effects of miR-122 on the cell that may also benefit the virus (Huys et 
al., 2013; Jangra et al., 2010b; Jopling et al., 2006; Jopling et al., 2008; Li et al., 2013d; Machlin 
et al., 2011; Norman and Sarnow, 2010; Shimakami et al., 2012a; Shimakami et al., 2012b; 
Thibault et al., 2013; Wilson et al., 2011; Zhang et al., 2012). However, in many cases when 
binding at just one site is abolished this way, and in almost every case when binding at both sites 
is abolished this way, replication of the viral RNA is undetectable without reinstating binding with 
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the mutant miRNA, which again highlights the previous difficulty of studying replication of HCV 
RNA without miR-122 binding.  
In our lab, we have used our miR-122-independent system to validate the requirement for miR-
122 (or lack thereof) for particular host proteins to impact the virus’ life cycle. Particularly, we 
have shown that while knockdown of Ago2 (the major effector protein in the miRNA and siRNA 
silencing pathways) significantly impacts miR-122-dependent replication of HCV, it has no impact 
on miR-122-independent replication. This confirms our and others’ hypotheses that not only does 
miR-122 require Ago2 to positively modulate HCV RNA accumulation, but Ago2 does not impact 
HCV RNA replication in any other way than mediating the interaction between HCV RNA and 
miR-122/RISC (Conrad et al., 2013; Shimakami et al., 2012a; Wilson et al., 2011). We have also 
shown the converse: DDX6, a protein downstream in the miRNA pathway, is responsible for 
enhancing some aspect of HCV RNA replication; while others have hypothesized that it is 
involved in miR-122-dependent modulation of HCV RNA accumulation, we determined that 
DDX6 has the same impact on both miR-122-dependent and miR-122-independent replication, 
which shows that DDX6 enhances HCV RNA replication in some way that is entirely independent 
of miR-122 (Ariumi et al., 2011a; Huys et al., 2013; Jangra et al., 2010a).  
We have used a combination of our initial miR-122-independent system (sub-genomic 
replication in Hep3B cells, where there is no endogenous miR-122) and the system we adapted for 
use in Huh7.5 cells (C to G mutations at position 3 of the miR-122 binding sites) to better 
characterize the functions of miR-122 in the HCV life cycle. The key to these systems was the 
finding that the p3 mutation did not impair miR-122-independent replication of sub-genomic 
RNA; we also explored a p5 mutation, but found that this would not permit detectable miR-122-
independent replication (data not shown). We then used this system to evaluate the role of miR-
122 in protecting HCV from Xrn1, a host cytoplasmic RNA exonuclease. Li et al. provided 
evidence that HCV RNA was vulnerable to degradation by Xrn1, and that miR-122 had the same 
effect on HCV RNA stability as knockdown of Xrn1, suggesting that miR-122 functioned partially 
to protect HCV RNA from degradation by Xrn1 (Li et al., 2013d). We used our system to show 
that when miR-122 binding was abolished, knockdown of Xrn1 increased replication of sub-
genomic RNA much more than when miR-122 was present; thus, in the absence of miR-122, HCV 
RNA is more vulnerable to Xrn1 than when miR-122 is present, confirming the conclusions of Li 
et al. (Li et al., 2013d).  
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Li et al. also concluded that miR-122 must play additional roles in the HCV life cycle, because 
knockdown of Xrn1 did not fully complement the effect of adding miR-122 to the cells, and 
because knockdown of Xrn1 did not rescue replication of full-length HCV RNA without miR-122 
binding (Li et al., 2013d). Because we observed no impairment of the sub-genomic replicon (with 
or without miR-122) with the p3 mutations, we generated a full-length replicon that bore p3 C to 
G mutations in its 5´ UTR miR-122 binding sites and tested the effect of Xrn1 knockdown on this 
construct. Contrary to what Li et al. found, we observed that knockdown of Xrn1 could permit 
detectable replication of miR-122-unbound full-length HCV RNA, either wild-type (in Hep3B 
cells) or p3 binding mutants (in Huh7.5 and Hep3B cells). Nonetheless, in either sub-genomic or 
full-length HCV RNA constructs, knockdown of Xrn1 did not restore miR-122-independent 
replication to miR-122-dependent levels, indicating that miR-122 has additional functions that 
further increase replication.  
In order to explore the potential additional functions of miR-122 in the HCV life cycle, we 
wished to determine what contribution each miR-122 binding site made to HCV replication. We 
initially hypothesized that miR-122 binding at the most 5´ site (S1) on the viral UTR would better 
protect from Xrn1, since it would better shield the 5´ tri-phosphate end from attack by Xrn1. We 
further hypothesized that if this were the case, then binding at S2 must serve a different function 
in the HCV life cycle. To test this, we first determined the relative overall contribution of each 
miR-122 binding site to the HCV life cycle by generating mutant sub-genomic and full-length 
constructs with the p3 mutation only in site S1 or only in S2 and testing their replication. We found 
that all mutants replicated to wild-type levels when both miR-122 binding sites were occupied (by 
endogenous miR-122 in Huh7.5 cells, exogenous miR-122 in Hep3B cells, and a mutant miR-122 
“miR-122/p3” that matches the mutated binding sites in both cell lines). We concluded that each 
miR-122 binding site contributes to an equal magnitude to increasing HCV RNA accumulation, 
since the sub-genomic S1:p3 and S2:p3 mutants replicated to the same levels when only one site 
was occupied in Huh7.5 cells, while in Hep3B cells, the full-length S1:p3 mutant demonstrated 
identical levels of replication when either S1 or S2 was occupied, as did the full-length S2:p3 
mutant. We also found that binding at both sites co-operatively impacted replication.  
We then used the full-length S1:p3 and S2:p3 mutants to test the effect of Xrn1 knockdown on 
each binding site, as well as to evaluate the impact of binding at each site on replication when the 
need for protection from Xrn1 was abolished. Our results demonstrated that miR-122 binding at 
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site S2 protected more from Xrn1 than binding at S1, although binding at S1 did also aid in 
protection from Xrn1. Because each site contributes equally in magnitude, but S2 protects more 
from Xrn1, binding at S1 must contribute more to an additional function of miR-122. However, 
these results are contrary to our hypothesis and a simplistic end-protection model of shielding HCV 
RNA from Xrn1. If binding at S2 is more important for protection from Xrn1 than binding at S1, 
then either the 5´ UTR and miR-122 binding assume a structure that is not yet understood, or the 
mechanism of Xrn1-mediated suppression of HCV RNA is not entirely through direct degradation 
of the viral RNA from the 5´-most nucleotide. Either of these possibilities is supported by our 
results when we evaluated the impact of each miR-122 binding site on viral translation with or 
without Xrn1 knockdown; both sites contribute equally to increasing translation under normal (no 
knockdown) conditions, but when Xrn1 is knocked down, binding at either site has no further 
impact on translation. This suggests that the only impact miR-122 had on viral translation was in 
fact stabilization of the viral RNA by protecting it from Xrn1, and because each site contributed 
equally to translation, each site therefore contributed equally to protection from Xrn1 during 
translation. Thus, either the viral RNA assumes a different conformation during translation only 
that allows either binding site to contribute equally to end-protection, or Xrn1 negatively impacts 
the viral RNA in some other way than the destabilization and degradation of the viral RNA 
measured in the course of a translation assay. 
Finally, the question remains: what are the other functions of miR-122, and how does each 
binding site singly or together contribute to these functions? miR-122 was originally hypothesized 
to enhance translation of the viral RNA by changing the structure of the IRES to increase its 
affinity for translation initiation factors, but this mechanism was never shown in vivo, and the 
effects of miR-122 on translation have now been attributed to increasing the stability of the viral 
RNA, which allows more RNA to be translated (Conrad et al., 2013; Diaz-Toledano et al., 2009; 
Li et al., 2013d; Shimakami et al., 2012a). miR-122 does function to protect the viral RNA from 
Xrn1, albeit perhaps not by the simple end-protection model first hypothesized. Others have also 
hypothesized that miR-122 must also protect the 5´ UTR from phosphatase activity: Xrn1 strongly 
prefers a mono-phosphate substrate to the tri-phosphate substrate found on the HCV 5´ UTR, and 
so it is possible that a phosphatase first “attacks” the viral 5´ tri-phosphate and removes the 
pyrophosphate, thus leaving the RNA unable to replicate (HCV requires a 5´ tri-phosphate to 
replicate) and vulnerable to Xrn1 (Garcia-Sastre and Evans, 2013; Li et al., 2013c; Wilson and 
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Sagan, 2014). This again leans heavily on a 5´ end-protection model, where miR-122 binding at 
S1 shields the very 5´ nucleotide of the viral RNA from this attack, but this has not yet been tested, 
as candidate phosphatases and pyrophosphatases have yet to be identified. Alternatively, miR-122 
binding at the 5´ end of the viral RNA may protect it from detection by such 5´ tri-phosphate innate 
immune sensors as RIG-I, MDA5, IFIT-1, or IFIT-5 (Li et al., 2013c; Wilson and Sagan, 2014). 
We have tested this possibility by co-electroporating miR-122-bound and miR-122-unbound HCV 
RNA into cells to see if any innate immune signaling or response occurs that could limit HCV 
RNA replication, and we observed no effect on miR-122-bound replication in the presence of miR-
122-unbound replication (unpublished data). We also could not detect increased transcripts of IFN-
β or TNF-α, downstream products of innate immune signaling, when miR-122-unbound 
replication was occurring (unpublished data). Together, this suggests that 5´ end-protection from 
detection to prevent an innate immune response is not a function of miR-122 in enhancing HCV 
RNA replication. 
miR-122 has been implicated in regulating the switch between different stages of the virus’ 
life cycle. In vitro, miR-122 has been shown to change the conformation of the 5´ UTR and IRES 
to a structure more available to translation initiation factors as discussed above, and was thus 
hypothesized to re-direct newly-produced HCV RNA from replication back to translation, or to 
promote translation of the viral RNA when it first enters the cell (Diaz-Toledano et al., 2009; 
Wilson and Sagan, 2014). However, the proposed structural changes occurred when single-
stranded miR-122 guide strand was provided, even though ss-miR-122 does not function in vivo, 
and the interactions involved structural coding regions that aren’t present in a sub-genomic 
replicon, even though sub-genomic replicons respond to miR-122 in the same way that full-length 
constructs do. Although the proposed mechanism is thus unlikely, the possibility of miR-122 
functioning as a switch is still plausible. Rather than promoting translation – which, as we and 
others have shown, is not a direct function of miR-122 (Huys et al., 2013; Li et al., 2013d; 
Shimakami et al., 2012a) – miR-122 binding or dissociation may act as the switch to send viral 
RNA from translation into replication; alternatively, it may be a switch to keep viral RNA in 
replication, where dissociation sends the viral RNA to be packaged. Studying this may require 
quantifying replication complexes and comparing to viral translation and/or particle production; 
the mechanism of this regulation would then also involve a complicated interaction between viral 
and host proteins and the miR-122/RISC/viral RNA complex. Other imaging and intracellular 
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tracking of miR-122 and viral RNA may also provide insight into the dynamics of miR-122/RISC 
interaction with the viral RNA, whether it is transient or stable, and at what points in the virus life 
cycle the interaction(s) occur(s). 
miR-122 binding could also be involved in direct initiation of replication. While there is no 
evidence for miR-122 modulating the elongation activity of the viral polymerase, researchers have 
been unable to study the initiation of the polymerase in a system that accurately reflects the in vivo 
conditions (Norman and Sarnow, 2010; Villanueva et al., 2010). HCV NS5b is thought to initiate 
replication of the viral RNA without the use of a primer, but this cannot be achieved in vitro, even 
with replication complexes isolated from infected cells; perhaps miR-122 and other RISC 
components are key to this step, or perhaps other viral proteins in the replication complex (Luo et 
al., 2000; Zhong et al., 2000). miR-122 and the RISC may be responsible for permitting replication 
without priming, either by acting as a protein/RNA primer, or by circularizing the viral RNA to 
permit replication as other Flaviviridae family members do (Filomatori et al., 2006; Khromykh et 
al., 2001; Villordo and Gamarnik, 2009). As yet, no one has been able to detect miR-122 in 
replication complexes, but this may not be surprising if miR-122 is only involved in the initial 
assembly and initiation of the replication complex and not in elongation, nor secondary initiation 
of later strand replication (Villanueva et al., 2010). It is also important to note that until recently, 
no one was able to show replication in the absence of miR-122, either. 
While hypothesizing about potential host and viral proteins involved in the additional functions 
of miR-122 may lead to discovery of these additional functions, it may also be beneficial to 
approach the question from a different angle. We have already identified Xrn1 as a host restriction 
factor from which miR-122 functions to protect HCV RNA; thus, later assays to determine other 
roles for miR-122 should occur in the context of Xrn1 knockdown or, if possible, Xrn1 knockout. 
We have also shown that binding at S2 is important for protection from Xrn1; in a simplistic model, 
eliminating the effects of binding at S2 and only examining the functions of miR-122 binding at 
S1 may also be useful to specifically target the process in question. Finally, the specific impairment 
of our full-length S2:p3 construct is intriguing and may itself be a valuable tool. This impairment 
is unique to the full-length construct, which suggests that a property of the sub-genomic construct 
compensates for this impairment, or that a long-range RNA-RNA interaction between the 5´ UTR 
and the structural protein coding region is initiated by the S2:p3 mutation, or that a detrimental 
long-range RNA-RNA interaction caused by the mutation is disrupted by the size or structure of 
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the EMCV IRES present in the sub-genomic replicon. However, this impairment does not appear 
to be present in the FL S1+S2:p3 mutant – within our ability to test it – since knockdown of Xrn1 
rescues the double-mutant but not the S2:p3 mutant, suggesting that generating the matching 
mutation in S1 somehow compensates for whatever has been disrupted by the p3 mutation in S2. 
When both binding sites are occupied, the S2:p3 mutant does not appear impaired for replication. 
Taken together, the impaired phenotype of the full-length S2:p3 mutant and exploring the possible 
mechanisms – structural or otherwise –for this impairment has the potential to offer considerable 
insight into processes regulated by miR-122 binding and their mechanisms, and may serve to 
generate hypotheses for the various functions of miR-122, as well as explaining the co-operative 
effect of binding at both sites over the lesser effect of binding at only one or the other site. 
Particularly, it would be interesting to create selectable full-length mono-cistronic replicons 
bearing either the S1:p3 or S2:p3 mutation, and select for compensatory mutations in the presence 
(Huh7.5 cells) and absence (Hep3B cells) of miR-122; comparison of the mutations achieved in 
the two constructs, and the two different conditions, may provide leads on structural changes and 
interactions within the viral RNA that are mediated by the miR-122 binding sites and miR-122 
binding, together or separately. 
More broadly, exploring other HCV isolates for their dependence on miR-122 and their ability 
to accommodate binding site mutations like p3, p3-4, p5, and p6 has the potential to validate – or 
invalidate – the findings we have made regarding dependence on miR-122 binding at specific sites 
for specific functions, and provide further avenues of exploration. Manipulating viral constructs 
to determine the mechanism for the differences between the full-length and sub-genomic JFH-1-
derived constructs and their interactions with miR-122 and binding site mutations has great 
potential to offer insight into how miR-122 affects HCV replication; preliminary data discussed 
above suggests that the presence of the p7 coding region may be a contributing factor in this 
difference, and this requires further exploration.  
Throughout the course of this work, we have developed model systems for the study of the 
Hepatitis C virus, and more particularly, for the study of the role of miR-122 in the virus’ life 
cycle. We have validated the miR-122-independent system for its usefulness in identifying and 
characterizing host components involved in the functions of miR-122 on the virus life cycle, and 
we have used it to further characterize the mechanisms for one of the functions of miR-122. 
Further, we have generated a system that offers several approaches to understanding other 
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functions of miR-122, and the future findings from this system have a wide variety of implications 
for the study of the unique interaction between Hepatitis C virus and miR-122, as well as the 
potential interactions between the recently-discovered non-primate Hepaciviruses and miR-122.  
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